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Abstract 
 
The small GTPase Rab7 is a key component of the endocytic pathway that 
controls endosomal maturation and fusion of late endosomes with lysosomes. 
Rab7 also regulates growth factor signaling by modulating receptor levels at the 
plasma membrane. While it is known how Rab7 is regulated through the 
GTPase cycle and interaction with its GEF and GAP, little is known about its 
regulation by post-translational modifications.  
 
In this study, I identified two kinases, TBK1 and IKKε, which phosphorylate 
Rab7 at S72 in in vitro kinase assays. Both kinases are highly homologous and 
are activated in the innate immune response to bacterial and viral infection. 
Importantly, phosphorylation of Rab7 at S72 was increased by approximately 4-
fold in mouse embryonic fibroblasts following 4 h stimulation of Toll-like receptor 
(TLR)3 with poly(I:C), a synthetic analog of viral dsRNA. A similar increase was 
also seen following stimulation of TLR4 with bacterial lipopolysaccharide after 8 
h stimulation.  
 
Through a pull-down and mass spectrometry analysis of differential interactors 
of unphosphorylated and S72-phosphorylated GST-Rab7, I found that 
phosphorylation of Rab7 at S72 inhibited interaction with RILP, one of its best 
known effectors, while, it increased interaction with the p150(Glued) subunit of 
the dynactin complex. The mass spectrometry analysis also identified a novel 
interactor, TNFR associated factor 3 (TRAF3), which is activated via the 
MyD88-independent pathway following stimulation of various TLRs. TRAF3 also 
leads to the downstream activation of TBK1 and IKKε.  
 
Using subcellular fractionation and immunofluorescence with an anti-phospho-
Rab7(S72) antibody, I found that the ratio of phosphorylated to 
unphosphorylated Rab7 is significantly higher on the membrane compared to 
the cytosol. Furthermore, the membrane staining of the S72-phosphorylated 
Rab7 indicates that it is a subpopulation of the total Rab7 that is associated with 
  4 
vesicular structures. These results indicate that phosphorylation may occur on 
the membrane and could be a mechanism of controlling late 
endosome/lysosome transport and/or fusion.  
 
As the S72 site is highly conserved and located in the switch II region, which is 
required to bind the switch I region upon GTP binding and activation, I 
performed an in vitro GTP hydrolysis assay using [α-P32]GTP to determine the 
GTPase activity of S72-phosphorylated Rab7 compared to the 
unphosphorylated protein. Interestingly, there was a significant increase in GTP 
hydrolysis over time in the phosphorylated Rab7 compared to the 
unphosphorylated protein.  
 
The results of this study indicate that phosphorylation of Rab7 at S72 promotes 
differential interaction of Rab7 with certain effectors, which may promote its 
recruitment for specific functions. These results also indicate that 
phosphorylation may increase Rab7 turnover in vivo by stimulating the intrinsic 
GTPase activity. 
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TGFβ   transforming growth factor-β 
TGN   trans-Golgi network 
TIP47   tail-interacting protein of 47 kDa 
TNFα    tumour necrosis factor-α 
TNFR   tumour necrosis factor receptors 
TRAF   TNFR associated factor 
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TRIF   TIR domain-containing adapter inducing IFN-β 
Trk   tropomyosin-related kinase 
Tyr   tyrosine 
ULK   unc-51-like kinase 
VAMP   vesicle-associated membrane protein 
VAP   VAMP-associated ER protein 
Vps   vacuolar protein sorting-associated protein 
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Chapter 1. Introduction 
1.1 Rab GTPases & the endocytic pathway 
The Rab family of small Ras-like GTPases is an important regulator of vesicular 
transport along the endocytic pathway. Rabs were initially discovered as 
important regulators of membrane trafficking; however, they are now believed to 
be key players in cell signalling, growth, survival and development (Romero 
Rosales et al., 2009; Tu et al., 2010; Wang et al., 2012). These processes are 
controlled by the endocytosis of a large variety of cargoes, including activated 
receptors, nutrients and their carriers, lipids, extracellular matrix proteins, fluids, 
viruses and bacteria. Once internalised, these molecules can be sorted via a 
number of different routes, including recycling back to the plasma membrane or 
to the lysosome for degradation. In mammals, more than 60 Rabs have been 
identified, each of which functions in an organelle-specific manner to control the 
passage and sorting of different cargoes (Hutagalung and Novick, 2011) (Figure 
1.1). The initial internalisation of cargoes and the fusion of early endosomes are 
controlled by Rab5. Cargo is then sorted and recycled back to the plasma 
membrane by Rab4, Rab11, and Rab25, or sent to the lysosome for 
degradation by Rab7. Other important vesicular transport pathways in cells 
include transport between the endoplasmic reticulum (ER), Golgi and lysosomal 
networks. The ER is a major site of protein and lipid synthesis that forms a vast 
network throughout the cell. It is also a major site of synthesis of membranes for 
all organelles of the endocytic pathway. Thus, transport between the ER and 
other compartments is fundamental for the correct functioning of intracellular 
transport. The Golgi apparatus is composed of a stack of four to six membrane-
bound flattened cisternae, which are usually classified as cis- medial- or trans-
Golgi networks (Gu et al., 2001). The Golgi is responsible the post-translational 
modification of many proteins, while the trans-Golgi network (TGN) is also 
involved in the sorting of proteins to their final destinations, including numerous 
signalling receptors that are destined for the plasma membrane (Figure 1.1). 
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Figure 1.1. The endocytic pathway. 
The endocytic pathway is controlled by over 60 members of the Rab family, which 
function in organelle specific manner to control the trafficking and sorting of different 
cargo. The membranes of these organelles are also characterised by their different 
phosphoinositide composition, which also controls the recruitment of different proteins 
and their effectors. Figure generated from Jean and Keger, 2012.  
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Rab6 is an important regulator of this secretory pathway, while Rab1 functions 
in ER-Golgi transport and Rab9 mediates trafficking between the ER and the 
lysosome. 
 
Rab proteins are GTPases, which cycle between guanosine diphosphate 
(GDP)-inactive and guanosine triphosphate (GTP)-active forms (Figure 1.2). 
Newly synthesised GDP-bound Rabs interact with a Rab escort protein (REP) 
in the cytosol, which binds and presents the Rab to Rab geranylgeranyl 
transferase (RabGGTase). The RabGGTase transfers one or two 
geranylgeranyl groups to C-terminal cysteines for correct insertion of the Rab 
into its target membrane (Pereira-Leal et al., 2003). Following prenylation, REP 
chaperones the GDP-bound Rab to the correct membrane, where it becomes a 
substrate for a guanine nucleotide exchange factor (GEF), which catalyses the 
conversion of GDP to GTP. The active Rab can then interact with its effector(s) 
proteins to perform its specific function(s). Following interaction with its effectors, 
molecules, a GTPase-activating protein (GAP) binds the Rab and catalyses the 
hydrolysis of GTP to GDP, thereby converting it back to an inactive state. 
Inactive Rab7 then dissociates from the membrane back into the cytosol, where 
it is bound to a GDP-dissociation inhibitor (GDI). While in this state the Rab 
binds a GDI dissociation factor (GDF), which removes the GDI and allowing the 
Rab to re-enter the cycle. 
 
Common structural elements and the presence of specific motifs are important 
for the correct binding of shared interactors and specific effectors of Rabs. They 
have similar structural features to other Ras-related GTPases, containing a six-
stranded β sheet, with five parallel strands and one anti-parallel strand, flanked 
by five α helices. Rabs are distinguished from other GTPases by the presence 
of five distinct motifs, known as Rab family motifs (RabFs) (Pereira-Leal et al., 
2003) (Figure 1.3). These motifs are proposed to mediate binding of Rabs to 
common interactors, such as Rab escort protein 1 (REP1). Indeed, it was 
shown that residues within the RabF1, RabF3, and RabF4 motifs of Rab3A 
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Figure 1.2. The Rab GTPase cycle. 
Rab proteins cycle between active GTP-bound and GDP-bound forms, which are 
characterised by different affinities with the cellular membranes. GTP-bound Rabs are 
recruited to their respective membranes where they interact with different effectors to 
perform specific functions. Following this step, a GAP catalyses the conversion of GTP 
to GDP and the Rab is recycled back into the cytosol. Figure generated from Bento et 
al., 2007. 
 
mediate binding to REP1 (Pereira-Leal et al., 2003). Some of these regions also 
contain sites of the switch I and II regions of Rab3A. These switch regions are 
responsible for changes in conformation of Rabs in their GTP- and GDP-bound 
forms. In the active GTP-bound form the conformation is stabilized by 
hydrophobic contacts between the switch I and II regions (Dumas et al., 1999). 
The orientation of the switch I and II domains distinguishes Rabs from Ras. The 
Rab family is further subdivided based on the presence of four subfamily motifs 
(RabSFs), which are highlighted in yellow inFigure 1.3 These RabSF motifs, 
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along with the switch I and II regions, are responsible for the specificity of 
binding differential interactors for each Rab protein. 
 
 
Figure 1.3. Generic structure of Rab proteins. 
A. Schematic representation of the domain structure of Rab proteins, showing the 
RabF (red) and the RabSF (yellow) regions, and the switch I and II regions (SWI and 
SWII) and the hypervariable domain (HVD), as indicated by black bars. The prenylation 
motif (GG) is located at the C-terminal region. B. A three-dimensional model showing 
the positions of the RabF and RabSF motifs. Figure adapted from Zhu et al., 2004. 
 
Rab proteins mostly differ in their C-terminal region, which are approximately 35 
to 40 amino acids in length. This region, known as the hypervariable domain, 
was proposed to be responsible for the specific membrane targeting of different 
Rabs. It was originally shown that swapping the C-terminal 35 amino acids of 
Rab5 with that of Rab7 resulted in relocalisation of the hybrid Rab to Rab7-
positive vesicles. However, a subsequent study created a series of hybrid Rabs 
by swapping the hypervariable domains of Rab1, Rab2, Rab5, Rab7 and Rab27 
(Ali et al., 2004). They found that certain hybrids retained their original 
SWI SWII HVD
A
B N
C
SF1 SF2 F1 F2 F3 F4 F5 SF3 SF4 GG
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subcellular localisation and function, indicating that other regions of the protein 
or effector proteins may recruit them to their respective membranes. 
 
Other major components of the machinery controlling the endocytic pathway 
include soluble N-ethylmaleimide-sensitive factor activating protein receptor 
(SNARE) proteins, which are crucial for membrane fusion, scaffolding proteins 
mediating the formation of endosomal organelles and their fission from the 
plasma membrane, sorting complexes such as endosomal sorting complexes 
required for transport (ESCRT), homotypic fusion and protein-sorting (HOPS) 
and retromer, and the numerous effector molecules that interact different Rabs. 
Importantly, regulatory roles are not only restricted to protein complexes, but 
extend to specialised lipid moieties, such as phosphoinositides and 
lysobisphosphatidic acid (LBPA) (Billcliff and Lowe, 2014; Chevallier et al., 
2008). Phosphoinositides are critical regulators of the endocytic pathway. There 
are seven different forms of phosphoinositide, generated by differential 
phosphorylation of the phosphatidylinositol head group at one or more of three 
positions (D-3, D-4 or D-5). The different phosphoinositide species are localized 
to distinct subcellular compartments or domains within different compartments, 
similar to the Rab family (Figure 1.1). Numerous effector proteins specifically 
bind the different phosphoinositides, making them important regulators of signal 
transduction, membrane trafficking, cell migration, and other cellular functions 
(Billcliff and Lowe, 2014). Phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2) 
and phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3) are signalling 
molecules involved in cell proliferation and survival, which are generated in 
response to the stimulation of receptors at the plasma membrane. Changes in 
the levels of phosphatidylinositol-3-phosphate (PI(3)P), phosphatidylinositol-4-
phosphate (PI(4)P), phosphatidylinositol-3,5-bisphosphate (PI(3,5)P2) and 
phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) can also occur through 
external stimuli, but they mostly remain stable and are distributed at specific 
membranes throughout the cell (Mayinger, 2012) (Figure 1.3). The production 
and regulation of the different phosphoinositide species is controlled by various 
phosphoinositide kinases and phosphatases.  
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1.2 The early endocytic pathway 
There are numerous mechanisms of endocytosis, including clathrin-mediated, 
caveolae-dependent, flotillin-dependent, or Arf6-dependent endocytosis, 
phagocytosis, macropinocytosis and entosis. Clathrin-mediated endocytosis is 
probably the most widely understood mechanism of endocytosis. Cargo 
internalised by clathrin-mediated endocytosis are taken up into clathrin-coated 
pits, where they subsequently form clathrin-coated vesicles. Clathrin, which is 
located on the cells limiting membrane, forms a polyhedral lattice as it binds to 
the cytoplasmic surface of the plasma membrane. Binding of clathrin to the 
membrane is mediated by interaction with a number of adaptor proteins, 
including the AP-2 complex, which links clathrin to the plasma membrane and is 
capable of binding the cytoplasmic domain of cargo proteins. Other members of 
the AP family of adaptors, (AP-1, -3, -4), serve as clathrin adaptors in other 
parts of the cell, such as the TGN and endosomes (Owen et al., 2004). Other 
clathrin adaptors at the plasma membrane include amphiphysins 1 and 2, β-
arrestins 1 and 2, epsins 1, 2, and 3, and sorting nexin 9 (Snx9). The clathrin 
lattice acts as a scaffold for the binding of proteins that are important for 
membrane curvature and the formation of the clathrin-coated pit. Upon 
formation of the pit, the cytoplasmic GTPase dynamin forms a ring around the 
top of the pit to pinch off the clathrin-coated vesicle from the membrane.  
 
Many plasma membrane receptors, such as receptor tyrosine kinases and G-
protein-coupled receptors are internalised by clathrin-mediated endocytosis; 
however, some of these receptors can be internalised by alternative 
mechanisms. For example the epidermal growth factor receptor (EGFR), which 
has eight different ligands, can still be internalised following clathrin knockdown 
by stimulation with betacellulin and heparin-binding EGF-like growth factor (HB-
EGF), but this is not the case following stimulation with epidermal growth factor 
(EGF) and transforming growth factor-α (TGF-α) (Henriksen et al., 2013). It has 
Chapter 1. Introduction 
 25 
also been shown that stimulation of fibroblasts and epithelial cells with EGF 
causes internalisation of the EGFR by macropinocytosis (Orth et al., 2006).  
 
Rab5 is one of the key regulators of the early endocytic pathway, regulating 
endocytosis, homotypoic fusion of endocytic vesicles with themselves or early 
endosomes, along with uncoating of clathrin-coated vesicles, and initiates early 
sorting events and intraluminal vesicle formation. Rab5 has a number of 
different effectors, including hRME-6, which promotes AP-2 uncoating of 
clathrin-coated vesicles (Semerdjieva et al., 2008), early endosome antigen-1 
(EEA1) (Merithew et al., 2003), required for membrane fusion, and Hrs, a 
component of the ESCRT-0 complex, required for intraluminal vesicle formation 
(Pons et al., 2008). It also interacts with vacuolar protein sorting-associated 
protein (Vps)34, Vps45, and Rabex-5, the Rab5 GEF. The recruitment of Hrs 
and EEA1 occurs prior to binding of Vps34, a phosphoinositide 3 [PI(3)] kinase, 
which is responsible for the generation of PI(3)P on early endosomal 
membranes. 
 
Early endosomes have a complex structure, with vacuolar and tubular domains, 
which are responsible for the sorting of specific cargo towards different routes 
to which they are destined. A number of different proteins, including sorting 
nexins (Snxs) are phox homology (PX) domain-containing proteins, are 
believed to be involved in the sorting of cargo along the endocytic pathway. 
Indeed, it has been shown that Snx1 has the ability to form dimers and sense 
membrane curvature, which allows it to form tubular microdomains on early 
endosomes (Carlton et al., 2004). This is important for endosome-TGN 
transport of the cation-independent mannose 6-phosphate receptor (CI-MPR), 
with no effects of EGFR and transferrin receptor (TfR) sorting. Other 
microdomains will be discussed in the following section, which are required for 
the recycling of cargo back to the plasma membrane. 
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1.3 The recycling pathway 
The majority of internalised cargo is recycled back to the plasma membrane, via 
fast and slow recycling endosomes. Rab4 and Rab11 are two of the main Rabs 
involved in the recycling route. The role of Rab4 has been widely investigated, 
but its exact function remains unclear. Most studies have looked at the 
involvement of Rab4a in the recycling of the TfR, which is constitutively 
recycled back to the plasma membrane. However, different studies have found 
that both the overexpression and knockdown of Rab4a results increased levels 
of TfR at the plasma membrane (Deneka et al., 2003). In contrast, Rab11 
knockdown has been shown to increase the number of recycling endosomes 
unable to tether and fuse with the plasma membrane (Takahashi et al., 2012). 
This indicate that Rab4 plays a role in the sorting of different cargoes in 
different domains of the endosomal compartment for recycling at an earlier 
stage than Rab11, which is more important for transport and fusion of these 
vesicles with the plasma membrane. Indeed, it has been recently shown by 
D’Souza et al. that Rab4 recruits Arl1, which in turns recruits the Arf GEFs BIG1 
and BIG2 to early endosomes to promote the formation of elongated tubules or 
sorting domains (D'Souza et al., 2014). Furthermore, Ward et al. showed that 
the major histocompatibility complex class I (MHC-I)-related receptor, FcRn, 
initially leaves sorting endosomes in Rab4/Rab11- or Rab11-positive 
endosomes, following which the Rab4/Rab11-positive endosomes segregate 
into two distinct compartments which eventually separate. The Rab11-positive 
recycling endosomes fuse with the plasma membrane, whereas the Rab4-
positive carriers do not (Ward et al., 2005).  
 
The recycling pathway plays an important role in many different functions. In the 
case of signalling receptors, it allows for further activation of the pathway 
following their reintegration at the plasma membrane. It has also been shown to 
participate in cell migration and tumour invasion, through integrin recycling. 
Integrins are a family of receptors that mediate cell adhesion to extracellular 
matrix (ECM). They play key roles in numerous processes, including cell 
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migration, differentiation, proliferation and survival, and in pathological 
conditions, such as cancer progression and metastasis. Integrins are constantly 
undergoing endocytosis and recycling back to the plasma membrane, a process 
that is very important in cell migration. Syntaxin 6 (STX6) is a SNARE located in 
the TGN that is responsible for transport of integrins to the plasma membrane. 
STX6 has been shown to be upregulated in numerous types of cancers, and its 
depletion inhibits chemotactic cell migration (Riggs et al., 2012).  
 
1.4 The late endocytic pathway 
1.4.1 Ubiquitination & targeting for degradation 
Receptors internalised by the endocytic pathway are targeted for degradation 
by ubiquitination. Ubiquitination occurs via the covalent addition of one or more 
ubiquitin moieties to lysine (Lys) residues, in a three-step process by the 
sequential action of E1 ubiquitin-activating, E2 ubiquitin-conjugating and E3 
ubiquitin-ligating enzymes. Ubiquitin itself contains several Lys residues (Lys6, 
Lys11, Lys27, Lys29, Lys33, Lys48 and Lys63), all of which can be modified 
with ubiquitin to form chains of varying lengths. Therefore, proteins can be 
ubiquitinated by three different modifications: monoubiquitination, the 
attachment of a single ubiquitin, multiple monoubiquitination, the attachment of 
multiple single ubiquitin molecules to different Lys residues, and 
polyubiquitination, modification with ubiquitin chains of different lengths and 
linkages. Ubiquitination is a reversible process via the action of deubiquitinating 
enzymes (DUBs) that recycle ubiquitin back into the cytosol (Haglund and Dikic, 
2012). As such, ubiquitination targets protein substrates to many different fates 
such as lysosomal or proteasomal degradation or specific intracellular routing, 
and controls many cellular functions, including endocytosis, sorting, NF-κB 
signalling and DNA repair.  
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1.4.2 Intraluminal vesicle formation & the ESCRT machinery 
The correct targeting of ubiquitinated proteins for degradation is controlled by 
interaction with proteins containing ubiquitin-binding domains, which include the 
ESCRT machinery (Haglund and Dikic, 2012). The ESCRT machinery is 
responsible for the formation of intraluminal vesicles, which begins in the early 
endosome and is one of the main characteristic steps of the maturation of early-
to-late endosomes. It is for this reason that late endosomes are often referred to 
as multivesicular bodies (MVBs). The ESCRT pathway is characterised by five 
complexes (ESCRTs -0, -I, -II, and -III, and Vps4), which play key roles in cargo 
recognition and sorting (Henne et al., 2011). Interestingly, although ESCRTs 
bind ubiquitinated proteins to target them for degradation, ESCRT-0 and 
ESCRT-III also interact with DUBs to remove ubiquitin prior to sorting into 
intraluminal vesicles and targeting to the lysosome. ESCRT-0, ESCRT-I and 
ESCRT-II all contain ubiquitin-binding domains and function in the early stages 
of cargo recognition and clustering. ESCRT-III subunits do not contain ubiquitin-
binding domains, but the ESCRT-III complex plays a crucial role in membrane 
deformation and scission through its Snf7 subunit, which can form oligomeric 
assemblies similar to dynamin. ESCRT-I and ESCRT-II can induce membrane 
deformation in vitro but are unable to perform membrane scission (Henne et al., 
2011). ESCRTs also play an important role in cytokinesis and are hijacked by 
viruses, such as HIV budding at the surface of infected host cells.  
 
1.4.3 Intraluminal acidification & lysosomal hydrolases 
The maturation of endosomes is accompanied by intraluminal acidification and 
the formation of intraluminal vesicles. Early endosomes are mildly acidic at pH 
5.9–6.8, whereas late endosomes/lysosomes can range between pH 4.9–6.0. 
Acidification is largely dependent on the vacuolar V-type ATPases, which is a 
proton pump that also regulates the intake of cations, such as Na+, Ca2+ and 
Cd2+, from the cytosol into the lumen of the lysosome (Beyenbach and 
Wieczorek, 2006). Endosomal acidification is responsible for a number of 
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processes, including the uncoupling of ligands from their receptors, which 
occurs around pH 6.5 for TGF-α and HER2/EGFR, with EGF dissociating at 
pH5.5, while the degradation of cargoes in the lysosome occurs between pH 
4.5–5.0. Lysosomes contain about 50 different acid hydrolases, which include 
proteases, glycosidases, lipases, nucleases and phosphatases, which break 
down macromolecules in the lysosome. Mutations in the genes that encode 
these enzymes cause over 30 different diseases, called lysosomal storage 
diseases, such as Gaucher’s disease, which is caused by a mutation in 
glucocerebrosidase, an enzyme involved in the digestion of glycolipids. Many of 
these enzymes are synthesised in the ER and pass through the TGN before 
trafficking to the late endosome/lysosome. Rab9, together with its effector tail-
interacting protein of 47 kDa (TIP47), is located on late endosomes, and is 
involved in regulating transport to the TGN (Ganley et al., 2004). TIP47 binds 
MPR, which transports newly synthesized lysosomal enzymes from the Golgi to 
late endosomes. Rab9, TIP47 and MPRs all reside in a microdomain of late 
endosomes that does not contain Rab7 (Ganley et al., 2004). Transport of MPR 
back to the Golgi is mediated by the retromer complex, which is composed of 
two functional sub-complexes: the cargo-selective trimer of Vps35, Vps29, 
Vps26, and the membrane tubulating dimer of sorting nexin (Snx)1 and Snx2. 
Seaman et al. identified an interaction between Vps35/29/26 complex and Rab7, 
which was required for its recruitment to the membrane to complex with Snx1/2 
(Seaman et al., 2009). They also found that the Rab-GAP TBC1D5 interacts 
with Vps25/29/26 to inhibit its recruitment to the membrane.  
 
1.4.4 Rab7 recruitment and membrane fusion 
The recruitment of Rab7 and simultaneous dissociation of Rab5 controls early-
to-late endosome maturation and fusion with the lysosome (Hutagalung and 
Novick, 2011). Rab7 also mediates the fusion of mature autophagosomes with 
the lysosome, see section 1.6.2 (Jager et al., 2004). Fusion of endosomal 
membranes is usually performed by the interaction of Rabs, SNAREs, and 
different tethers. The HOPS complex is an important tethering complex involved 
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in the fusion of late endosomes and phagosomes with lysosomes. It is a 
conserved hexatetrameric complex composed of Vps11, Vps16, Vps18, Vps33, 
Vps39, and Vps41. Rab7 binds the Vps39 and Vps41 subunits of the HOPS 
complex. It was originally believed that the Vps39 subunit of the HOPS complex 
acted as the GEF for Rab7, as it increased the rate of nucleotide exchange on 
Ypt7 in vitro (Wurmser et al., 2000). However, subsequent work indicates that 
Vps39 serves as an effector rather than a GEF, as Vps39 preferentially binds 
GTP-bound Ypt7 and the addition of Gyp7, the Ypt7 GAP, causes release of 
Vps39 from the vacuolar membrane (Ungermann et al., 2000).  
 
Interestingly, Rab5 also binds a hexatetrameric complex known as class C core 
vacuole/endosome tethering (CORVET) complex, which also contains the VPS-
C core subunits, Vps11, Vps16, Vps18, Vps33, as well as the Rab5-binding 
subunits, Vps3 and Vps8 (Balderhaar and Ungermann, 2013). Both the HOPS 
and CORVET complexes contain subunits with SNARE binding domains. 
SNAREs are membrane-bound proteins that enable membrane fusion 
(Balderhaar and Ungermann, 2013). It has been proposed that there may be an 
intermediate complex based around the VPS-C core complex between Rab5-
CORVET and Rab7-HOPS that helps mediate the maturation of early to late 
endosomes. Following this, Rab7-HOPS mediates fusion of the late endosome 
and autophagosome with the lysosome. 
 
1.4.5 TBC1D15 and the Mon1-Ccz1 complex - the Rab7 GAP and GEF  
TBC domain family, member 15 (TBC1D15) was first identified by Zhang et al. 
as the GAP for Rab7 using an in vitro [γ-32P]GTP hydrolysis assay, where is 
stimulated the GTPase activity of Rab7 by approximately 90-fold compared to 
its intrinsic abilities (Zhang et al., 2005). They also tested it against Rab4, Rab6 
and Rab11, with Rab11 exhibiting an approximately 8-fold increase in activity, 
whereas there was no effect on the other two Rabs. This was confirmed by 
Peralta et al. using a Rab-interacting lysosomal protein (RILP) pull-down assay 
for GTP-bound Rab7, which showed that overexpression of TBC1D15 
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significantly reduced the amount of active Rab7 (Peralta et al., 2010). They also 
showed that overexpression of TBC1D15 had no effect on TfR recycling, which 
requires Rab4, Rab5 and Rab11, indicating its specificity for Rab7 in this 
pathway. 
 
Most of the insight into the GEF for Rab7 has been through studies using the 
yeast homolog of Rab7, Ypt7. Only recently, Nordmann et al. identified the 
Mon1-Ccz1 complex as the GEF for Ypt7, with neither being able to perform the 
activity on their own (Nordmann et al., 2010). Furthermore, knockdown of 
MON1 or CCZ1 both result in lysosomal fragmentation, consistent with an 
inhibition of Rab7 activity. Interestingly, this study also used an in vitro GEF 
assay, whereby a fluorescent GDP analog MANT-GDP is lost from Ypt7 upon 
incubation with the GEF, to show that Mon1-Ccz1 was indeed the GEF for Ypt7, 
while neither Vps39 nor the HOPS complex were active in the assay 
(Nordmann et al., 2010). This same group showed in a later study that the 
Mon1-Ccz1 GEF activity for Ypt7 was highly stimulated by the presence of PI3P, 
a major component of cellular membranes, which both Mon1 and Ccz1 could 
also bind individually (Cabrera et al., 2014). Poteryaev et al. showed that the 
loss of Rab5 from early endosomes and the acquisition of Rab7 are controlled 
by SAND-1/Mon1, while knockdown of Mon1a/b causes an accumulation of 
enlarged early endosomes in mammalian (HeLa) cells (Poteryaev et al., 2010). 
They also showed that Mon1a/b overexpression in HeLa cells caused a 
redistribution of Rabex5 to smaller vesicles and an increase in cytosolic Rab5. 
They concluded that SAND-1/Mon1 acts as a switch to control the localization 
of Rab5 and Rab7 GEFs. However, this group were basing their findings on the 
belief that the HOPS complex was the GEF for Rab7, while more recent data 
indicates that it is actually Mon1 itself (Cabrera et al., 2014). Thus, SAND-1 
may regulate the Rab5-Rab7 conversion, while Mon1 simultaneously acts as 
the GEF for Rab7. 
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1.4.6 Rab7 and its protein interactions in the dynamics of late 
endosomes and lysosomes 
RILP was first identified as a Rab7 interactor in a yeast two-hybrid screen using 
the constitutively active Rab7Q67L to identify specific interactors of GTP-Rab7. 
Its binding to Rab7 occurs through the C-terminal domain of RILP and the 
expression of a truncated form lacking the N-terminal domain results in 
dispersal of late endosome/lysosomes similar to overexpressing dominant-
negative Rab7 (Cantalupo et al., 2001). This was subsequently shown to be 
caused by the fact that the N-terminal domain of RILP interacts with the 
p150(Glued) subunit of the dynactin complex and drives the recruitment of the 
dynein-dynactin motor to late endosomes (Jordens et al., 2001). It was shown 
from the crystal structure of the Rab7-RILP interaction that the Rab7-binding 
domain of RILP forms a coiled-coil homodimer that interacts with two separate 
GTP-bound Rab7 molecules, resulting in a complex of Rab7-RILP-RILP-Rab7 
(Wu et al., 2005).  
 
While the Rab7-RILP complex is sufficient to recruit p150(Glued), it is not 
sufficient to drive microtubule minus-end directed transport. The complex must 
also recruit oxysterol-binding protein (OSBP)–related protein 1L (ORP1L) and 
βIII spectrin (Rocha et al., 2009). ORP1L contains three major domains, a 
pleckstrin homology (PH) domain that binds phosphoinositides, a FFAT (two 
phenylalanines [FF] in an acidic tract) motif that binds various proteins, and a C-
terminal OSBP-related domain (ORD) that binds cholesterol. The FFAT motif of 
ORP1L also binds VAMP (vesicle-associated membrane protein)-associated 
ER protein (VAP)-A and VAP-B, which are involved in the ER export of proteins 
and lipids (Rocha et al., 2009). It was originally believed that ORP1L was a 
cholesterol sensor that bound to VAP-A or VAP-B on the ER membrane, 
resulting in the removal of p150(Glued) to allow for binding of kinesin motors 
and transport in the opposite direction. However, Vihervaara et al. showed that 
ORL1L also binds several oxysterols and cholesterols, with the overexpression 
of a sterol binding-deficient mutant of ORP1L causing scattering of late 
endosomes/lysosomes, while still colocalising with Rab7 (Vihervaara et al., 
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2011). In contrast to this, overexpression of ORP1L causes perinuclear 
aggregation of late endosomes/lysosomes. This study also revealed that 
ORP1L is capable of recruiting both p150(Glued) and KIF3A for dynein- and 
kinesin-mediated transport. Overexpression of the sterol binding-deficient 
ORP1L mutant recruited both p150(Glued) and KIF3A to late endosome, 
whereas these proteins were mostly cytosolic in untransfected cells. Thus, 
binding of ORP1L to Rab7 appears to be the major factor determining transport 
of late endosome/lysosomes, with the recruitment of other factors possibly 
influencing the choice of direction and/or the efficiency of the transport process 
by influencing the processivity of the motor complexes. 
 
Furthermore, although the role of RILP in transport and recruitment of 
p150(Glued) and the dynein motor may not be as important as previously 
believed, it may be involved in regulating other important functions. Most 
recently, RILP was shown to interact with the V-ATPase, by regulating 
recruitment of its V1G1 subunit to the late endosomal/lysosomal membrane, 
while also regulating the proteasomal degradation of ubiquitinated V1G1; 
however, this only appears to occur upon overexpression of RILP and not Rab7 
(De Luca et al., 2014). Furthermore, they showed that RILP can bind both 
p150(Glued) and V1G1 in the same complex in vitro. Thus, RILP could stabilise 
the V-ATPase on the membrane during transport of late endosomes/lysosomes 
towards the MTOC to help promote acidification of these vesicles.  
 
Interestingly, RILP is also an effector of Rab34 and Rab36, two highly similar 
Rabs (56% amino acid identity) located on the Golgi, who are responsible for 
the correct positioning of late endosomes and lysosomes. Expression of the 
constitutively active forms of Rab34 or Rab36 causes the perinuclear 
aggregation of late endosomes/lysosomes, whereas the dominant-negative 
forms are cytosolic and have not effect on late endosome/lysosome distribution 
(Chen et al., 2010; Wang and Hong, 2002). Both of these proteins could serve 
as tethering factors between late endosomes/lysosomes and the Golgi allowing 
for the recruitment of factors for cargo sorting and exchange.  
Chapter 1. Introduction 
 34 
1.5 Rab7 in axonal retrograde transport 
Another important function of Rab7 is in sustaining axonal retrograde transport 
of motor and sensory neurons(Deinhardt et al., 2006)(Deinhardt et al., 
2006)(Deinhardt et al., 2006). Intracellular transport of proteins and organelles 
is more important in neurons than any other cell in the body, as proteins 
synthesised in the cell body need to transported over long distances, 
sometimes over 1 metre, to the distal parts of the axon or dendrites. Axonal 
retrograde transport is essential for the transport of signalling molecules, 
including members of the neurotrophin family: nerve growth factor (NGF), brain-
derived neurotrophic factor (BDNF), neurotrophin (NT)-3 and NT-4/5; and their 
receptors, the tropomyosin-related kinases TrkA, TrkB, and TrkC, and the p75 
neurotrophin receptor (p75NTR), over long distances from distal sites to the 
soma where they relay signals for survival and growth Figure 1.4). Deinhardt et 
al. showed that TrkB, p75NTR, and their ligand BDNF all travel together in the 
same compartment as the binding fragment of tetanus toxin (HCT), which is just 
one example of how pathogens can highjack the normal transport pathways of 
a cell during infection. The transport of these ‘axonal signalling endosomes’ is 
controlled by the sequential action of Rab5 and Rab7. Rab5 is involved in the 
early sorting step, whereas Rab7 is crucial for the transport of fast retrograde 
carriers (Deinhardt et al., 2006). Expression of the dominant-negative GFP-
Rab5N133I in motor neurons completely abolished HCT retrograde transport, but 
did not inhibit internalisation, indicating that Rab5 is essential for the early 
sorting steps prior to retrograde transport. In contrast, expression of the 
constitutive-active GFP-Rab7Q67L gave a similar profile as the wild-type, 
whereas the dominant-negative GFP-Rab7N125I completely blocked HCT, p75NTR, 
and TrkB transport, without affecting mitochondrial morphology or dynamics, 
indicating that this inhibition was specific to a subset of transport carriers 
(Deinhardt et al., 2006). 
 
Following this, another study showed that Rab7 interacts with TrkA to regulate 
signalling and neurite outgrowth (Saxena et al., 2005). Expression of dominant-
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negative Rab7T22N resulted in significantly enhanced neurite outgrowth in PC12 
cells following stimulation with NGF, the ligand of TrkA.  
 
 
 
Figure 1.4. Axonal transport pathways. 
Cargo internalised at distal sites in neurons must be trafficked to the cell body over 
long distances. Rab7 is required for the dynein-mediated retrograde transport of 
signalling endosomes, known to contain growth factor receptors and their ligands, 
including TrkA, NGF and p75NTR.  
 
Interestingly, TrkA has also been shown to phosphorylate dynein intermediate 
chain (DIC) 1B on serine (Ser) 80, for the recruitment of cytoplasmic dynein and 
the axonal retrograde transport of signalling endosomes (Mitchell et al., 2012). 
This phosphorylation did not affect transport of recruitment of dynein to 
mitochondria, indicating that this was specific for the transport of signalling 
endosomes to promote neuron survival. These results were interesting as it had 
been previously indicated that phosphorylation of dynein subunits inhibited its 
recruitment to membrane-bound organelles. Thus, phosphorylation may be a 
mechanism of promoting interaction with recruitment factors specific to certain 
organelles, thus providing an organelle-specific mechanism of recruiting 
transport machinery.  
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1.6 Rab7 in disease 
1.6.1 Charcot-Marie Tooth type 2B & other neurological disorders 
Charcot-Marie-Tooth type 2B (CMT2B) is a common inherited peripheral 
neuropathy, characterized by sensory loss, with distal muscle weakness and 
wasting. A direct link between Rab7 and CMT2B was established with the 
identification of four missense mutations, L129F, V162M, N161T, and K157N, in 
four different families with this hereditary sensory neuropathy (Verhoeven et al., 
2003; Zhang et al., 2013). Follow-up studies have investigated the differences 
in activities of these mutant forms of Rab7, where they observed higher 
nucleotide exchange rates and slower GTP hydrolysis than wild-type Rab7 
(Spinosa et al., 2008). However, this mechanism is not completely agreed upon. 
A crystal structure of the GTP-bound Rab7L129F suggested an alteration in the 
nucleotide-binding pocket that would affect GTP-binding (McCray et al., 2010). 
They also showed by biochemical analyses that the Rab7L129F did not have an 
intrinsic GTPase defect, but allowed for unregulated nucleotide exchange 
leading to both excessive activation and hydrolysis-independent inactivation. All 
mutations were also shown to exhibit a marked inhibition of neurite outgrowth in 
PC12 and Neuro2A cells. Although the exact mechanism behind the 
neurodegeneration in CMT2B is not know, it has been shown that the four 
known mutations all exhibit faster axonal anterograde transport, without 
increasing the speed of retrograde movements, in dorsal root ganglion (DRG) 
neurons (Zhang et al., 2013). Furthermore, this study also showed that TrkA 
transport was suppressed in both directions, while also reducing surface levels 
of TrkA, and inhibiting NGF binding and internalization. CMT2B Rab7 mutants 
inhibit NGF-induced differentiation in PC12M cells and cause axonal 
degeneration in DRG neurons, based on retraction of neurons by approximately 
80%, three days after transfection with CMT2B mutants (Zhang et al., 2013).  
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Rab7 has also been shown to interact with peripherin, a 57 kDa type III 
neuronal intermediate filament protein, primarily expressed in peripheral 
neurons and CNS neurons that project towards peripheral structures. This 
interaction is inhibited in CMT2B. Interestingly, a frameshift deletion and a 
neurotoxic splice variant of peripherin have also been discovered in 
amyotrophic lateral sclerosis (ALS), a common, neurodegenerative disorder 
characterized by degeneration of motor neurons in the cortex, brainstem, and 
spinal cord, leading to progressive muscle weakness, atrophy, and ultimately 
paralysis and death, usually within 3–5 years of disease onset. Most cases of 
ALS are sporadic; however, approximately 10% are familial. Mutations in the 
superoxide dismutase gene (SOD1) gene have been the most well-
characterised, with the SOD1G93A mouse being commonly used as a model for 
the investigation of mechanisms and potential therapies. Bilsland et al. that the 
SOD1G93A mouse exhibits slower retrograde transport compared with its wild-
type counterpart at an early pre-symptomatic stage, with no decrease in KIF5A-
mediated anterograde transport (Bilsland et al., 2010). The exact mechanism 
how mutant SOD1 affects axonal transport is not yet understood, but it is known 
that it affects transport of specific cargoes differently. For example, a common 
pathological finding of ALS is the accumulation of neurofilaments in the cell 
body as a result of a defect in its anterograde transport, whereas fast transport 
vesicles exhibit defects in both directions, and mitochondria exhibit defects in 
anterograde only (De Vos et al., 2008).  
 
Defects in endocytic transport resulting in the accumulation of organelles and 
proteins in axons and cell bodies have also been implicated in a number of 
other neurological disorders, including frontotemporal lobar degeneration, 
Alzheimer’s, Huntington’s, and Parkinson’s disease (De Vos et al., 2008). In 
Alzheimer's disease, the presence of neurofibrillary tangles containing paired 
helical filaments, which are assembled from hyperphosphorylated tau, is a 
common hallmark of the disease. The other major hallmark is the presence of 
amyloid plaques, which are areas of degenerating neurites surrounding a core 
of amyloid-β peptide, which is produced by proteolytic cleavage of the amyloid 
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precursor protein (APP) (De Vos et al., 2008). Mutations in the tau and APP 
gene have been associated with familial forms of Alzheimer’s. Furthermore, 
defects in axonal transport have been shown to be an early pathological feature 
in animal models, while amyloid-β peptide has been shown to disrupt transport 
of a variety of cargoes, including mitochondria, possibly even damaging them 
(Manczak et al., 2006). Mutant huntingtin may also damage axonal transport, as 
huntingtin has been shown to interact with huntingtin-associated protein 1 
(HAP1), which interacts with kinesin light chain 1 (KLC1) and p150(Glued). In 
addition, Smith et al. found changes in the levels of proteins associated with 
axonal transport and microtubules, including kinesin family member 3A (KIF3A), 
dynein and dynactin, in the striatum, motor cortex, prefrontal cortex and 
hippocampus in a mouse model of Huntington’s disease in the early stages of 
onset (6 months) (Smith et al., 2014). This was associated with neuronal 
degeneration and dense mutant huntingtin inclusion formation, along with 
decreased striatal dopamine levels and loss of striatal BDNF, indicating a defect 
in axonal transport.  
 
Parkinson’s disease is characterised by the presence of Lewy Bodies, which 
are cytoplasmic accumulations of proteins in neurons. Interestingly, α-synuclein 
is one of the main proteins that accumulate in Lewy Bodies. It is a long-lived 
protein that is degraded by the lysosome, through chaperone-mediated 
autophagy, and its upregulation is a cause of autosomal dominant Parkinson’s 
disease. Furthermore, mutant forms of α-synuclein involved in the 
pathogeneisis of Parkinson’s disease have been shown to inhibit its 
degradation, resulting in accumulation and neurotoxicity. Interestingly, the 
brains of Parkinson’s disease patients have also been shown to have reduced 
numbers of lysosomes, characterised by decreased lysosomes-associated 
membrane protein (LAMP)1- and LAMP2-positive vesicles (Chu et al., 2009). 
This indicates that both axonal transport and lysosomal dysfunction are 
impaired in a number of neurological disorders, with Rab7 being an essential 
regulator of both. 
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1.6.2  Rab7 in autophagy & infection 
The endocytic and autophagic pathways are both membrane trafficking 
pathways that are crucial for cell survival, and Rab7 plays a crucial role in both. 
Autophagy is a catabolic process that involves the formation of double-
membrane vesicles, called autophagosomes, which surround and engulf 
cytosolic components, following which they fuses with lysosomes for 
degradation. This results in the generation of nutrients, from the recycling of 
damaged organelles, mitochondria, and proteins back into the cell to maintain 
cellular homeostasis. Under normal conditions, the cell energy sensor AMP-
activated protein kinase (AMPK), and the cell growth regulator mammalian 
target of rapamycin (mTOR), are key players in the regulation of autophagy. 
Under conditions of stress, AMPK is activated, subsequently inhibiting mTOR, 
which leads to phosphorylation and activation of the unc-51-like kinase (ULK) 
complex and, consequently, the rapid induction of autophagy. The ULK 
complex is one of the key regulators of the initial steps in the formation of the 
autophagosome. Under periods of stress, such as amino acid starvation, 
hypoxia, oxidative stress, and infection, autophagy can be significantly 
upregulated. Fusion of the autophagosomes with the lysosome is a key process 
in autophagy induced by many mechanisms, and Rab7 is a key regulator of this 
process (Lin and Zhong, 2011).  
 
Approximately 30 autophagy-related (Atg) proteins were identified in yeast that 
are essential for autophagosome biogenesis, most of which function in the 
initiation steps. PI3P is also extremely important in autophagosome biogenesis 
and it recruits and activates proteins with FYVE and PX (Phox) domains. Pankiv 
et al., identified FYCO1 (FYVE and coiled-coil [CC] domain containing 1) as a 
LC3-, Rab7-, and PI3P-interacting protein, which is required for the transport of 
autophagosomes in the microtubule plus-end direction (Pankiv et al., 2010). 
This study also showed that overexpression of FYCO1 was shown to 
redistribute LC3- and Rab7-positive vesicles to the periphery in a microtubule-
dependent manner. It is still unknown if FYCO1 also plays a role in the transport 
of late endosomes and lysosomes. 
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Autophagy is the cells first line of defence against a number of invading 
pathogens, such as Group A Streptococcus (GAS) and Salmonella (Wild et al., 
2011). Invading bacteria enter non-phagocytic cells by pathogen-induced 
endocytosis. Maturation of these endocytic vesicles will eventually lead to 
fusion with the lysosome and degradation of the bacteria. Thus, numerous 
bacteria have evolved mechanisms to avoid this process. Streptococcus can 
escape into the cytosol, where they are engulfed by GAS-containing 
autophagosome-like vacuoles (GcAVs). These GcAVs can be up to 10-fold the 
size of normal autophagosomes and their formation requires Rab7, which is not 
normally involved at such an early stage in the formation of autophagosomes. 
In contrast, upon infection with Salmonella most of the bacteria survive and 
proliferate within a phagosome-like organelle, known as the Salmonella-
containing vacuole (SCV). However, some are released into the cytoplasm 
upon entry and damage to the SCV membrane. The cytosolic bacteria are 
rapidly ubiquitinated and recognised by at least three autophagy receptors, p62, 
NDP52, and optineurin (OPTN), resulting in their clearance by autophagy. Loss 
of either one of these receptors results in hyperproliferation of Salmonella within 
the cytosol (Wild et al., 2011). In contrast, SCVs form tubular structures by 
recruiting Arl8B for kinesin-mediated elongation in Salmonella-induced 
filaments (Sifs), which somehow inhibit fusion with the lysosome (Kaniuk et al., 
2011). These Sifs subsequently migrate to the cell periphery to fuse with the 
membrane infect neighbouring cells. Interestingly, Rab7 and Arl8 are both 
required for the tubulation of lysosomes in macrophages following their 
activation by bacterial lipopolysaccharide (LPS). Furthermore, the class II major 
histocompatibility complex compartment, a lysosome-related organelle, of 
dendritic cells also requires Rab7 and Arl8 for the formation of a tubular network 
following their activation (Mrakovic et al., 2012). 
 
Rab7 and a number of autophagy proteins, including Atg5, Atg7, Atg4B and 
LC3, also play an important role in osteoclastic bone resorption. Osteoclasts 
degrade bone via the action of secretory lysosomes, which deliver lysosomal 
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hydrolases and hydrochloric acid into the extracellular resorptive area. This 
secretion occurs in ruffled borders, which is also the same region where 
resorption occurs. It was previously found that the localisation of Rab7 to these 
ruffled borders is Atg5-dependent, and efficient secretion required Atg5, Atg7, 
and Atg4B/LC3 (DeSelm et al., 2011). 
 
Mycobacterium tuberculosis is responsible for the most deadly bacterial disease 
in history, tuberculosis. Worldwide, millions of people are latently infected with 
M. tuberculosis, with the number of people with active disease in the millions. A 
large proportion of HIV-infected individuals are also infected with M. 
tuberculosis, with the combination of tuberculosis and AIDS being recognised 
as a global health emergency by the World Health Organisation (WHO). M. 
tuberculosis infects cells by phagocytosis and can infect and survive in 
macrophages by inhibiting fusion of the phagosome with the lysosome. Seto et 
al. showed that Rab7 is transiently recruited to M. tuberculosis phagosome, 
where it recruits cathepsin D, lysosomal protease (Seto et al., 2009). They 
showed that at 30 min approximately 80% of phagosomes are Rab7-positive, 
whereas at 6 h it is absent from most. This is in contrast to Staphylococcus 
aureus, which localises to approximately 80% of phagosomes at 6 h. This 
indicates that Rab7 is actively removed from M. tuberculosis phagosomes (Seto 
et al., 2009). Interestingly, the interaction between Rab7 and RILP is also 
disrupted in M. tuberculosis infected cells, which could contribute to the 
inhibition of acidification via the recent findings of RILP effects on the V-ATPase. 
Furthermore, it has been shown that the induction of autophagy in infected 
macrophages by starvation, or treatment with rapamycin or interferon (IFN)-γ, 
resulted in acidification of phagosomes and fusion with the lysosomes to inhibit 
bacterial survival (Gutierrez et al., 2004).  
 
Human immunodeficiency virus (HIV) has the ability to cause a chronic disease 
that can lead to the more progressive autoimmune disorder syndrome (AIDS). 
To do this, HIV must evade the immune system of infected individuals. HIV 
encodes a protein Nef that has the ability to downregulate the levels of a 
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number of important surface molecules, such as the MHC-I and MHC II on 
antigen-presenting cells (APCs) and target cells, and CD4 and CD28 on helper 
T cells. Schaefer et al. showed that Nef binds CD4 and removes it from the cell 
surface of T cells, while also inhibiting MHC-I transport from the TGN to the 
plasma membrane (Schaefer et al., 2008). Furthermore, they showed that the 
Nef-interacting protein, β-COP, targets CD4 and MHC-I to Rab7-positive 
vesicles for lysosomal degradation. This process is highly efficient with 94% of 
CD4-positive vesicles being also positive for Rab7. HIV has also been show to 
colocalise and replicate in early autophagosomes, while Nef also interacts with 
Beclin-1, an essential autophagic factor, to inhibit their maturation and fusion 
with lysosomes in macrophages (Kyei et al., 2009). 
 
1.6.3  Rab7 implications in cancer 
With the importance of the endocytic pathway in controlling cell signalling 
pathways that govern proliferation, differentiation and survival, it is no surprise 
that defects in this pathway have been implicated in numerous types of cancer. 
Rab7 has been linked to melanoma (Alonso-Curbelo et al., 2014), breast (Wang 
et al., 2012), prostate (Steffan et al., 2014), and lung (Steffan et al., 2014) 
cancers, with an increasing number of publications in recent years. Indeed, 
EGFR signalling is tightly controlled by the endocytic pathway, by both the 
recycling and degradative routes. Both EGFR and human epidermal growth 
factor receptor 2 (HER2), are frequently overexpressed or activated by 
mutations in lung and breast cancers and promote cancer cell survival by 
activating PI3K/Akt signalling. Approximately 20-25% of breast cancers 
overexpress HER2, which when activated, stimulates cell proliferation and 
inhibits apoptosis. Using short-hairpin RNA (shRNA)-mediated knockdown of 
Rab7 in several breast cancer tumour cells lines, Wang et al. found that 
inhibition of HSP90 reduced the level of EGFR and Her2, and promoted 
apoptosis in Rab7 knocked-down cells but had no effect in control cells (Wang 
et al., 2012). Thus, Rab7 appears to stabilise EGFR-Her2 to sustain Akt 
survival signalling in breast cancer cells. This is a surprising finding, as Rab7 is 
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involved in the degradation of EGFR, whereas in these breast cancers this does 
not appear to be occurring indicating they have possibly evolved to bypass 
lysosomal degradation.  
 
Many cancers deregulate proliferation and differentiation-related genes to drive 
invasion and metastasis. However, some studies believe that cancers can 
hijack lineage-specification genes to promote malignancy, and this is why some 
genes are involved in only certain types of tumours. Alonso-Curbelo et al. 
examined human cells, clinical specimens, and mouse models to look for 
melanoma-enriched genes. They found a lysosomal cluster of genes, and 
examined the role of Rab7 in this type of cancer. They found that inhibition of 
Rab7 reduced tumour cell proliferation and colony formation, whereas it 
increased cell motility and invasiveness. They also showed that melanoma cells 
had a significantly higher level of Rab7 expression compared with normal 
surrounding skin, and that its activity was regulated by the oncogenic 
transcription factor Myc and an early melanocytic lineage specification 
transcription factor, Sox10 (Alonso-Curbelo et al., 2014).  
 
The increased invasiveness of tumour cells following the downregulation of 
Rab7 was also seen in prostate cancer invasion (Steffan et al., 2014). The 
same group had previously shown that the distribution of lysosomes in a tumour 
cell correlate with invasiveness, with less invasive cells having lysosomes 
clustered in the perinuclear region and more invasive cells having lysosomes 
near the periphery. Invasive cells secrete lysosomal enzymes into the 
extracellular space to facilitate invasion by decreasing cell-cell adhesion. Stefan 
et al. proposed that Rab7 is a potential tumour suppressor in vivo, as shRNA 
expressing cells formed larger tumours in vivo (Steffan et al., 2014). These 
tumours were associated with increased proliferation, decreased apoptosis, and 
increased invasiveness. Rab7 shRNA tumours also exhibited an upregulation of 
the proto-oncogene c-Met, which could lead to increased oncogenesis. 
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1.7 Rab7 Regulation by Phosphorylation 
One of the main mechanisms of protein regulation by post-translational 
modification is through phosphorylation at serine (S), threonine (T) or tyrosine 
(Y) residues. The human kinome contains 518 kinases, most of which are either 
serine/threonine or tyrosine kinases, while a select few phosphorylate both. 
Numerous Rab proteins have been previously reported as being 
phosphorylated at different residues, including Rab4 (van der Sluijs et al., 1992), 
Rab24 (Ding et al., 2003), Rab3, Rab6, Rab8 (Karniguian et al., 1993) and 
Rab5a (Ong et al., 2014). Most recently, Rab5a was shown to be 
phosphorylated by PKCε on its Thr7 residue in response to integrin or 
chemokine stimulation, in a process that results in Rac1 activation, actin 
rearrangement, and T-cell motility (Ong et al., 2014). In another study, Rab3b, 
Rab6 and Rab8 were all shown to be phosphorylated following thrombin-
induced activation of human platelets, which leads to the secretion of the 
dense- and α-granule contents (Karniguian et al., 1993). Both Rab6 and Rab8 
proteins were preferentially targeted to the plasma membrane and the α-
granules, whereas Rab3b was mainly cytosolic. Rab4 was also found to be 
phosphorylated by p34cdc2 kinase on S196 during mitosis, which regulates its 
cycling between the membrane and cytoplasm, as the phosphodeficient 
Rab4S196A, mutant preferentially localised to membranes (van der Sluijs et al., 
1992). Thus, phosphorylation appears to play diverse role in regulating the 
GTPase activity and/or interaction with effectors, GAPs or GEFs for different 
Rab proteins. 
 
Rab7 has been previously identified in a number of phosphoproteomic screens 
as being phosphorylated on 11 different sites, S17, Y37, T40, S72, S101, T168, 
T178, Y183, S201, S204 and S206, with S72 and Y183 being detected in 
significantly more screens that any other position. Phosphorylation of Rab7 at 
S72 was identified 22 independent screens, covering a diverse range of cellular 
processes and signalling pathways, including basal conditions in numerous 
tissues throughout the body, such as the liver, brain, lung, pancreas, spleen 
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and testis (Huttlin et al., 2010; Villen et al., 2007). Although phosphorylation of 
Rab7 at S72 has been identified in numerous screens, there are no publications 
to date that have investigated this mechanism further. 
 
Mayya et al. performed a phosphoproteomic screen to identify proteins that 
were phosphorylated in response to T cell receptor (TCR) stimulation human 
Jurkat T cell leukaemia cells (Mayya et al., 2009). The found that the proteins 
identified were involved in processes controlling endocytosis of the TCR, F-
actin cup formation, integrin activation, microtubule polarization, cytokine 
production, and alternative splicing of mRNA, all of which are associated with 
TCR signalling. For example, the polarisation of microtubules towards antigen-
presenting cells occurs following TCR activation to facilitate exocytosis of 
effector proteins, and they found that tubulin was phosphorylated during this 
process on six different serine residues. Rab7 phosphorylation also increased 
following TCR activation, but this was not examined as it was below the 
threshold. Interestingly, Rab7 knockout T cells show deceased proliferation in 
response to TCR activation, It has been suggested that this may be the result of 
increased reactive oxygen species (ROS) generation secondary to mitophagy 
or through an inhibition of autophagy, which may be upregulated following TCR 
activation to generate energy from internal stores (Roy et al., 2013). 
 
Increased phosphorylation of Rab7 at S72 was also detected in 
lipopolysaccharide (LPS)-stimulated macrophages (Weintz et al., 2010). LPS 
stimulates Toll-like receptor (TLR)4 on the plasma membrane, which is 
internalised by clathrin-mediated endocytosis, and undergoes ubiquitin-
mediated lysosomal degradation (Husebye et al., 2006). Furthermore, 
trafficking of TLR4 via the degradative pathway, which is highly dependent on 
Rab7, is required for signal termination and LPS-associated antigen 
presentation. In the results of the phosphoproteomic screen, the authors also 
noted that the annotation term ‘Rho GTPase cycle’ was significantly enriched 
for LPS regulated phosphoproteins, along with the term ‘cytoskeletal’ (Weintz 
et al., 2010). TLR4 also induces activation of mTOR, which is interesting as 
Chapter 1. Introduction 
 46 
increased phosphorylation of Rab7 at S72 was also detected in two 
independent phosphoproteomic screens using insulin to active mTORC1 (Hsu 
et al., 2011; Yu et al., 2011). This is also interesting, as it has been previously 
shown that inhibition of endosomal maturation by overexpression of 
constitutively active Rab5 or knockdown of the Rab7 effector Vps39 inhibits 
activation of mTORC1/S6K1 by insulin- or amino acid-stimulation (Flinn et al., 
2010). 
 
Two independent phosphoproteomic screens also detected increased levels of 
phosphorylation of Rab7 at S72 during mitosis (Dephoure et al., 2008; Olsen et 
al., 2010). Both groups used stable isotope labeling of amino acids in cell 
culture (SILAC) to examine changes in phosphorylation between cells arrest in 
G1 phase by double-thymidine and M phase by nocodolzole. Both screens 
identified phosphorylation at S72 during the G1 phase, but not in the M phase. 
Interestingly, it has been shown that endosomal fusion is inhibited during 
mitosis, and one of the mechanisms by which it is inhibited is the 
phosphorylation of vimentin, a class III intermediate filament protein, on S459 
by Polo-like kinase 1 (Plk1) (Ikawa et al., 2014). Another study also found that 
Rab7 directly interacts with vimentin, resulting in increased phosphorylation of 
vimentin and inhibition of its assembly into filaments (Cogli et al., 2013). 
Furthermore, Rab11 has been shown to regulate dynein-dependent endosome 
localization at the mitotic spindle, and its depletion delays mitosis, causing 
disruption of astral microtubules and redistribution of spindle pole proteins 
(Hehnly and Doxsey, 2014). In addition, phosphorylation of Rab7 at S72 has 
also been detected in the DNA damage response after ionizing radiation, which 
causes massive changes in cellular pathways including DNA replication, cell 
cycle progression, and gene expression (Bennetzen et al., 2010). These results 
indicate that endosomal transport undergoes big changes during the cell cycle, 
which may be mediated by phosphorylation of different Rabs, such as Rab7. 
 
Most recently, phosphorylation of Rab7 at S72 was detected in a screen 
investigating the role of TANK-binding kinase 1 (TBK1)-induced 
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phosphorylation in lung cancer cells (Kim et al., 2013). TBK1 is a potential 
therapeutic target for a subset of lung cancers cells, as it appears to promote 
prosurvival signalling through the activation of nuclear factor-κB (NF-κB) and 
AKT signalling pathways. This study also identified Plk1 as a target of TBK1 
phosphorylation during mitosis, as knockdown of TBK1 decreased mitotic 
phosphorylation of Plk1. Thus, TBK1 may be a regulator of mitosis through Plk1, 
indicating that it may also regulate endosomal dynamics during the cell cycle.  
 
From these studies, phosphorylation of Rab7 at S72 occurs during multiple 
regulatory events, and can be induced by various stimulations. From the results 
of studies investigating other Rab proteins, it is difficult to hypothesise exactly 
what effect this may have of Rab7 activity, as for other Rabs, phosphorylation 
appears to have different effects for different members. Thus, the aim of this 
thesis was to examine the effect S72 phosphorylation has on Rab7 activity and 
determine the cellular mechanisms responsible for this process. 
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Chapter 2. Materials & Methods 
2.1 Materials 
2.1.1 Reagents 
Laboratory reagents were purchased from the following companies, unless 
otherwise stated: Biorad, Calbiochem, Clontech, Fisher Scientific, GE 
Healthcare, Gibco, Life Technologies, Millipore, Qiagen, Sigma, Thermo 
Scientific. Distilled water (dH2O), phosphate-buffered saline (PBS), tris-buffered 
saline (TBS), glutamine, Lurai Bertani (LB) broth, 2YT broth, Super Optimal 
broth with Catabolite repression (SOC) medium, ethylenediaminetetraacetic 
acid (EDTA; pH 7.5, 8.0, 9.5), trypsin, versene, Hank’s balanced salt solution 
(HBSS), and penicillin/streptomycin were provided by Cancer Research UK. 
 
2.1.2 Cells lines 
HEK293 cells and SV40-immortalised mouse embryonic fibroblasts (MEFs) 
were a gift from Sharon Tooze (Secretory Pathways, Cancer Research UK 
London Research Institute, London, UK). 
 
2.1.3 Bacteria 
Escherichia coli strain XL1-Blue was used for DNA amplification, and strain BL-
21 was used for protein expression. 
 
2.1.4 Vectors & expression plasmids 
pEGFP-Rab7 and pcDNA3.1-HA-Rab7, containing the canine sequence of 
Rab7, and pGFP-RILP were gifts from Cecilia Bucci (Università del Salento, 
Department of Biological and Environmental Sciences and Technologies 
(DiSTeBA), Italy); Raichu-Rab7-A441 was a gift from Takeshi Nakamura (Tokyo 
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University of Science, Research Institute for Biomedical Sciences, Japan); and 
pEGFP-ORP1L was a gift from Vesa Olkkonen. 
2.1.5 Primers 
The following primers were used for site-directed mutagenesis of the pEGFP-
Rab7, pcDNA3.1-HA-Rab7 and Raichu-Rab7-A441 plasmids: 
 
Table 2.1. Site-directed mutagenesis primers. 
 
Primer Direction Sequence 
S72A Forward CAGGAACGGTTCCAGGCCCTTGGTGTGGCCT 
S72A Reverse AGGCCACACCAAGGGCCTGGAACCGTTCCTG 
S72E Forward CAGGAACGGTTCCAGGAACTTGGTGTGGCCT 
S72E Reverse AGGCCACACCAAGGTTCTGGAACCGTTCCTG 
S72P Forward CAGGAACGGTTCCAGCCCCTTGGTGTGGCCT 
S72P Reverse AGGCCACACCAAGGGGCTGGAACCGTTCCTG 
 
 
The following primers were used for genotyping the Rab7S72P mice: 
 
Table 2.2. Genotyping primers. 
 
Primer Direction Sequence 
Wild-type Forward CCGGTCAAGAACGGTTCCAGT 
S72P  Forward CCGGTCAAGAACGGTTCCAGC 
Both Reverse ACGACAACGACGCCCACCTG 
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The following primers were used for sequencing the pEGFP, pcDNA3.1, and 
pGEX-4T2 plasmids: 
 
Table 2.3. Sequencing primers. 
 
Primer Direction Sequence 
EGFP Forward CATGGTCCTGCTGGAGTTCGTG 
EGFP Forward CAGTCCGCCCTGAGCAAAGAC 
SP6 Forward ATTTAGGTGACACTATAG 
T7 Forward GTAATACGACTCACTATAGGGC 
T7 Forward TAATACGACTCACTATAGGG 
pGEX Forward GTGGCAAGCCACGTTTGGTG 
pGEX Reverse GGAGCTGCATGTGTCAGAGG 
 
2.1.6 Antibodies 
Flourescently-conjugated secondary antibodies were from Life Technologies, 
and used at a concentration of 1:500. HRP-conjugated secondary antibodies 
eere from DAKO or GE Healthcare, and used at 1:4000. The primary antibodies 
used are shown in Table 2.4. 
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Table 2.4. Primary antibodies. 
 
Antigen Name Species Supplier Dilution 
Actin clone AC 15 Mouse 
(monoclonal) 
Sigma 1:4000 
WB 
EEA1 610457 Mouse 
(monoclonal) 
BD Transduction 
Laboratories 
1:250 IF 
EGFR DB831 Rabbit 
(monoclonal) 
Cell Signalling 1:1000 
WB 
GAPDH mab374 Mouse 
(monoclonal) 
Millipore 1:4000 
WB 
GFP Cone 4E12/8 Mouse 
(monoclonal) 
Monoclonal antibody 
facility, CRUK 
1:4000 
WB 
HA Clone 3F10 Rat 
(monoclonal) 
Roche 1:1000 
WB 
HA Clone 12CA5 Mouse 
(monoclonal) 
Monoclonal antibody 
facility, CRUK 
1:1000 
WB 
LAMP2 CD107B Mouse 
(monoclonal) 
BD Pharmingen 1:250 IF 
ORP1L  Rabbit 
(polyclonal) 
Gift from Vesa 
Olkkonen 
1:1000 
WB 
phospho-
Rab7(S72) 
 Rabbit 
(polyclonal) 
 1:100 WB 
Rab7 9367S Rabbit 
(monoclonal) 
Cell Signalling 1:100 IF 
Rab11    1:250 IF 
RILP ab54559 Rabbit 
(monoclonal) 
Abcam 1:500 WB 
Vps26  Rabbit Gift from Matthew 
Seaman 
1:250 IF 
WB: western blot, IF: immunofluorescence. 
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2.2 Methods 
2.2.1 Mouse breeding & genotyping 
The Rab7S72P strain were a kind gift from Abraham Acevedo-Arozena (MRC 
Harwell, UK). The mice were generated via N-ethyl-N-nitrosourea (ENU) 
mutagenesis. The colony was maintained by crossing Rab7S72P+/- mice with 
wild-type C57BL/6 mice for over 10 generations.  
 
The extraction of DNA from adult ear snips, or tail and yolk sac from embryos, 
was performed in a 120 µl reaction mixture of Viagen Biotech DirectPCR® tail 
lysis reagent, with 0.1 mg/ml proteinase K, overnight at 55°C in a shaking 
hotblock. The reaction was inactivated at 85°C for 30 min.  
 
Genotyping was performed using MegaMix-Blue (Microzone Ltd.), which a Taq 
polymerase-based PCR mixture. Each reaction contained 15 µl Megamix-Blue, 
2 µl extracted DNA and 1.6 µl of each primer (2 µM stock). 
 
The reaction conditions were as follows:  
1. Initial denaturation    95°C   3 min 
2. Denaturation    95°C   30 s 
3. Annealing     Tm - 5°C 1 min 
4. Extension     72°C   1 min 
5. Repeat steps 2–4   29 times 
6. Final extension   72°C  5 min 
 
2.2.2 Generation of the anti-pRab7(S72) antibody  
A peptide sequence corresponding to the region surrounding the S72 site, 
which is completely conserved in human, mouse, rat, dog, and rabbit, was 
produced by the Peptide Synthesis facility at Cancer Research UK London 
Research Institute, with the S72 site phosphorylated. The peptide was sent to 
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Biogenes GmBH (Berlin, Germany) for immunisation of two rabbits. Pre- and 
post-bleeds were sent for testing of the antibody specificity. 
 
The peptide sequence was as follows: CERFQpSLGVA-CONH2 
 
2.2.3 DNA techniques 
2.2.3.1  Site-directed mutagenesis 
Site-directed mutagenesis of the pEGFP-Rab7, pcDNA3.1-HA-Rab7 and 
Raichu-Rab7-A441 plasmids were performed according to the QuikChange® 
Site-Directed Mutagenesis Kit (Stratagene) protocol. The QuikChange site-
directed mutagenesis method is performed using PfuTurbo® DNA polymerase, 
which replicates both plasmid strands with high fidelity and without displacing 
the mutant oligonucleotide primers. This reduces the chances of amplifying the 
original construct without the mutation. 
 
The reaction mixture contained the following:  
 5 µl    10× reaction buffer  
 5–50 ng   dsDNA template  
 0.5 µM   each oligonucleotide primer 
 200 µM   each deoxynucleoside triphosphate (dNTP) 
 1 µl    PfuTurbo 
 up to 50 µl   ddH2O 
 
A control reaction without the polymerase was also prepared. 
 
The PCR conditions were as follows: 
1. Initial denaturation    95°C   30 s 
2. Denaturation    95°C   30 s 
3. Annealing     55°C  1 min 
4. Extension     68°C   1 min/kb plasmid length 
5. Repeat steps 2–4   16 times 
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Following the PCR reaction, the original plasmid was digested by addition of 1 
µl DpnI restriction enzyme for 2 h at 37°C. DpnI digests methylated DNA from 
dam+ E. coli strains, and will therefore only digest the parental DNA. 2 µl of the 
final reaction mix after DnI digestion was then transformed in E. coli XL1-Blue. 
 
2.2.3.2 Ligation of DNA 
Subcloning of constructs used for site-directed mutagenesis was performed by 
digesting the insert and original vector with the same restriction enzymes and 
ligating overnight with T4 DNA ligase at 16°C, with a vector to insert ratio of 1:5. 
Samples were then transformed in E. coli XL1-Blue and selected for on 
kanamycin or ampicillin agar plates. All newly ligated plasmids were sequenced 
to ensure the correct insert was obtained. 
 
2.2.3.3 Agarose gel electrophoresis 
DNA from all PCR reactions and restriction digest analyses were subjected 
agarose gel electrophoresis in 0.8–2% agarose in TBE buffer (90 mM Tris/HCl, 
90 mM boric acid, 2 mM EDTA pH 8.0), with one drop ethidium bromide per 50 
ml. Gels were run at 80–120V for various time periods, depending on the size of 
the DNA being analysed. 
 
2.2.3.4 DNA extraction from agarose gels 
DNA bands were cut from the agarose gels using a clean scalpel and the DNA 
was extracted using the QIAquick Gel Extraction kit (Qiagen), according to the 
manufacturer’s instructions. The extracted DNA was quantified using a 
Nanodrop® spectrophotometer.  
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2.2.3.5 Plasmid sequencing 
DNA sequencing was performed using BigDye® Terminator Cycle Sequencing 
kit (Applied Biosystems). The reaction was performed using, 200 ng DNA, 3.2 
pmol of primer, 8 µl of BigDye® Terminator, in a reaction volume made to 20 µl 
with dH2O.  
 
The PCR reaction was as follows: 
 
1. Initial denaturation    95°C   2 min 
2. Denaturation    95°C   30 s 
3. Annealing     47°C  15 s 
4. Extension     72°C   4 min 
5. Repeat steps 2–4   25 times 
6. Cooling    12°C   
 
The DNA was purified from the reaction using DyeEx™ 2.0 Spin kit (Qiagen), 
according to the manufacturer’s instructions. Following this, the reaction was 
dried in a speed vacuum and sequenced by the Cancer Research UK 
Sequencing facility. Sequence alignment was performed using ApE software (M. 
Wayne Davis). 
 
2.2.3.6 Bacterial transformation 
Both electro-competent XL1-Blue bacteria and chemically-competent XL1-Blue 
and BL-21 strains of E. coli were used throughout this project. For electro-
competent transformation, 2 µl of the DNA mixture were added to 50 µl bacteria 
for 20 min on ice, prior to electroporating at 2.5 kV. Bacteria were recovered by 
adding 500 µl SOC medium to and incubating at 37°C and 1,000 rpm for 1 h. 
Transformants were then selected by plating on LB agar plates containing, 50 
µg/ml kanamycin or 100 µg/ml ampicillin, depending of the plasmid resistance.  
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For the chemically-competent transformations, 2 µl DNA mixture was mixed 
with 120 µl bacteria in CaCl2 + 20% glycerol for 20 min on ice. Bacteria were 
then heat-shocked for 45 s at 42°C, following which they were cooled on ice for 
1 min. 500 µl of prewarmed SOC medium was then added and bacteria were 
recovered and selected for as above. 
 
2.2.4 Cell culture 
2.2.4.1 Cell culture 
Both HEK293 cells and MEFs were maintained in Dulbecco's Modified Eagle's 
medium (DMEM; Gibco), containing 10% foetal bovine serum (FBS) and 2 mM 
L-glutamine. Cells were passaged when almost confluent at 1:10–20 dilutions, 
by trypsinisation, which was inhibited by addition of normal growth medium 
containing FBS. Medium was changed every 3–4 days. 
 
2.2.4.2 Transfection procedures 
Three different transfection reagents were used throughout this study. Initially, 
FuGENE® 6 (Promega) was used to transfect HEK293 cells, as it transfected 
>70% of cells but at lower levels than Lipofectamine 2000, which can be 
extremely strong. FuGENE® 6 is a nonliposomal reagent that has very low 
toxicity, but it is very poor at transfecting MEFs. Thus, Lipofectamine 2000, 
which can exhibit high toxicity when cells are below 70% confluency, was used 
to transfect MEFs. Thus, FuGENE® 6 was used to transfect HEK293 cells for 
the EGFR degradation assay, and Lipofectamine 2000 was used for all MEF 
experiments. Both transfection mixes were prepared similarly, with a 3:1 ratio of 
transfection reagent (µl) to plasmid (µg) in Opti-MEM® I Reduced Serum Media 
(Life Technologies), which were incubated at room temperature for 20–30 min 
before adding to cells in antibiotic-free DMEM, containing 10% FBS and L-
glutamine. Cells were incubated in the transfection mixture for 24 h, before 
assaying or medium change. 
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2.2.4.3 Poly(I:C) & bacterial lipopolysaccharide stimulation of MEFs 
MEFs were transfected with GFP-Rab7Wt for 48 h, then stimulated with 10 
µg/ml LMW poly(I:C) (Invivogen) or 1 µg/ml LPS from Escherichia (E.) coli strain 
0111:B4 (Sigma) for various time periods. In experiments using BX795 or 
MRT67307, cells were preincubated for 2 h or overnight with 2 µM of each 
inhibitor prior to stimulation. Cells were lysed in RIPA buffer containing HALT™ 
Protease & Phosphatase Inhibitor Cocktail, and incubated with GFP-Trap® 
beads to immunoprecipitate GFP-Rab7 prior to western blotting with the anti-
pRab7(S72) antibody. 
 
2.2.4.4 EGFR degradation assay 
HEK293 cells in 24-well plates were transfected with GFP-Rab7Wt, GFP-
Rab7S72A and GFP-Rab7S72E overnight. The next day, cells were serum-starved 
DMEM containing L-glutamine for 4 h, following which they were stimulated with 
100 ng/ml EGF (Preprotech) at 37°C for 0, 15, 30, 60 and 90 min. Cells were 
lysed in RIPA buffer containing HALT™ Protease & Phosphatase Inhibitor 
Cocktail, and boiled with Laemmli sample buffer for 5 min. Immunoblotting was 
performed with antibodies to EGFR, and actin. 
 
2.2.5 Biochemical techniques 
2.2.5.1 Preparation of cell lysates 
Adherent cells were placed on ice, washed once with ice-cold HBSS and lysed 
using either RIPA (10 mM Tris/HCl pH 7.5 150 mM NaCl, 0.1% SDS, 1% Triton 
X-100, 1% deoxycholate, 5 mM EDTA) or TNTE (20mM Tris pH 7.4, 150 mM 
NaCl, 150 mM EDTA, 5 mM 1% Triton X-100) lysis buffers containing HALT™ 
Protease & Phosphatase Inhibitor Cocktail. Samples were incubated on ice for 
20 min, following which they were centrifuged at maximum speed for 10 min to 
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pellet the nuclear material. The supernatants were removed and placed in fresh 
tubes. Protein concentration was measured by Bradford assay, using Bio-Rad 
Protein Assay Reagent (Bio-Rad). Briefly, 1 µl of each sample was added to 1 
ml of diluted assay reagent (200 µl regent + 800 µl dH2O) and incremental 
dilutions of BSA (1–10 µg/ml) were used as a standard. Samples were 
incubated for 5 min. and then the absorbances were read at 595 nm using a 
spectrophotometer (BioPhotometer, Eppendorf). Concentrations of samples 
were determined from the BSA standard curve. 
 
2.2.5.2 SDS-PAGE 
Laemmli sample buffer (60 mM Tris-Cl pH 6.8, 2% SDS, 10% glycerol, 5% β-
mercaptoethanol, 0.01% bromophenol blue) was prepared as a 5× solution and 
added to protein samples to a minimum final concentration of 2×, or 5× if adding 
to beads for immunoprecipitation or pull-down experiments, and samples were 
boiled for 5 min at 100°C or at 65°C for 10 min for membrane proteins. Samples 
were then loaded in precast 4–12% NuPAGE® gels (Life Technologies), or 12% 
NuPAGE® gels for subcellular fractionation. Proteins were separated at 200 V 
for 60–70 min in MES (2-ethanesulfonic acid) buffer (Life Technologies). 
 
2.2.5.3 Western blot analysis 
Following SDS-PAGE, proteins were transferred to a methanol-activated 
polyvinylidene fluoride (PVDF) membrane in NuPAGE® transfer buffer 
containing 15% methanol for 120 min at 30V. The efficiency of transfer was 
monitored by Ponceau S staining, following which nonspecific binding sites 
were blocked with 5% milk (Marvel) or 5% membrane blocking agent (GE 
Healthcare) for phospho-antibodies for 1 h at room temperature. Membranes 
were then incubated with primary bodies diluted in blocking buffer overnight at 
4ºC, following which they were washed extensively with TBS containing 1% 
Triton X-100 (TBST) and incubated with horseradish peroxidase (HRP)-
conjugated secondary antibodies (1:4000) for 1 h at room temperature. 
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Membranes were then washed extensively with TBST, followed by a brief final 
wash in dH2O. 
 
Immunoreactivity of blots was measured using enhanced chemiluminescence 
(ECL) reagent (GE Healthcare). The intensities of bands on the blots were 
quantified using ImageJ software (National Institutes of Health, USA). 
 
2.2.5.4 Production of recombinant His-Rab7  
E. coli BL-21 transformed with pcDNA3.1-His6-Rab7Wt and pcDNA3.1-His6-
Rab7S72P were grown overnight in 5 ml 2YT containing 100 µg/ml ampicillin. The 
following morning, the 5 mL was added to 200 ml 2YT containing 100 µg/ml 
ampicillin and grown to log phase (OD600nm ~0.6–0.8). 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added to induce protein expression for 4 h. 
Bacteria were harvested by centrifugation at 5,000 rpm for 15 min at 4°C, 
washed in ice-cold PBST, and lysed by passing through a French Press 
machine twice at 1300 psi. Bacterial lysates were then centrifuged at 17,500 
rpm for 25 min at 4°C. The supernatant was then added to a column containing 
1.5 ml Ni2+-agarose resin, pre-equilibrated with buffer containing 50 mM NaxPi 
and 300 mM NaCl (pH 7.8), and placed on a rotator for 2 h at 4°C. The column 
was washed once with 15 ml of high-salt buffer (50 mM NaxPi, 600 mM NaCl, 
pH 7.8) containing 1 mM ATP and 1 mM Mg2+ to remove chaperones, followed 
by a wash with 15 ml 50 mM NaxPi, 300 mM NaCl, 20 mM imidazole, pH 7.8). 
Proteins were eluted with 50 mM Tris pH 7.8, 100 mM NaCl). Concentrations 
were determined using the Bradford assay. Proteins were subjected to SDS-
PAGE on a 4–12% NuPAGE® gels to determine purity of different fractions 
(P1–3), using Coomassie staining method. 
 
2.2.5.5 Production of recombinant GST-Rab7 
E. coli BL-21 transformed with pGEX-4T2-Rab7 were grown overnight in 5 ml 
2YT containing 100 µg/ml ampicillin. The following morning, the 5 mL was 
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added to 200 ml 2YT containing 100 µg/ml ampicillin and grown to log phase 
(OD600nm ~0.6–0.8). 1 mM IPTG was added to induce protein expression for 4 h. 
Bacteria were harvested by centrifugation at 5,000 rpm for 15 min at 4°C, 
washed in ice-cold PBST, and centrifuged again. Bacteria were then 
resuspended in resuspension buffer (0.05% PBST, 2 mM EDTA, 0.1% β-
mercaptoethanol, 1 mM phenylmethylsulfonyl fluoride, 2 µg/ml pepstatin A). 
Bacteria were lysed by sonication at 90% power for 3 × 20 s, and 1 × 40 s. 
Bacterial lysates were then centrifuged at 15,000 rpm for 15 min at 4°C, and the 
supernatant was incubated with 2 ml 50% reduced glutathione (GSH)-agarose 
beads for 2 h at 4°C. The beads were then washed 3 × 10 ml ice-cold PBST, 
then added to a column the bound GST-Rab7 was eluted in 3 × 1 ml elution 
buffer (10 mM GSH, 50 mM Tris/HCl pH 8.0). Proteins were dialysed overnight 
in dialysis buffer (10 mM HEPES-NaOH pH 7.4, 100 mM NaCl) using Slide-A-
Lyzer® Dialysis Cassettes (Thermo Scientific), with a molecular weight cut-off 
of 10,000 kDa. Proteins were subjected to SDS-PAGE on a 4–12% NuPAGE® 
gels to determine purity of different fractions (P1–3), using Coomassie staining 
method.  
 
2.2.5.6 Anti-phospho-Rab7(S72) antibody purification 
Around 4–8 mg of the phosphorylated peptide used for immunisation of the 
rabbits to produce the anti-pRab7(S72) antibody, and the corresponding 
unphosphorylated peptide, which was also produced by the Peptide Synthesis 
Facility, were dissolved 2 ml coupling buffer (50mM Tris/HCl pH 8.5, 5mM 
EDTA). The dissolved peptides were added to 0.5 mL 100% Sulpholink resin 
(Thermo Scientific), which was pre-equilibrated by washing twice with coupling 
buffer using 2 × 1 mL washes. These were placed on a rotator for 60 min to 
bind the peptides. The beads were washed once with 2 mL of wash buffer 1 (50 
mM cysteine-HCL in coupling buffer) and placed on a rotator for 30 min at RT to 
remove non-covalently bound peptide. All procedures after this step were 
performed at 4°C. The supernatant was eluted and the column was washed 
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once with 5 ml dH2O, followed by wash buffer 2 (1M NaCl, 200 µM glycine pH 
2.4), and another wash with 5 ml dH2O.  
 
Samples were routinely taken during the above process to check coupling 
efficiency by Ellman’s method. Briefly, samples were prepared containing 86 µl 
coupling buffer, 4 µl Ellman’s reagent, and 10 µl of each sampling. These were 
incubated at room temperature for 15 min and measured on the Nanodrop at 
410 nm. 
 
The antibody serum was diluted 1:1 with TBS and centrifuged at maximum 
speed for 10 min to pellet any debris. 1 mL was added per column and placed 
on a rotator at 4°C for 2 hrs for the antibody to bind the peptide. The 
supernatant was eluted, which would for the unphosphorylated peptide column, 
should contain serum that has been depleted of unphosphorylated anti-Rab7 
antibody. The columns were washed twice with 10 ml ice-cold TBS, followed by 
elution in 3 × 0.5 mL 200mM glycine (pH2.4). The eluants were neutralised on 
ice with 140 µl 1.5 M TCl (pH 8.8). The purified antibody samples were desalted 
in a Centricon® (Millipore) using 10 mM HEPES, 100 mM NaCl (pH 7.4), and 
centrifugation at 4,000 × g for 5 min at 4°C.  
 
2.2.5.7 ELISA for antibody testing 
The anti-pRab7(S72) antibodies were examined by ELISA to determine whether 
they were specific for pS72 of S72-OH. 0.01–10 ng dilutions of the 
unphosphorylated and S72 phosphorylated peptides were diluted in TBS and 
added to well of a 96-well plate in 50 µl volume and allowed air dry overnight. 
Plates were blocked for 1 h with 100 µl of TBST + 1% BSA at room temperature, 
followed by two washes with TBST. Each bleed was incubated at 1:200 dilution 
in TBST for 2 h, followed by 3 washes in TBST, and incubation with the anti-
rabbit peroxidase secondary antibody (1:2,000 in TBST + 1% BSA). The plates 
were then washed 5–-6 times for 3 min each with TBST, followed by blocking in 
TBST + 1% BSA for 10 min. After rinsing in water, 75 µl of SIGMAFAST™ OPD 
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Substrate (Sigma) was added to each well and the plate was covered from light. 
After incubation for 10 min, the reaction was stopped by addition of 50 µl 2 M 
HCl. Absorbances were read at 490 nm. 
 
2.2.5.8 Antibody testing by western blot 
After the ELISA revealed that the anti-pRab7(S72) antibody serum from rabbit 
192 was more specific for pRab7(S72), the antibody was tested against 
recombinant His-Rab7 +/- TBK1 phosphorylation by western blot. The non-
phosphoantibody was firstly saturated with 1 mg/ml unphosphorylated peptide 
for 1 h at 4°C on a rotator. Recombinant protein was loaded corresponding to 
80, 160 and 320 ng protein per lane. The anti-pRab7(S72) antibody serum was 
used at a dilution of 1:100 overnight at 4°C. The same blot was stripped and 
reprobed with a mouse anti-Rab7 antibody (1:1000) fro 1 h at room temperature 
as a control. 
 
2.2.5.9 In vitro phosphorylation  
Phosphorylation of Rab7 in vitro by His-TBK1 or GST-IKKε was performed in a 
reaction buffer containing 20 mM TCl pH 7.5, 10 mM MgCl2, 1 mM EGTA, 10 
µM Na3VO4, 0.5 mM β-glycerophosphate, 2 mM dithiothreitol (DTT) and 0.01% 
Triton X-100, with 100 µM ATP and > 100 ng kinase per 50 µl reaction. 
Samples were incubated at 30°C for 30–60 min, depending on the amount of 
protein used. 
 
2.2.5.10 Immunoprecipitation experiments 
Immunoprecipitation was performed using GFP-Trap® for GFP-Rab7 
expressing samples of Dynabeads with the mouse anti-HA antibody for HA-
Rab7. Both will be described separately. For most immunoprecipitations, equal 
amounts of cells were seeded per condition and the amount used was based on 
the volume lysed in and not quantification. This method was consistent for 
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loading as quantified by known standards, actin, GAPDH or GFP or HA 
transfection.  
 
Immunoprecipitation for GFP-Rab7: 
 
Following protein extraction, lysates were incubated with 10–15 µl GFP-Trap® 
beads for 1–2 h, depending on volume of sample, at 4°C on a rotator. Following 
this the beads were pelleted and the supernatant was removed and sampled to 
determine efficient of binding, and the beads were washed three times with ice-
cold TBS contain 0.1% Triton X-100. Samples were then boiled in Laemmli 
sample buffer for 5 min, and analysed by SDS-PAGE western blot. 
 
Co-immunoprecipitation of HA-Rab7 and effectors: 
5 µg/ml mouse anti-HA antibody per sample was bound to 20 µl Dynabeads® 
(Life Technologies). 
 
2.2.5.11 Pull-down experiment 
For the GST-Rab7 pull-down of differential interactors of unphosphorylated 
Rab7 and pRab(S72), 1 µg GST-Rab7 was bound to 50 µl GSH-agarose beads 
per condition, which had been prewashed twice with 10 volumes of wash buffer  
(TBS containing 0.1% NP-40). These were placed on a rotator for 30 min to 
bind the proteins. The beads were then washed twice with ice-cold wash buffer, 
followed by one wash with reaction buffer (20 mM TCl pH 7.5, 10 mM MgCl2, 1 
mM EGTA, 10 µM Na3VO4, 0.5 mM β-glycerophosphate, 2 mM dithiothreitol 
(DTT) and 0.01% Triton X-100). The phosphorylated sample was then 
incubated with TBK1 reaction buffer containing 100 µM ATP and 1 µl of TBK1 
(0.14 mg/ml) at 30°C for 1 h with gentle shaking. The nonphosphorylated 
sample was incubated with reaction buffer only. The samples were then 
washed once with ice-cold reaction buffer, followed by two quick washes with 
10 volumes of 1M guanidine-HCl at 4°C to remove bound nucleotides, and then 
twice with ice-cold GTPγS loading buffer (20 mM Tris-HCl pH7.8, 100 mM NaCl, 
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5 mM MgCl2, 1 mM NaH2PO4, 10 mM β-mercaptoethanol).  Bound proteins 
were then loaded with 10 µM GTPγS in loading buffer for 30 min at 4°C on a 
rotator. Following this, they were washed three times with ice-cold TNTE buffer, 
and incubated with the cell lysates for 2 h at 4°C on a rotator for the effector 
pull-down. Following this, samples were washed three times with wash buffer 
and boiled in 5× Laemmli sample buffer. 
 
The sample was split into two, one for mass spectrometry analysis and the 
other for western blot. The mass spectrometry sample was separated on a 
precast 10% NuPAGE® gel at 200 V for approximately 10 min, followed by 
staining in GelCode Blue Stain Reagent (Thermo Scientific) and destaining with 
HPLC grade water (Fisher Scientific). The lanes were then cut into 8 equal 
sections, which were then placed in a 96-well plate in HPLC grade water and 
sent for mass spectrometry analysis. The results were analysed using Scaffold 
4.3.4 software analysis (Proteome Software, Inc.). Change in levels of protein 
associations with unphosphorylated Rab7 or pRab7(S72) were compared using 
intensity-based absolute quantification (iBAQ) values, which calculates protein 
intensities as the sum of total peptide intensities of a protein.  
 
2.2.5.12 Subcellular fractionation 
To examine subcellular localisation of phospho-Rab7(S72), GFP-Rab7Wt was 
transfected in MEFs and cells were stimulated with poly(I:C) to see if any 
changes occur compared with unstimulated controls. On day 1, MEFs were 
seeded on 1 × 150 cm2 dish per condition. On day 2, GFP-Rab7Wt was 
transfected for 48 h, following which they were stimulated with 10 µg/ml 
poly(I:C) for 4 h. Cells were then placed on ice, washed once with ice-cold 
HBSS, and scraped in subcellular fractionation buffer (250 mM sucrose, 20 mM 
HEPES (7.5), 10 mM KCl, 2.5 mM MgOAc, 1 mM EDTA, 1mM DTT) containing 
HALT™ Protease & Phosphatase Inhibitor Cocktail. The cells were allowed to 
swell on ice for 20 min, following which they were lysed by passing through a 
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17.5-gauge needle (15-20 times). Nuclei and any remaining whole cells were 
removed by two centrifugations at 1000 × g, for 10 min each.  
 
2.2.5.13 Immunofluorescence staining 
Cells on coverslips were fixed by adding equal volume of 8% paraformaldehyde 
(PFA), which had been prewarmed to 37°C, to the culture medium in each well 
for 10 min at room temperature. Membranes were then permeabilised for 10 
min with 0.1% Triton X-100, followed by blocking in 5% bovine serum albumin 
(BSA) for 1 h at room temperature. The cells were then incubated with the 
primary antibodies fro 1 h at room temperature or overnight at 4°C. After 
washing 3 × 5 min with PBS, they were incubated with the appropriate 
AlexaFlour secondary antibodies for 1 h at room temperature. 
Immunofluorescence was visualised using Zeiss LSM 710 or 780 confocal 
microscopes, using a 63× 1.4 NA Plan-Apochromat oil immersion objective. 
 
2.2.5.14 Fluorescent-activated cell sorting 
HEK293 cells were transfected with GFP-Rab7Wt, GFP-Rab7S72A and GFP-
Rab7S72E overnight, following which they were fixed in 4% PFA, washed three 
times with PBS for 5 min each, and incubated with the primary antibodies 
against Vps26 and LAMP2 for 2 h at room temperature. Cells were washed 
again as before, followed by incubation with the corresponding AlexaFlour 
secondary antibodies for 1 h at room temperature. Cells were then washed 
again and analysed by fluorescent-activated cell sorting (FACS). 
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Figure 2.1. Setting of thresholds for the FACS analysis. 
Cells for FACS analysis were firstly thresholded by selecting only the cell population, 
excluding any debris or dead cells. Following this, cells were selected based on size to 
include only a single cell population. From this, cells were then selected based on GFP 
expression (bottom panel), excluding the lowest expressing cells. These cells were 
than used to analyse Vps26 and LAMP2 expression. 
 
 
When setting the threshold on the FloJo vX.0.6 software for the BD 
FACSCalibur™ flow cytometer, cells were initially selected based on their size 
to exclude any dead cells or debris (Figure 2.1). Following this, single cells were 
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selected, followed by GFP-positive only cells. These GFP-positive cells were 
then used to determine overall intensity of Vps26 and LAMP2 expression.  
 
2.2.5.15 In vitro GTPase assay 
In vitro hydrolysis of [α-P32]GTP by unphosphorylated Rab7 and phospho-
Rab7(S72) was examined using recombinant His-Rab7Wt ± IKKε 
phosphorylation. 2 × 10 µl aliquots of Ni2+ agarose resin, which had been 
preswelled in TBS overnight, were prepared for each time point (0, 15, 30, 60, 
120 min) by washing twice with 10 volumes of loading buffer (20 mM Tris-HCl 
pH7.8, 100 mM NaCl, 5 mM MgCl2, 1 mM NaH2PO4, 10 mM β-mercaptoethanol) 
and incubating them on a rotating wheel with 1 pmol of purified His-Rab7Wt ± 
IKKε phosphorylation in loading buffer for 20 min at 25°C.  
 
Bound nucleotides were eluted by washing quickly twice with 10 volumes of 1M 
guanidine-HCl at 4°C and then twice with ice-cold loading buffer. After 
aspirating as much buffer as possible, 1 pmol of [a-32P]GTP (400Ci/mmol) was 
added in 20 ml of ice-cold loading buffer and incubated at 0°C for 10 min. 50 ml 
of loading buffer was then added to each aliquot and samples were incubated 
at 37°C for the various time periods (0, 15, 30, 60, 120 min). After incubations, 
each sample was washed three times with ice-cold loading buffer, following 
which 8 ml of boiling buffer (0.2% SDS, 2 mM EDTA, 10 mM GDP, 10 mM GTP, 
pH 7.5) was then added.  
 
Spot 2 ml of each sample onto PEI cellulose sheets and proceed with thin layer 
chromatography in 0.6 M Na-phosphate buffer, pH 3.5, for approximately 1 h. 
The thin layer chromatography sheets were placed in a PhosphorImager 
overnight and the radioactive spots corresponding to [a-32P]GDP and [α-
32P]GTP were quantified by scanning the PhosphorImager and using ImageJ 
software (NIH) for quantification. GTP hydrolysis was calculated as the signal in 
the GDP spot relative to the total signal (GDP + GTP). 
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2.2.5.16 In vitro kinase assay 
IKKα, IKKβ, TBK1 and IKKε phosphorylation of Rab7 was examined in [γ-
32P]ATP in vitro kinase assays. Each assay was performed in 50 µl of 
autophosphorylation buffer, containing 100 mM Tris-HCl, pH 7.5, 50mM MgCl2, 
50 µg/ml phosphatidylserine, 100 ng/ml TPA, with 50 ng of kinase, 2 µg His-
Rab7Wt or His-RabS72P (control), 10 mM cold ATP and 100 µM [γ-32P]ATP (3000 
Ci/mmol, Amersham). After mixing well, the samples were incubated at room 
temperature for 1 h, then the assay was stop by precipitating the protein 0.5µl of 
5% NaDOC and 3.2 µl of TCA for 10 min. Samples were then centrifuged at 
maximum speed for 10 min and the supernatant was carefully discarded. The 
precipitated samples were boiled in sample buffer (10 mM Tris pH 8.2, 0.1 mM 
EDTA, 10% SDS, 0.01% bromophenol blue) for 3 min and loaded on a 4–12% 
NuPAGE® gel at 200 V for 40 min, following which it was stained with 
Coomassie Brilliant Blue (Bio-Rad) for 1 h on a shaker. The gel was then 
destained for 1 h using 40% methanol and 10% glacial acetic acid, and dried in 
a radioactive gel dryer for 1 h. The gel was then exposed overnight using a 
Biomax MR film and developed the following morning. Images were quantified 
with ImageJ software. 
 
Chapter 3. Results 1 
 69 
Chapter 3. Impact of phosphomimetic and 
phosphodeficient Rab7 proteins on the endocytic 
pathway 
3.1 Analysis of the Rab7S72P mouse model 
A previous member of the Molecular Neuropathobiology laboratory, Olga 
Martins de Brito, together with Abraham Acevedo-Arozena (MRC Harwell) and 
Elizabeth Fisher (UCL Institute of Neurology), examined a collection of mouse 
strains obtained via a N-ethyl-N-nitrosourea (ENU) mutagenesis screen for 
mutations in Rab7. In particular, they identified three point mutations in Rab7 at 
potential phosphorylation sites, two of which had previously been identified in 
phosphoproteomic screens (Rab7S72P and Rab7Y183H). Preliminary analysis of 
the Rab7S72P strain revealed that this mutation was lethal in homozygosis, 
indicating that this residue is essential for Rab7 function and for life.   
 
ENU is a mutagen usually administered as a series of intraperitoneal injections 
to adult male mice, with the optimal concentration predicted to induce one 
mutation every 1–1.5 Mb. Premeiotic spermatogonial stem cells are one of the 
primary targets of ENU. To screen for mutations, ENU-treated males (G0) are 
crossed with wild-type females to produce G1 progeny, which have an 
estimated 30–50 potential functional mutations in their genome. These G1 
progeny are then backcrossed to a wild-type strain for approximately 10 
generations to reduce the likelihood of residual mutations that may affect the 
analysis of the phenotype of a particular mutation. 
 
After backcrossing the Rab7S72P strain for 10 generations into the C57BL/6 
strain, I set up Rab7S72P heterozygous mating pairs to analyse the specific 
phenotype induced by this mutation. Analysis of six litters from E13.5, three 
litters from E12.5, three litters from E11.5 and four litters from E10.5 revealed 
that no homozygous embryos were obtained for any of the days examined 
(Table 3.1). Furthermore, analysis of the ratios of wild-type to heterozygous 
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mice revealed that for all embryonic days the ratio was slightly below the 1:2 
Mendelian ratio (Table 3.2), but I do not believe this was low enough to be of 
major concern. In almost all litters, there were also approximately 1–5 
reabsorptions that I attempted to genotype, but none were homozygous. Finally, 
the transgenic facility at the LRI also attempted to obtain embryonic stem (ES) 
cells from the Rab7S72P strain, without success. Together, these results indicate 
that the Rab7S72P mutation is lethal at a very early stage in embryogenesis, 
possibly even before E4.5 when the ES cells are harvested. It is worth noting 
that both the male and female mice are fertile and produce heterozygous 
progeny when crossed with wild-type mice, so the lethality occurs after 
fertilisation. 
 
The MNP group also obtained a Rab7 gene-trap clone (E284E11) from the 
German Genetrap Consortium. This is a knockout-first genetrap that should 
produce homozygous Rab7-/- progeny when the heterozygous mice are crossed. 
Unfortunately, no Rab7-/- mice or ES cells could be obtained from these matings. 
The strain was subsequently crossed with FlpO mice, which, through the 
expression flippase (Flp) recombinase, inverts the genetrap cassette. When the 
cassette is inverted, the splice acceptor site is removed and the genetrap is 
inactivated. These mice can then be mated to produce progeny homozygous for 
the inactive cassette, which can then be crossed with Cre recombinase 
expressing strains to invert the cassette again into the active conformation and 
produce conditional knockout mice for Rab7. ES cells and MEFs can also be 
harvested and transfected with a Cre expression plasmid to produce knockout 
cells. However, the insertion site for the cassette is not known, so we could not 
distinguish between heterozygous and homozygous mice. The Edinger 
laboratory at University of California, Irvine, previously produced a conditional 
knockout mouse for Rab7 in T cells, in which they found that Rab7 was 
important in negatively regulating growth or division during T cell development. 
Furthermore, these mice exhibited an increased rate of developing lymphomas. 
Prof. Edinger kindly provided us with Rab7-/- MEFs, but this was very recently, 
so they have yet to be examined. 
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Table 3.1. Genotype analysis of E10.5–13.5 embryos from Rab7Wt/S72P × 
Rab7Wt/S72P timed-matings 
Litter Embryonic Day Rab7Wt/Wt Rab7Wt/S72P Rab7S72P/S72P 
1 13.5 3 5 0 
2 13.5 3 8 0 
3 13.5 4 5 0 
4 13,5 3 2 0 
5 13.5 3 7 0 
6 13.5 3 3 0 
7 12.5 4 5 0 
8 12.5 3 7 0 
9 12.5 3 5 0 
10 11.5 5 7 0 
11 11.5 4 7 0 
12 11.5 4 8 0 
13 10.2 3 6 0 
14 10.5 6 10 0 
15 10.5 5 9 0 
16 10.5 6 7 0 
 
Table 3.2. Genotype ratio analysis of Rab7Wt/S72P × Rab7Wt/S72P timed-matings 
Embryonic day Rab7Wt/Wt Rab7Wt/S72P Rab7S72P/S72P Ratio 
13.5 19 30 0 1:1.58 
12.5 10 17 0 1:1.7 
11.5 13 22 0 1:1.69 
10.5 20 32 0 1:1.6 
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3.2 Rab7 sequence conservation and structural predictions for 
phosphorylation at S72 
 
Rab GTPases belong to the Ras superfamily of proteins, which contains four 
other members: Arf, Rab, Ran, and Rho. The Rab family is the largest of the 
five members, with over 60 known Rabs in mammalian cells. Of the Rab 
proteins known to date, around 20 appear to have been present in the last 
eukaryotic common ancestor. Of these 20 Rabs, only five (Rab1, Rab5, Rab6, 
Rab7 and Rab11) are present in most of the well-characterized genomes 
studied to date (Klopper et al., 2012). Of the five kingdoms (Animalia, Plantae, 
Fungi, Bacteria, and Protozoa), Bacteria is the only kingdom in which Rab 
proteins are not found.  
 
Based on its good evolutionary conservation, I decided to examine the Rab7 
sequence to see if the S72 residue was well conserved using the EMBL Clustal 
Omega tool (http://www.ebi.ac.uk/Tools/msa/clustalo/). The species chosen 
spanned the Animalia (human, mouse, rat, zebrafish, fruit fly), Plantae 
(Arabidopsis thaliana), Fungi (Saccharomyces cerevisiae) and Protozoa 
(Entamoeba histolytica) kingdoms, where Rab7 is found. Interestingly, the 
results revealed that the S72 site was conserved across all species examined, 
along with 16 surrounding residues, or 27 residues excluding Saccharomyces 
cerevisiae and Entamoeba histolytica (Figure 3.1). Thus, the S72 site and 
surrounding region appear to be highly important for Rab7 function, as it has 
been completely conserved throughout evolution.  
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Figure 3.1. Rab7 sequence conservation. 
Sequence conservation was examined by aligning sequences of various organisms 
from the different kingdoms where Rab7 is found. The S72 site is completely 
conserved, while the region surrounding it is also highly conserved. Colour coding: red 
indicates small, hydrophobic residues, including aromatics; blue indicates acidic 
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residues; magenta indicates basic residues; and green indicates hydroxyl, sulphydryl, 
amine and G residues. * indicates a fully-conserved residues; : indicates conservation 
between groups of strongly similar properties; and . indicates conservation between 
groups of weakly similar properties. Obtained using Clustal Omega software (EMBL-
EBI). 
 
Another insight into the importance of the S72 residue is that it is conserved in a 
number of other Rabs operating in the endocytic (Rab5) and the secretory 
(Rab6, Rab9 and Rab27) pathways; however, it is not present in two of the five 
most commonly found Rabs, Rab1 and Rab11 (Figure 3.2). 
 
 
 
Figure 3.2. S72 conservation between different Rab proteins. 
Conservation of the S72 site was examined in across the most common Rabs. The five 
Rabs present in most of the well-characterized genomes studied to date (Rab1, Rab5, 
Rab6, Rab7 and Rab11) are shown in the above alignment, along with Rab9 and 
Rab27, both of which have the conversed S72 site. Colour coding: red indicates small, 
hydrophobic residues, including aromatics; blue indicates acidic residues; magenta 
indicates basic residues; and green indicates hydroxyl, sulphydryl, amine and G 
residues. * indicates a fully-conserved residues; : indicates conservation between 
groups of strongly similar properties; and . indicates conservation between groups of 
weakly similar properties. 
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3.3 Cellular localisation of serine 72 phosphomimmetic and 
phosphodeficient Rab7 mutant proteins 
Without knowing what kinases phosphorylate Rab7 at S72, I first decided to 
create GFP-Rab7S72A (phosphodeficient), GFP-Rab7S72E (phosphomimmetic) 
and GFP-Rab7S72P (mouse model) constructs using site-directed mutagenesis 
of wild-type pcDNA3-GFP-Rab7Wt to determine if phosphorylation at S72 could 
affect cellular localisation of Rab7. The mouse mutation was included to 
determine if it acted similarly to the phosphodeficient or phosphomimmetic 
mutations. 
 
All four constructs were transfected in MEFs overnight with Lipofectamine 2000 
transfection reagent and visualised by confocal microscopy on a Zeiss LSM 710 
upright microscope  (Figure 3.3). Both Rab7Wt and Rab7S72A expressed similarly 
and are localised to numerous puncta throughout the cell, which are 
reminiscent of multivesicular bodies (MBVs)/late endosomes. The distributions 
of both proteins were varied, exhibiting some cells with large amounts of 
perinuclear clustering and others with much higher cytosolic localisation. These 
can be seen in the lower magnification images in Figure 3.3, which show that 
variations were evident in cells of similar morphology in the same region. In 
contrast, both the Rab7S72E and Rab7S72P mutants are cytosolic and uniform, 
indicating that these cannot be recruited to endosomal membranes for 
activation. Both mutant proteins are also found in the nucleus; however, the 
reason for this is unclear. As GFP-Rab7 is below the cut-off size for diffusing 
through the nuclear pore (>60 kDa), these mutants may simply cross as their 
localisation signals could be affected. Overall, these results indicate that 
phosphorylation at S72 may inhibit Rab7 activity by affecting its recruitment to 
endosomal membranes. 
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Figure 3.3. Subcellular localisation of GFP-Rab7Wt, GFP-Rab7S72A, GFP-
Rab7S72E, and GFP-Rab7S72P. 
GFP-Rab7Wt, GFP-Rab7S72A, GFP-Rab7S72E and GFP-Rab7S72P were transfected for 24 
h in MEFs to determine whether the phosphomimetic (S72E), phosphodeficient (S72A) 
or mouse (S72P) mutations had any effects on subcellular localisation of Rab7. Images 
GFP-Rab7Wt
GFP-Rab7S72A
GFP-Rab7S72E
GFP-Rab7S72P
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were obtained by confocal microscopy. The second and third columns show lower 
magnification images to illustrate the variations in expression of GFP-Rab7Wt and GFP-
Rab7S72A. Both proteins exhibit perinuclear clusters as well as scattered distributions 
throughout the cell. Scale bar = 10 µm. 
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3.4 Comparison of the effects of serine 72 phosphomimmetic 
and phosphodeficient mutations of Rab7 on markers of the 
endocytic pathway 
As there were such a striking difference in the cellular localisation of Rab7S72E 
compared to Rab7Wt and Rab7S72A, I decided to examine whether these 
mutations had any effects on the localisation and expression of other endocytic 
markers. The markers chosen were are follows: EEA1, a peripheral membrane 
protein that co-localizes with Rab5 on early endosomes; Rab11, a regulator of 
the trafficking of recycling endosomes; Vps26, an essential component of the 
retromer complex, which is required for endosome-to-Golgi retrieval of 
receptors, such as insulin-like growth factor receptor 2 (IGF2R) and M6PR; and 
LAMP2, a lysosomal membrane protein believed to play roles in protecting the 
membrane from proteolytic enzymes within lysosomes and aiding the import of 
proteins into the lumen of the lysosome. 
 
GFP-Rab7Wt, GFP-Rab7S72A and GFP-Rab7S72E were transfected in MEFs on 
coverslips overnight with Lipofectamine 2000, following which cells were fixed in 
4% PFA and stained for the intracellular markers discussed above. Images 
were acquired using a Zeiss LSM 780 microscope. The results revealed that 
although there were striking differences in localisation of GFP-Rab7Wt and GFP-
Rab7S72A, compared to GFP-Rab7S72E, there appeared to be no differences in 
the subcellular localisation or total intensity of any of the markers tested, 
supporting that these mutants do not induce a rearrangement of intracellular 
organelles cells (Figure 3.4–3.7).  
 
As the levels GFP-Rab7 can be quite heterogeneous when overexpressing the 
cells, it can be very difficult to quantify changes in the overall intensity of 
specific markers in cells that are expressing similar levels of GFP-Rab7. Thus, 
the total intensities of LAMP2 and Vps26 were examined by FACS in the total 
population of GFP-positive cells for GFP-Rab7Wt, GFP-Rab7S72A and GFP-
Rab7S72E. As the antibodies are from different species, both were analysed in 
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the same sample of cells. The results of the FACS analysis revealed that there 
was no difference in the total intensity of LAMP2 or Vps26 in GFP-Rab7Wt, 
GFP-Rab7S72A and GFP-Rab7S72E expressing (Figure 3.8). 
 
 
 
Figure 3.4. LAMP2 expression in cells overexpressing GFP-Rab7Wt, GFP-Rab7S72A 
and GFP-Rab7S72E. 
GFP-Rab7Wt, GFP-Rab7S72A and GFP-Rab7S72E were transfected for 24 h in MEFs, 
following which LAMP2 expression was examined using a mouse anti-LAMP2 antibody. 
Images were obtained by confocal microscopy. Scale bar = 10 µm. 
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Figure 3.5. Vps26 expression in cells overexpressing GFP-Rab7Wt, GFP-Rab7S72A 
and GFP-Rab7S72E. 
GFP-Rab7Wt, GFP-Rab7S72A and GFP-Rab7S72E were transfected for 24 h in MEFs, 
following which Vps26 expression was examined using a mouse anti-Vps26 antibody. 
Images were obtained by confocal microscopy. Scale bar = 10 µm. 
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Figure 3.6. EEA1 expression in cells overexpressing GFP-Rab7Wt, GFP-Rab7S72A 
and GFP-Rab7S72E. 
GFP-Rab7Wt, GFP-Rab7S72A and GFP-Rab7S72E were transfected for 24 h in MEFs, 
following which EEA1 expression was examined using a mouse anti-EEA1 antibody. 
Images were obtained by confocal microscopy. Scale bar = 10 µm. 
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Figure 3.7. Rab11 expression in cells overexpressing GFP-Rab7Wt, GFP-Rab7S72A 
and GFP-Rab7S72E. 
GFP-Rab7Wt, GFP-Rab7S72A and GFP-Rab7S72E were transfected for 24 h in MEFs, 
following which Rab11 expression was examined using a mouse anti-Rab11 antibody. 
Images were obtained by confocal microscopy. Scale bar = 10 µm.  
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Figure 3.8. Total LAMP2 and Vps26 expression in cells expressing GFP-Rab7Wt, 
GFP-Rab7S72A, GFP-Rab7S72E and GFP-Rab7S72P. 
GFP-Rab7Wt, GFP-Rab7S72A and GFP-Rab7S72E were transfected for 24 h in MEFs, 
following which total LAMP2 and Vps26 levels were examined by FACS using mouse 
anti-LAMP2 and rabbit anti-Vps26 antibodies.  
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3.5 Comparison of the effects of serine 72 phosphomimmetic 
and phosphodeficient mutations of Rab7 on EGFR 
degradation 
The endocytic pathway is highly important for the control of many signalling 
pathways, including the EGFR, which plays an important role in cell growth, 
migration, and differentiation. When the EGFR binds its ligand, EGF, it is 
internalised by clathrin-mediated endocytosis. Following internalisation, the 
EGFR can be recycled back to the plasma membrane for further activation or it 
can be targeted for degradation in a Rab7-dependent manner (Ceresa and 
Bahr, 2006).  
 
To determine if the phosphomimetic or phosphodeficient mutations affect Rab7 
activity, I decided to perform an EGFR degradation assay in HeLa cells 
overexpressing GFP-Rab7Wt, GFP-Rab7S72A or GFP-Rab7S72E. Cells were 
transfected with the constructs for 24 h using Fugene6 transfection reagent, 
serum-starved for 2 h and stimulated with 100 ng/ml recombinant human EGF 
for 0, 15, 30, 60 and 90 min.  
 
From the results, it appears that the phosphodeficient Rab7S72A causes 
increased EGFR degradation at 15 min compared to the wild-type expressing 
cells, while the phosphomimetic Rab7S72E causes decreased degradation 
(Figure 3.9). Following this, the levels of EGFR appear to increase, which could 
be the result of neosynthesis of the receptor. There is a large increase in EGFR 
levels at 30, 60 and 90 min with Rab7S72E, with the levels at 90 min being much 
higher than the unstimulated condition (0 min).  In contrast, Rab7Wt and 
Rab7S72A are similar to the unstimulated condition. Thus, these results indicate 
that phosphorylation may inhibit Rab7 activity. Ideally this experiment should be 
repeated in Rab7 knockout cells, as although repeats of this experiment did 
show the same trend in degradation, the differences reported were high, 
possibly due to the compensatory effects of endogenous Rab7.  
  
Chapter 3. Results 1 
 85 
 
 
 
 
 
 
Figure 3.9. Comparison of EGFR degradation in cells overexpressing GFP-
Rab7Wt, GFP-Rab7S72A or GFP-Rab7S72E. 
HEK293 cells were transfected with GFP-Rab7Wt, GFP-Rab7S72A or GFP-Rab7S72E 
overnight, serum-starved for 2 h and stimulated with 100 ng/ml EGF for the indicated 
time-points. Cells were lysed and subjected to western blot for anti-EGFR and anti-β-
actin antibodies. 
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3.6 Co-immunoprecipitation of wild-type, phosphomimmetic 
and phosphodeficient HA-Rab7 with GFP-RILP and GFP-
ORP1L 
RILP and ORP1L are two of the best-studied effectors of Rab7. As described in 
the introduction, RILP can bind both p150(Glued) and the V1G1 subunit of the 
V-ATPase, which may help stabilise the V-ATPase during minus-end directed 
transport of late endosomes/lysosomes to promote endosomal acidification. 
The crystal structure of the Rab7:RILP complex revealed that the interactions 
between these proteins involves residues directly surrounding the S72 site, 
indicating that phosphorylation at S72 could affect binding of RILP to Rab7. In 
contrast, ORP1L appears to be a master regulator of late endosomal/lysosomal 
transport as it recruits both p150(Glued) and KIF3A for dynein- and kinesin-
mediated transport. It also binds VAP, an ER membrane protein, at ER-late 
endosome contact sites.  
 
To examine whether phosphorylation of Rab7 at S72 could be a mechanism of 
promoting/inhibiting transport in the minus or plus direction, HA-Rab7Wt, HA-
Rab7S72A and HA-Rab7S72E were co-transfected with GFP-RILP, GFP-ORP1L or 
GFP-FYCO1 overnight in HEK293 cells using Lipofectamine 2000 transfection 
reagent. Using a mouse anti-HA antibody bound to Dynabeads, HA-Rab7Wt, 
HA-Rab7S72A and HA-Rab7S72E were immunoprecipitated from cell lysates and 
samples were subjected to SDS-PAGE followed by western blot for GFP-RILP 
or GFP-ORP1L using a mouse-anti-GFP antibody. Levels of transfection of HA-
Rab7Wt, HA-Rab7S72A and HA-Rab7S72E were determined using a rat anti-HA 
antibody. Results were subjected to one-way ANOVA, followed by Tukey’s 
multiple comparisons test using GraphPad Prism software. A P < 0.05 was 
considered statistically significant. Both experiments were repeated three times 
(n = 3). 
 
Results revealed that there was no significant difference in the interaction 
between GFP-RILP and HA-Rab7Wt and HA-Rab7S72A, whereas there was 
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approximately 80% decrease in binding to HA-Rab7S72E (Figure 3.10). This 
indicates that phosphorylation of Rab7 at S72 inhibits binding of Rab7 to RILP.  
 
 
 
Figure 3.10. Co-IP of HA-Rab7Wt, HA-Rab7S72A and HA-Rab7S72E with GFP-RILP. 
HA-Rab7Wt, HA-Rab7S72A and HA-Rab7S72E were co-transfected with GFP-RILP 
overnight in HEK293 cells using Lipofectamine 2000. The HA-Rab7 variants were 
immunoprecipitated with anti-HA antibody on Dynabeads and the immunoprecipitates 
were subjected to western blot using an anti-GFP antibody to probe for GFP-RILP. 
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In contrast, there was no significant difference in the interaction between GFP-
ORP1L and any of the three Rab7 proteins (Figure 3.11). This indicates that 
ORP1L binding is unaffected by phosphorylation of Rab7 at S72. 
 
 
 
Figure 3.11. Co-IP of HA-Rab7Wt, HA-Rab7S72E and HA-Rab7S72E with GFP-ORP1L. 
HA-Rab7Wt, HA-Rab7S72A and HA-Rab7S72E were co-transfected with GFP-ORP1L 
overnight in HEK293 cells using Lipofectamine 2000. The HA-Rab7 variants were 
immunoprecipitated with anti-HA antibody on Dynabeads and the immunoprecipitates 
were subjected to western blot using an anti-GFP antibody to probe for GFP-ORP1L.  
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3.7 Analysis of the effect of serine 72 phosphomimmetic and 
phosphodeficient mutations on Rab7 activity using novel 
Raichu-Rab7 FRET sensors 
The Matsuda laboratory at Kyoto University, Japan, previously produced FRET 
sensors for a number of small GTPases, including Ras, RhoA and Rab5, which 
they termed Raichu-Ras, Raichu-RhoA and Raichu-Rab5, respectively. The 
term Raichu is an acronym for Ras and interacting protein chimeric unit. For the 
Raichu-Rab5 FRET sensor Rab5 and the N-terminal Rab5-binding domain 
(RBD) of EEA1 were fused to YFP and CFP in the order of YFP-RBD-CFP-
Rab5, with Rab5 at the C-terminus, as the REP requires access to the lipid 
modification site of Rab5 at the C-terminus for insertion into the endosomal 
membrane. This is the same organisation for the Raichu-Rab7 sensor created 
by the Nakamura laboratory at Tokyo University of Science, Japan, in 
collaboration with the Matsuda laboratory (Figure 3.12). In Raichu-Rab7, the 
RBD is the Rab7-binding domain of Rabring7 (Rab7-interacting RING finger 
protein), a Rab7 effector that specifically binds the GTP-bound form at the N-
terminus. Rabring7 itself has not been very well characterised, although it its 
overexpression has been shown to cause increased EGFR degradation and 
perinuclear aggregation of lysosomes, whereas Rabring7C229S, which lacks its 
E3 ligase activity, inhibits EGFR degradation (Mizuno et al., 2003; Sakane et al., 
2007). When Rab7 is in its inactive GDP-bound state, excitation of CFP at 433 
nm will result in emission at 475 nm, as the two fluorescent proteins are 
separated. However, in the GTP-bound state, Rab7 binds the RBD resulting in 
the CFP and YFP being in close proximity. When in this conformation, 
excitation at 433 nm will cause an energy transfer from CFP to YFP and an 
emission at the higher wavelength of 575 nm. This process is known as 
fluorescence energy resonance transfer (FRET).  
 
In collaboration with the Nakamura laboratory, which provided the original wild-
type Raichu-Rab7 (hereafter referred to as Raichu-Rab7Wt), I created Rab7 
point mutants for S72A (Raichu-Rab7S72A) and S72E (Raichu-Rab7S72E). These
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Figure 3.12. Design of the Raichu-Rab7 FRET sensor. 
Structure of the Raichu-Rab7 probe, showing the YFP-RBD-CFP-Rab7 confirmation in 
the inactive and active states. In the inactive GDP-Rab7 state, excitation of CFP at 433 
nm results in emission at 475 nm, whereas in the GTP-Rab7 state, binding of Rab7 to 
the RBD domain brings CFP and YFP in close proximity resulting in FRET and 
emission at the higher YFP emission wavelength of 525 nm. 
 
constructs were transfected in wild-type MEFs for 48 h, following which they 
were imaged using a Zeiss LSM inverted 780 microscope. The cytosol and 
endosomal FRET ratios were quantified and compared between Raichu-Rab7Wt, 
Raichu-Rab7S72A and Raichu-Rab7S72E (Figure 3.14). As Raichu-Rab7S72E is 
completely cytosolic (Figure 3.13), there was no endosomal measurement. 
Intensities were quantified using ImageJ software and the ratios were subjected 
to one-way ANOVA, followed by Sidak’s multiple comparisons test, comparing 
endosomal-to-endosomal and cytosolic-to-cytosolic ratios between each group. 
The results revealed that there was a significant decrease in the cytosolic FRET 
ratio between Raichu-Rab7S72E and the other two probes. In contrast, there 
were no significant differences between endosomal and cytosolic Raichu-
Rab7Wt and Raichu-Rab7S72A FRET ratios. 
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Figure 3.13. Localisation of Raichu-Rab7Wt, Raichu-Rab7S72A and Raichu-Rab7S72E 
FRET probes. 
Raichu-Rab7Wt, Raichu-Rab7S72A and Raichu-Rab7S72E were transfected for 48 h in 
MEFs, following which they were fixed and imaged by confocal microscopy. The 
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subcellular localisation of each Raichu-Rab7 probe was similar to the profiles obtained 
with the GFP-tagged versions of Rab7Wt, Rab7S72A and Rab7S72E (Figure 3.3), 
indicating that the YFP-RBD-CFP-tag at the N-terminus did not affect Rab7 function. 
 
 
 
 
 
 
 
Figure 3.14. Quantification of FRET ratios for endosomal and cytosolic Raichu-
Rab7Wt, Raichu-Rab7S72A and Raichu-Rab7S72E. 
Raichu-Rab7Wt, Raichu-Rab7S72A and Raichu-Rab7S72E were transfected for 48 h in 
MEFs, following which they were imaged by confocal microscopy. FRET, CFP and 
YFP intensities were measured using ImageJ software and the mean FRET:CFP ratios 
were subjected one-way ANOVA using GraphPad Prism. 
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3.8 Discussion 
Previous members of the MNP laboratory identified Rab5 and Rab7 as key 
components of endocytic sorting and axonal retrograde signalling (Deinhardt et 
al., 2006; Schmieg et al., 2014) They found that Rab5 is essential for an early 
step in sorting but is absent from axonal signaling endosomes, whereas Rab7 is 
essential for the transport of fast retrograde vesicles. This conversion of Rab5 
to Rab7 on endosomes is a commonly agreed upon mechanism for endosomal 
maturation and targeting of cargo towards the degradative pathway. While 
numerous proteins have been identified that regulate Rab7 activity, none of 
these regulate it by phosphorylation. This is quite surprising as Rab7 has been 
identified in a number of phosphoproteomic screens as being phosphorylated 
on 11 different sites, with Y183 and S72 being the most frequently found. 
However, none of these studies further investigated Rab7 and no studies have 
been published on any of these phosphorylation sites. In contrast, previous 
studies have identified phosphorylation sites on a number of other Rabs, 
including Rab4, which is phosphorylated on S196 during mitosis to promote its 
accumulation in the cytosol (van der Sluijs et al., 1992).  
 
From a sequence and structural point of view, the S72 site of Rab7 appears to 
be extremely important for Rab7 function, as so much of the surrounding 
sequence is very well conserved, even in plants (Arabidopsis thaliana) and 
yeast (Saccharomyces cerevisiae). In addition, the severe phenotype of the 
Rab7S72P mouse indicates that this residue is essential for life. However, the 
Rab7S72P mutation is not ideal since it is too drastic to provide key information. 
The Rab7S72P mutation is predicted to stabilize the switch II region, which may 
prevent interaction with the switch I region for GTP-binding and activation. This 
could potentially lock the structure in a GDP-bound form. The Rab7S72P 
mutation may also block interaction with REP1, thereby inhibiting the C-terminal 
prenylation of Rab7 and preventing it entering the GTPase cycle. The mass 
spectrometry facility at the London Research Institute attempted to detect 
prenylation of Rab7Wt, but as they were unsuccessful, we did not have any 
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effective means to test the prenylation status of the Rab7S72P mutant. 
Furthermore, as this mutation is lethal so early in embryogenesis, there was no 
logic for investigating this any further.  
 
The mechanisms by which Rab7S72P function is inhibited may also be applied to 
the phosphomimetic mutation Rab7S72E, as it too displays a similar cytosolic 
localisation (Figure 3.3). As Rab7S72E is never seen localised to vesicular 
structures in when overexpressed, the initial hypothesis was that 
phosphorylation of Rab7 at S72 inhibits Rab7 function, preventing its 
recruitment to endosomal membranes; however, this was disproved in later 
experiments, which will be discussed in the following chapters. The hypothesis 
was strengthened by fact that both Rab7Wt and the phosphodeficient Rab7S72A 
display numerous puncta throughout the cell, reminiscent of late 
endosomes/multivesicular bodies and lysosomes, with some clustering in the 
perinuclear region. In addition, both Rab7Wt and Rab7S72A also display some 
cytosolic localisation, but to only a fraction of the Rab7S72E and Rab7S72P 
proteins. This localisation of Rab7Wt and Rab7S72A both on vesicles and in the 
cytosol indicates that they are freely able to cycle through the active GTP- and 
inactive GDP-bound forms.  
 
In light of the striking differences between Rab7Wt and Rab7S72A compared to 
Rab7S72E, it was expected that overexpression of these proteins may affect the 
progression of cargo along the endocytic pathway or the dynamics of 
endosomal organelles. However, none of the endocytic markers examined 
exhibited a change in localisation upon expression of the three Rab7 forms, 
tagged with either GFP (Figure 3.4–3.7) or HA (not shown). In addition, the 
overall expression levels of LAMP2 and Vps26 were examined by FACS, as 
comparison of their overall intensities in GFP-positive cells is complicated 
because the punctate distribution of Rab7Wt and Rab7S72A makes it difficult to 
create a mask using GFP that would outline the entire cell and restrict the 
quantification to only GFP-Rab7-positive cells. The results showed that there 
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were no differences in expression of LAMP2 or Vps26 between Rab7Wt and any 
of the mutants.  
 
Believing that the cells may require more than 24 h to adjust to the expression 
of these plasmids, I created stable cell lines expressing the GFP-Rab7 
constructs. Unfortunately, after selecting stable populations from high and low 
expressing clones with similar levels of GFP-Rab7Wt, GFP-Rab7S72A and GFP-
Rab7S72E, I found that the cells began to cleave the GFP within one or two 
weeks of culture. After this, I used human siRNA to knockdown endogenous 
Rab7 in HEK283 cells, so that they could then be transfected with the GFP-
Rab7 constructs, as they were produced from the canine sequence, and were 
thus resistant to siRNA. However, following transfection, the morphology of the 
cells changed dramatically and they began to form clusters in the dishes and 
detached easily when changing the media. Ideally these experiments would 
have been performed in Rab7-/- MEFs, but as these were only recently obtained 
there was no time to perform these experiments. 
 
As the localisation of the phosphomimetic and phosphodeficient proteins 
indicate that phosphorylation may prevent Rab7 recruitment to endosomal 
membranes, I performed EGFR degradation assays to determine the effect 
these mutation might have. Indeed, the Rab7S72E mutation appeared to 
decrease EGFR degradation, while still allowing for receptor activation and the 
induction of neosynthesis, which I believe occurred as the levels at 90 min were 
much higher than the initial levels without stimulation. In contrast, the Rab7S72A 
mutation increased EGFR degradation at 15 and 30 min. While this does 
appear to be very quick, the EGFR has been shown to colocalise with Rab7 at 
15 min (Gomez-Suaga et al., 2014). This decrease in EGFR degradation for 
Rab7S72E indicates that phosphorylation at S72 inhibits Rab7 activity. This could 
be by locking it in a GDP-bound form in the cytoplasm by blocking interaction of 
the switch I and II regions or it could abolish the interaction with certain effects, 
such as RILP, which has been shown to be involved in EGFR degradation 
(Progida et al., 2007). 
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Figure 3.15. Interaction sites of RILP with Rab7. 
Sequence of the human Rab7 protein showing the residues interacting with RILP 
(labelled as *). The S72 of Rab7 is highlighted in red and is located in close proximity 
to a number of known interaction sites. 
 
Analysis of the crystal structures of the Rab7:RILP and Rab7:REP1 complexes 
revealed that the S72 site of Rab7 and the surrounding region play important 
roles in these interactions. However, S72 was never mutated in either of these 
studies to determine if it has any effect on binding of these interactors. The S72 
site was shown to interact with REP1, but as inhibition of this interaction would 
only affect newly synthesised Rab7, I decided to examine the interaction with 
RILP first. Although there was no interaction shown in the Rab7:RILP complex 
at S72, phosphorylation of this residue could still affect binding, as it may inhibit 
interaction between the switch regions required for Rab7 activation and binding 
of RILP. Furthermore, other resides in the surrounding region (F70, L73 and 
L77) form binding sites within the Rab7:RILP complex and phosphorylation 
could their interaction (Figure 3.15). Indeed the results revealed that the 
phosphomimetic Rab7S72E inhibited RILP binding by approximately 80% (Figure 
3.10). If phosphorylation of Rab7 at S72 inhibits RILP binding, this could also 
affect microtubule minus end-directed transport of late endosomes/lysosomes 
and/or acidification. In contrast, the interaction of Rab7 with ORP1L was not 
affected by the phosphomimetic or phosphodeficient mutation (Figure 3.11). 
        1  MTSRKKVLLK  VIILGDSGVG   KTSLMNQYVN  KKFSNQYKAT  IGADFLIKEV  MVDDRLVTMQ
 
       61  IWDTAGQERF  QSLGVAFYRG  ADCCVLVFDV  TAPNTFKTLD   SWRDEFLIQA  SPRDPENFPF
      121 VVLGNKIDLE  NRQVATKRAQ  AWCYSKNNIP  YFETSAKEAI    NVEQAFQTIA  RNALKQETEE
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Unfortunately, as FYCO1 did not immunoprecipitate with any of the Rab7 
proteins expressed, there is not enough data to speculate whether 
phosphorylation is a mechanism of regulating transport in a particular direction.  
 
Finally, the comparison of the FRET ratios between Raichu-Rab7Wt, Raichu-
Rab7S72A and Raichu-Rab7S72E indicates that the phosphomimetic mutation 
decreases the affinity of Rab7 for the GEF, as there was a significant decrease 
cytosolic ratio for Raichu-Rab7S72E compared with both Raichu-Rab7Wt and 
Raichu-Rab7S72A. Furthermore, as there was no significant difference in the 
cytosolic or endosomal FRET ratios for Raichu-Rab7Wt and Raichu-Rab7S72A, 
this indicates that both have similar interaction profiles with GEF and GAPs, 
and hence similar activities overall.  
 
Overall, the results obtained with the phosphomimetic and phosphodeficient 
Rab7 proteins indicate that phosphorylation at S72 decreases Rab7 activity, 
possibly by inhibiting its interaction with certain effectors, such as RILP.  
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Chapter 4. Phosphorylation of Rab7 by the non-
canonical IKK family members TBK1 and IKKε  
4.1 An in vitro kinase screen to identify candidates for Rab7 
phosphorylation at serine 72 
To determine the kinases that phosphorylate Rab7 at S72, we expressed and 
purified recombinant His-tagged Rab7Wt and Rab7S72P proteins in E. coli BL-21, 
which were subsequently sent to ProQuinase GmbH (Germany) for testing of 
190 Ser/Thr kinases in in vitro kinase assays. The results of each assay are 
expressed as the ratio between Rab7 activity (cpm) and kinase 
autophosphorylation (cpm). As can be seen from the results in Figures 4.1–4.5 
and the summarised potential hits in Table 4.1, TBK1 and IKKε were the only 
two kinases out of the 190 tested that showed a significant decrease in 
phosphorylation between Rab7Wt and Rab7S72P. A number of other kinases, 
listed in Table 4.1, may also phosphorylate Rab7 but as the differences 
between Rab7Wt and Rab7S72P are negligible, they most likely phosphorylate at 
different sites.  
 
Notably, a number of protein kinase C (PKC) family members were potential 
hits in the screen for phosphorylating Rab7 at sites other than S72. A previous 
publication has investigated the possible role of PKCδ as an activator of Rab7 
(Romero Rosales et al., 2009). In this publication they showed that PKCδ 
inhibition causes lysosomal fragmentation comparable to when Rab7 is directly 
inhibited. Furthermore, PKCδ inhibition promotes growth factor-independent cell 
survival, which is reversed by expression of the constitutively active Rab7 
mutant, Rab7Q67L. Thus, as PKCδ expression is highly induced upon growth 
factor withdrawal and the amount of Rab7-GTP simultaneously increases, they 
was hypothesised that PKCδ could function as a Rab7 activator. We tested 
PKCα, PKCδ, PKCε and PKCζ in in vitro kinases assays in our lab and found 
that while all appeared to phosphorylate Rab7 to a certain extent, none were 
specific for the S72 residue. Thus, phosphorylation of Rab7 at alternative 
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residues to S72 by PKC family members could be alternative mechanisms of 
regulating Rab7 function. 
 
 
Table 4.1. Hits from the in vitro kinase screen 
 
Name WT  S72P  WT-S72P Protein Family 
IKK-ε 2.03 0.85 1.18 Ser/Thr protein kinase 
TBK1 2.56 0.67 1.89 Ser/Thr protein kinase 
IRAK4 1.32 4.73 -3.4 TKL Ser/Thr protein kinase 
ACV-R1 1.5 4.11 -2.61 TKL Ser/Thr protein kinase 
MST1/STK4 4.73 5.69 -0.96 STE Ser/Thr protein kinase 
MST2/STK3 9.13 11.04 -1.9 STE Ser/Thr protein kinase 
DYRK3 1.11 2.05 -0.94 CMGC Ser/Thr protein kinase 
MARK3/PAR-1a 1.69 2.08 -0.39 CAMK Ser/Thr protein kinase 
NEK1 3.61 4.2 -0.59 NEK Ser/Thr protein kinase 
PKCα 2.26 2.8 -0.53 AGC Ser/Thr protein kinase 
PKCβ1 3.39 3.37 0.02 AGC Ser/Thr protein kinase 
PKCβ2 4.56 4.6 -0.05 AGC Ser/Thr protein kinase 
PKCδ 3.29 3.9 -0.61 AGC Ser/Thr protein kinase 
PKCζ 1.97 2.65 -0.67 AGC Ser/Thr protein kinase 
ROCK2 1.5 3.28 -1.78 AGC Ser/Thr protein kinase 
CAMK2D 1.95 2.86 -0.91 CAMK Ser/Thr protein kinase 
PHKG1 1.56 2.6 -1.04 CAMK Ser/Thr protein kinase 
PIM3 2.39 3.05 -0.66 CAMK Ser/Thr protein kinase 
TSSK1 1.67 2.19 -0.52 CAMK Ser/Thr protein kinase 
 
Values are presented as activity/kinase autophosphorylation (cut off > 2). 
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   Figure 4.2. ProQuinase screen results 2. 
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   Figure 4.3. ProQuinase screen results 3. 
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   Figure 4.4. ProQuinase screen results 4. 
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   Figure 4.5. ProQuinase screen results 5. 
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4.1.1 The inhibitor of NF-κB kinase family 
TBK1 and IKKε are members of the IκB [inhibitor of NF-κB (nuclear factor κB)] 
kinase family, which are key regulators of the NF-κB and interferon (IFN) 
regulatory factor (IRF) families of transcription factors. The IKK family is 
composed of four members, which are grouped into two subgroups based on 
sequence homology and substrate specificity (Figure 4.6). IKKα and IKKβ are 
known as the canonical IKKs, whereas TBK1 and IKKε are the non-canonical 
IKKs. Within the IKK family, IKKα and IKKβ share 52% identity with one another, 
while TBK1 and IKKε share 61%. In contrast, sequence identity between the 
noncanonical and canonical kinases is only 24-27%. Furthermore, within the 
catalytic kinase domain, the noncanonical and canonical kinases share only 
33% identity between groups. This difference in homology in the kinases 
domain most likely accounts for the different specificities of the two groups: 
while all four members are involved in regulation of the NF-κB pathway, only 
TBK1 and IKKε are also involved in IRF-3 and IRF-7 signalling. 
 
The NF-κB pathway is involved in a number of different processes, including 
immunity, survival, development and activity of a number of different tissues, 
including the nervous system (Mincheva-Tasheva and Soler, 2013). 
Pathological dysregulation of NF-κB, and the IKKs, has been linked to 
inflammatory and autoimmune diseases, obesity and cancer (Weissmann et al., 
2014) (Mincheva-Tasheva and Soler, 2013). NF-κB is a transcriptional factor 
that regulates the expression of pro-inflammatory cytokines, such as TNF-α, IL-
1 and IL-12, inducible nitric oxide synthase (iNOS), cyclooxygenase 2 (COX-2), 
growth factors, inhibitors of apoptosis and effector enzymes, following 
stimulation of receptors that include members of the Toll-like 
receptor/interleukin-1 receptor (TLR/IL-1R) superfamily. In mammals, the NF-κB 
family is composed of five members: p50, p52, RelA (p65), RelB and c-Rel 
(Moynagh 2005; Hoffmann et al., 2006). These factors are all related and can 
form homodimers or heterodimers through binding of their N-terminal Rel 
Chapter 4. Results 2 
 106 
homology domain (RHD). In unstimulated cells, NF-κB transcriptional activity is 
silenced by interaction with inhibitory IκB proteins present in the cytoplasm. 
Activation of the NF-κB pathway results in phosphorylation of IκB, leading to its 
dissociation from NF-κB, which subsequently translocates to the nucleus and 
induces the transcription of its target genes.  
 
 
 
 
Figure 4.6. Comparison of the IKK family members. 
Schematic structure of the IKK family members. The kinase domain is located at the N-
terminus, where K44A (IKKα and IKKβ) or K38A (IKKα and TBK-1) mutations within the 
ATP-binding pocket generates dominant-negative kinases; whereas S176/180E (IKKα) 
or S177/181E (IKKβ) phosphomimetic mutations within the kinase activation loop 
generates constitutively active kinases. There are no constitutively active IKKα or TBK-
1 mutations. Adapted from Hiscott et al., 2006. 
 
Activation of the NF-kB pathway by the IKKs occurs by a number of different 
routes. The canonical pathway involves stimulation of tumour necrosis factor 
receptors (TNFRs), IL-1R and TLRs. The TNFR superfamily is composed of 19 
members that play key roles in both the adaptive and innate immune responses, 
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through binding of TNFR associated factors (TRAFs) to activate both the NF-κB 
and mitogen-activated protein kinase (MAPK) pathways. Dysregulation of the 
TNFR pathway has been linked to a number of diseases, including autoimmune 
disorders and Alzheimer’s disease (Jacob et al., 1991) (Culpan et al., 2009). 
Furthermore, the ability of the TNFR ligands TNF, FasL, and TRAIL to induce 
apoptotic cell death has been widely exploited in various cancer 
immunotherapies (Bremer, 2013).  
 
TLRs recognise pathogen-associated molecular patterns (PAMPs), which are 
present on the surface of invading pathogens, or danger-associated molecular 
patterns (DAMPs), which are endogenous molecules released from necrotic or 
dying cells. There are 13 TLRs (TLR1-13) shown in Figure 4.7, all of which 
recognise specific PAMPs (e.g. TLR7 recognises viral ssRNA in the endosome, 
whereas TLR5 recognises the bacterial protein flagellin on the plasma 
membrane) (Tsan, 2006). Of the 13 TLRs, 10 have been characterised in 
humans (TLR1–10) and 12 in mice (TLR1–9, TLR11–13). While IKKα and IKKβ 
are activated by stimulation of all TLRs, TBK1 and IKKε are activated only by 
stimulation of TLR3 and TLR4 with extracellular viral double-stranded RNA 
(dsRNA) and bacterial LPS, a lipoglycan found in the cell walls of Gram-
negative bacteria, respectively. However, TBK1 and IKKε are also activated 
downstream of melanoma differentiation-associated gene 5 (MDA5) and retinoic 
acid-inducible gene-I (RIG-I), which are cytoplasmic sensors for viral dsRNA 
and ssRNA, respectively (Chau et al., 2008).  
 
Both TLRs and IL-1Rs have a conserved region known as the Toll/IL-1R (TIR) 
domain, which signals through a pathway involving myeloid differentiation 
primary response gene 88 (MyD88), IL-1R-associated kinase (IRAK)1, IRAK4, 
transforming growth factor beta-activated kinase 1 (TAK1), TAK1-binding 
protein (TAB)1, TAB2, and TNFR-associated factor 6 (TRAF6) (Lin et al., 2010). 
This results in the formation of the IKK complex, consisting of IKKα, IKKβ and 
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Figure 4.7. Toll-like receptor signalling pathways.  
 
Innate immune pathways are activated by stimulation of Toll-like receptors 
(TLRs) either on the plasma membrane or in endosomal compartments. These 
pathways lead to the induction of NF-κB- and/or IRF-dependent transcription of 
type I interferons and/or proinflammatory cytokines. Figure generated from 
O’Neill et al., 2013. 
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the scaffolding protein NF-κB essential modulator (NEMO). The IKK complex 
directly phosphorylates IκBα and targets it for degradation by the proteasome. 
Activation of TLRs by this route is known as the My88-dependent pathway. 
TLR3 is the only TLR that cannot activate the MyD88-dependent pathway. 
Furthermore, this pathway also activates the p38 mitogen-activated protein 
kinase (MAPK) and c-Jun N-terminal kinase (JNK) cascade (Janssens and 
Beyaert, 2002).  
 
Unlike other TLRs, TLR4 is the only member that can signal from both the 
plasma membrane and the endosome (Figure 4.7). Binding of the bridging 
factor MyD88 adaptor-like protein (Mal), also known as TIR-associated protein 
(TIRAP), to TLR4 on the plasma membrane allows signalling via the MyD88-
dependent pathway that leads to activation of the IKK complex. However, 
following internalisation, TLR4 recruits another bridging factor, TRIF-related 
adaptor molecule (TRAM), to activate a MyD88-independent pathway that leads 
to activation of TRAF3 and the subsequent activation of TBK1 and IKKε 
(Fitzgerald et al., 2003). 
 
TLR3 also signals via the MyD88-independent pathway. It is initially 
synthesized as a signalling-deficient full-length (~100 kDa) protein in the 
endoplasmic reticulum. Following stimulation of cells with viral dsRNA, it is 
rapidly transported to endolysosomes, where it is cleaved into the active form 
(~70 kDa) by cathespins B and H. Once cleaved and activated, TLR3 forms a 
homodimer that directly binds TIR domain-containing adapter inducing IFN-β 
(TRIF) to activate both TRAF3- and TRAF6-dependent pathways (Garcia-
Cattaneo et al., 2012) (Yamamoto et al., 2002). Both TLR3- and TLR4-
mediated activation of TBK1 and IKKε, and their subsequent phosphorylation 
and activation of the transcriptional factor IRF3, occurs via TRAF3 (Figure 4.7).  
 
A previously published large-scale analysis of protein-protein interactions in 
human cells used >400 bait proteins to pull down specific interactors for each 
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bait protein (Ewing et al., 2007). When they used IKKε and TRAF6 as bait 
proteins, Rab7 was identified as an interactor for both. In their analysis the 
authors used a cut-off of 0.3, where anything above was of high confidence and 
anything below was a low confidence hit; a value of 0 indicated that the prey 
protein was present at the lowest acceptable score. When they used IKKε as 
the bait protein, the confidence score for the interaction with Rab7 was 0.271, 
whereas when they used TRAF6 the score was 0 (Ewing et al., 2007). Thus, 
neither interaction of IKKε or TRAF6 with Rab7 was investigated any further. 
Although both interactions were below the cut-off, the interaction between IKKε 
and Rab7 was close enough that it could be a realistic interaction, especially 
following the results of our screen.  
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4.2 Rab7 is phosphorylated in vitro by the noncanonical IKK 
family members, TBK1 and IKKε 
The results of the ProQuinase kinase screen were subsequently validated in 
our laboratory by Giampietro Schiavo using [γ-32P]ATP in vitro kinase assays 
for TBK1 and IKKε. The other two members of the IKK family, IKKα and IKKβ, 
were also tested for phosphorylation at S72 to ensure the results of the screen 
were accurate and confirm specificity. Results revealed that Rab7Wt was 
phosphorylated by both TBK1 and IKKε, whereas neither phosphorylated 
Rab7S72P (Figure 4.8). Furthermore, neither IKKα nor IKKβ had any effect on 
the phosphorylation status of Rab7Wt or Rab7S72P.  
 
 
 
 
 
Figure 4.8. In vitro kinase assay for the phosphorylation of Rab7 at S72 by the 
IKK family members, IKK-α, IKK-β, TBK1 and IKK-ε.  
Recombinant Rab7Wt and Rab7S72P (control), 2 µg each, were incubated fro 1 h at room 
temperature in the presence of 32P, and analysed by SDS-PAGE and autoradiography. 
TBK1 and IKK-ε phosphorylated Rab7 specifically at S72, whereas IKKα and IKKβ did 
not phosphorylate anywhere. The lower panel is the Coomassie staining of the gel to 
show that equal amounts of protein were loaded in each lane.  
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4.3 Antibody testing 
Following confirmation that TBK1 and IKKε phosphorylate Rab7 at S72, I 
decided to test the specificity of two anti-pRab7(S72) antibodies that were 
produced by inoculating two rabbits with a short peptide containing the 
phosphorylated Ser72 within the wild-type human sequence (CERFQpSLGVA-
CONH2). Following inoculation, phosphatases present in the blood and tissue 
dephosphorylate some of the peptide, yielding sera containing antibodies 
against both the nonphosphorylated (Rab7-OH) and S72-phosphorylated Rab7 
(pRab7(S72)) peptides. The levels of each antibody can vary, so their specificity 
was firstly tested by ELISA against the phosphopeptide used for immunization 
and the corresponding nonphosphorylated CERFQSLGVA-CONH2 peptide. The 
final bleed from each rabbit was examined, using the corresponding prebleeds 
as controls. The results of the ELISA can be seen in Figure 4.9, which shows 
that the antiserum from the rabbit designated 192 is more specific than rabbit 
191.  
 
Following the ELISA, I tested whether this serum was specific for recombinant 
full-length Rab7 phosphorylated at S72. Recombinant His-tagged Rab7WT was 
phosphorylated in vitro with TBK1 and analysed by SDS-PAGE and western 
blot. The anti-pRab7(S72) antibody was incubated with 1 mg/ml of the 
unphosphorylated peptide for 2 h at 4°C prior to use to saturate the 
nonphospho-antibody. The antibody was used at a 1:500 dilution and incubated 
overnight at 4°C. As can be seen in Figure 4.9, the antibody recognized only 
the phosphorylated protein. The blot was reprobed with a mouse anti-Rab7 
antibody to confirm that equal amounts of phosphorylated and non-
phosphorylated protein were loaded (Figure 4.9), thus confirming that the 
antibody is specific for pRab7(S72). 
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Figure 4.9. Testing specificity of the anti-pRab7(S72) antibody. 
A. Antibody specificity of the anti-phospho-Rab7 (S72) antibody was examined 
by ELISA using the phosphorylated and non-phosphorylated versions of the 
peptide used for immunisation the rabbit. B. After saturating the non-
phosphoantibody with 1 mg/ml unphosphorylated peptide, the antibody was 
tested on recombinant Rab7 that had been in vitro phosphorylated with TBK1. 
Non-phosphorylated recombinant Rab7 was used as a control. As can be seen 
from the blots the antibody was highly specific for the phosphorylated Rab7. 
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4.4 BX795 and MRT67306 inhibit TBK1- and IKKε-mediated 
phosphorylation of Rab7 at serine 72 in vitro 
BX795 and MRT67307 are two published chemical inhibitors of TBK1 and IKKε 
(Clark et al., 2011; Clark et al., 2009). BX795 was originally discovered as a 
potent inhibitor of TBK1- and IKKε-mediated phosphorylation and activation of 
IRF3 and the subsequent production of IFNβ, without inhibiting NF-κB activation 
by IKKα and IKKβ. Although it blocked the autophosphorylation of both kinases, 
it did not inhibit phosphorylation at their active site (S172) following stimulation 
of mouse RAW264.7 macrophages with poly(I:C), LPS, TNFα or IL-1α, but 
actually enhanced phosphorylation of this residue (Clark et al., 2009). 
Furthermore, it also had off target effects as it suppressed the activation of JNK 
and p38α MAPK by LPS or poly(I:C). Thus, BX795 was modified to create the 
improved inhibitor MRT67307, which no longer suppressed the activation of 
JNK or p38α MAPK by inflammatory stimuli, such as poly(I:C) and IL-1 (Clark et 
al., 2011).  
 
Both inhibitors were tested to determine if they could suppress TBK1 and IKKε 
phosphorylation of Rab7 at S72 in vitro. BX795 and MRT67307 are both 
recommended for use at a concentration of 2 µM in cellular assays. Thus, to 
ensure sufficient activity in vitro, they were both examined at 0.2, 2 and 20 µM. 
Following incubation at 30°C for 30 min, samples were subjected to SDS-PAGE 
and western blot with the anti-pRab7(S72) antibody. 
 
The results revealed that BX795 was more effective at inhibiting TBK1 
phosphorylation of Rab7, but the differences at 2 µM were not significant, with 
both inhibiting phosphorylation by >95% (Figure 4.10). 
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Figure 4.10. Inhibition of TBK1-mediated phosphorylation of Rab7 at S72 with 
BX795 and MRT67306. 
Rab7 phosphorylation at S72 by TBK1 was performed under increasing 
concentrations of the two inhibitors of TBK1 and IKKε, BX795 and MRT67307. 
Both inhibitors were highly effective at concentrations of 2 µM and 20 µM, with 
BX795 exhibiting slightly stronger inhibition at 2 and 0.2 µM. 
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4.5 Rab7 is phosphorylated at serine 72 following stimulation 
of the viral dsRNA-activated toll-like receptor, TLR3  
Following the results of these in vitro experiments, I wanted to examine whether 
phosphorylation of Rab7 at S72 could be stimulated in a cellular model. It has 
been previously shown that TLR3 signalling requires endosomal acidification, 
as pre-treatment with chloroquine or bafilomycin A1 inhibits TLR3-induced 
cytokine secretion and IFN-β promoter activation (Funami et al., 2004; Itoh et al., 
2008). Thus, as TLR3 signalling is dependent on the endolysosomal system 
and possibly Rab7 activity, I decided to firstly determine if phosphorylation at 
S72 occurs following stimulation of TLR3 with poly(I:C), a synthetic analog of 
dsRNA. The experiment was performed in MEFs, as they have been previously 
shown to express TLRs 1-9 and transfect much better than immune lineage 
cells (Kurt-Jones et al., 2004). 
 
As there was no reliable Rab7 antibody for immunoprecipitation available, with 
GFP-Rab7WT was transfected in MEFs overnight, following which cells were 
stimulated with 10 µg/ml poly(I:C) for 30, 60 and 90 min. Unstimulated and 
serum-starved controls were included to compare basal levels of 
phosphorylation between the samples. One sample was also preincubated with 
BX795, an inhibitor of TBK1 and IKKε, for 2 h at 37°C to determine if it the basal 
levels of phosphorylation could be affected. Following stimulation with poly(I:C), 
GFP-Rab7WT was immunoprecipitated from cell lysates using GFP-trap beads 
and analysed by SDS-PAGE and western blot using the rabbit anti-pRab7(S72) 
antibody. Blots were probed with a mouse anti-Rab7 antibody (Abcam) for 
quantification of phosphorylation relative to the levels of transfection.  
 
Results were analysed using one-way ANOVA, followed by Dunnett’s multiple 
comparisons test to compare each sample with the untreated control. There 
was a steady increase in phosphorylation at S72 over the 180 min period, with 
a 3.6-fold increase compared to basal levels at the final time point. All poly(I;C)-
stimulated samples showed significant increases in phosphorylation compared 
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with the control sample, with the strength of significance increasing with time. 
There was very little difference in the starved condition, while there was a slight 
increase in phosphorylation in the cells treated with BX795.  
 
 
 
 
 
 
 
Figure 4.11. poly(I:C)-induced phosphorylation of GFP-Rab7 at S72 in MEFs. 
MEFs overexpressing GFP-Rab7 were stimulated with 10 µg/ml poly(I:C) for 30, 
60, 120 and 180 min to determine phosphorylation of Rab7 at S72. The BX795 
inhibitor of TBK1 and IKKε was included as a control but it increased the levels 
of phosphorylation rather than decrease them. A starved control was also 
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included as cells were starved for 2 h prior to stimulation. Poly(I:C) stimulation 
caused a steady increase in phosphorylation at S72 up to 180 min.  
 
BX795 is a pharmacological inhibitor of TBK1 and IKKε that has been shown to 
blocks the phosphorylation, nuclear translocation, and transcriptional activity of 
IRF3 and, consequently, the production of IFN-β in macrophages stimulated 
with poly(I:C) or LPS (Clark et al., 2009). Activation of TBK1 and IKKε requires 
phosphorylation of S172 in their active site. BX795 does not block 
phosphorylation of this residue, but actually enhances it in response to LPS, 
poly(I:C), IL-1α, or TNFα. Furthermore, BX795 inhibited the activation of JNK 
and p38α MAPK by inflammatory stimuli, thus limiting its use as a probe for 
IKKϵ and TBK1. Thus, BX795 was modified to produce MRT67307, which 
inhibited IRF3 phosphorylation and IFNβ production in macrophages, but no 
longer suppressed the activation of JNK or p38 MAPK (Clark et al., 2011). 
Similar to BX795, MRT67307 treatment of macrophages enhanced poly(I:C)- 
and LPS-stimulated phosphorylation of TBK1 at Ser172, and enhanced the 
catalytic activity of IKKϵ and TBK1 in in vitro enzymatic assays, following their 
immunoprecipitation from extracts of poly(I:C)-stimulated cells. 
 
After obtaining the improved TBK1 and IKKε inhibitor, MRT67307, I tested 
whether it could inhibit Rab7 phosphorylation at S72 following stimulation of 
MEFs with 10 µg/ml poly(I:C). Surprisingly, there was increased 
phosphorylation of Rab7 at S72 in cells treated with the inhibitor compared to 
the control. As there was also an increased basal level of phosphorylation at 
S72 when cells were incubated with the first generation inhibitor, BX795, the 
inhibitors were abandoned for future experiments. While these inhibitors inhibit 
IRF3 phosphorylation, they may not affect the activity of TBK1 and IKKε for 
other substrates. 
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Figure 4.12. Testing MRT67307 inhibition of poly(I:C)-induced phosphorylation of 
Rab7 at S72. 
 
MEFs overexpressing GFP-Rab7 were treated with 2 µM MRT67307 to inhibit 
TBK1 and IKKε activity or vehicle control for 2 h prior to stimulation with 10 
µg/ml poly(I:C) for 60, 120 and 180 min. Results revealed that there was 
increased phosphorylation in cells treated with the inhibitor compared to those 
without. 
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4.6 Rab7 is phosphorylated at serine 72 following stimulation 
of the bacterial LPS-activated toll-like receptor, TLR4 
As mentioned previously, TLR4 is a membrane-bound receptor that recognises 
bacterial LPS on the surface of immune and epithelial cells. It is the only TLR 
that requires a co-receptor, the small lipid-binding glycoprotein myeloid 
differentiation factor 2 (MD-2), to bind its ligand. After activation of TLR4 at the 
plasma membrane, signalling via the MyD88-dependent pathway occurs within 
minutes of binding the Mal-MyD88 adaptor pair; however, approximately 30 min 
later, TLR4 is internalised, where it interacts with the TRAM-TRIF complex to 
signal via the MyD88-independent pathway in endosomes and lysosomes 
(Kagan et al., 2008). Signalling through the MyD88-dependent pathway results 
in activation of IKKα and IKKβ, whereas signalling via the MyD88-independent 
pathway results in activation of TBK1 and IKKε.  
 
To ensure activation of the noncanonical IKKs, 0, 1, 2 and 4 h time points were 
used for stimulation with 1 µg/ml LPS from E. coli 0111:B4. As can be seen 
from the results in Figure 4.13, LPS caused a 1.7-fold increase in Rab7 
phosphorylation at S72 after 1 h stimulation, which increased to 2.4-fold at 2 
and 4 h.  
 
Unfortunately, at the time I was unable to repeat this experiment and when I 
thawed the next set of MEFs, they were SV40-immortalised, which the original 
cells were not, and did not respond to stimulation with LPS. The original cells 
were spontaneously immortalised in culture and had been given to me by a 
previous member of the group. Unfortunately, there were no vials of these left in 
the stocks when I went to repeat these experiments. 
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Figure 4.13. LPS stimulation of TLR4 in MEFs. 
MEFs overexpressing GFP-Rab7 were stimulated with 1 µg/ml LPS from E. coli 
0111:B4 for 1, 2 and 4 h to determine phosphorylation of Rab7 at S72. Levels were 
compared to the basal levels in unstimulated cells (0 h). LPS stimulation caused 2.4-
fold increase in phosphorylation at S72 at 2 h, and remained constant at 4 h. 
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4.7 Discussion 
Rab7 has been previously identified in phosphoproteomic screens as being 
phosphorylated on 11 different sites, with S72 and Y183 showing up in the 
highest number of screens, indicating that these are physiologically important 
and regulated by widespread-activated kinases. Phosphorylation of Rab7 at 
S72 was identified in various screens in human cells, including TBK1 signalling 
in lung cancer cells (Kim et al., 2013), the DNA damage response (Bennetzen 
et al., 2010), the mitotic phosphoproteome (Olsen et al., 2010), and T cell 
receptor signalling (Mayya et al., 2009), while in mouse cells it was identified in 
screens including TLR4-stimulated macrophages (Weintz et al., 2010), IFN-γ-
activated macrophages (Trost et al., 2009), and mTORC1-mediated inhibition of 
growth factor signalling (Hsu et al., 2011). S72 phosphorylation has also been 
identified in screens investigating the phosphoproteome of various tissues 
under basal conditions, including the brain, lung, liver, pancreas, spleen and 
testis (Huttlin et al., 2010). However, all of the publications identifying S72 as a 
possible site for phosphorylation on Rab7 excluded it from their main hits as it 
was below the study threshold values or undetected in repeat experiments, and 
thus it was never investigated in more detail.  
 
In this study, 190 serine/threonine kinases were screened for phosphorylation 
of Rab7Wt at S72, using Rab7S72P as a control. The screen identified only two 
kinases, TBK1 and IKKε, which specifically phosphorylate Rab7 at S72 in vitro. 
Most of the literature on TBK1 and IKKε has been focused on their roles in NF-
κB and IRF3/IRF7 signalling via activation of TLR3 and TLR4. Interestingly, a 
number of other kinases involved in pathways regulated by TBK1 and IKKε 
were also examined in the screen. IRAK4, an important regulator of the MyD88-
dependent pathway that is activated following TLR4 stimulation at the plasma 
membrane was also identified as a potential hit, but as it phosphorylated the 
Rab7S72P protein higher than Rab7Wt, it most likely phosphorylates Rab7 
elsewhere (Table 4.1). It would be interesting to determine if IRAK4 
phosphorylates Rab7 at another site and whether this has any effect on Rab7 
Chapter 4. Results 2 
 123 
activity as activation of the MyD88-dependent pathway promotes the 
degradation of TRAF3, an important regulator of TBK1 and IKKε activity.  
 
In unstimulated cells, TRAF3 is constitutively bound to NIK, an essential 
activator of the alternative NF-κB pathway, which is activated during the 
generation of B and T lymphocytes following ligation of lymphotoxin-β receptor 
(LTβR), B cell-activating factor receptor (BAFFR), and CD40R. NIK activates 
IKKα, which phosphorylates of IκB, resulting in its dissociation from NF-κB, 
which subsequently translocates to the nucleus and induces the transcription of 
its target genes. IKKα, IKKβ and NIK were all tested in the ProQuinase screen, 
but all three were well below the threshold and exhibited no differential 
phosphorylation between Rab7Wt and Rab7S72P (Figures 4.1–4.5). 
 
All four members of the IKK family were subsequently tested in [γ-32P]ATP in 
vitro kinase assays to confirm their phosphorylation activity on S72 and ensure 
specificity was restricted to the noncanonical IKKs. The results revealed that 
both TBK1 and IKKε phosphorylated Rab7 at S72, while neither IKKα nor IKKβ 
phosphorylated Rab7 at S72 or any position (Figure 4.8). TBK1 and IKKε are 
activated mainly by the MyD88-independent pathway following stimulation of 
TLR3, TLR4, MDA-5 and RIG-I. Indeed, stimulation of TLR3 with poly(I:C) in 
MEFs resulted 3.6-fold increase in phosphorylation of Rab7 at S72 after 180 
min, whereas stimulation of TLR4 with LPS resulted in a 2.4-fold increase after 
120 min. The increase in phosphorylation following LPS stimulation did not 
increase between 120 and 240 min, although this could be a result of saturation 
of the signal, as only a fraction of Rab7 is likely to be on this compartment at 
steady state. When these were repeated in SV40-immortalised cells they were 
unresponsive to stimulation.  
 
After showing phosphorylation of Rab7 at S72 increases in wild-type MEFs 
following stimulation of TLR3 and TLR4, the next step was to inhibit TBK1 and 
IKKε to see if this decreased phosphorylation following stimulation. Although the 
TBK1 inhibitors, BX795 and MRT67307, inhibited phosphorylation of Rab7 at 
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S72 in vitro and have previously been shown to inhibit TBK1- and IKKε-
mediated phosphorylation of IRF3 in macrophages, they did not reduce basal 
levels of Rab7 phosphorylation, even when incubated overnight in the presence 
of the inhibitors. This could be the result of other kinase(s) phosphorylating 
Rab7 at S72 under basal conditions. Further investigation is required to 
determine if there are other kinases responsible for phosphorylating under 
these conditions. Phosphorylation was also examined in TBK1-/- MEFs following 
stimulation of TLR3 and TLR4. However, the behaviour of the TBK1-/- MEFs in 
comparison to their wild-type littermates was completely different. The TBK1-/- 
MEFs transfected approximately five times their wild-type littermates and 
appeared to proliferate at a faster speed, thus making it very difficult to estimate 
the same levels of transfection and amount of protein when performing GFP-
Rab7 immunoprecipitation. There were also increased levels of phosphorylation 
at S72 after 8 h in the TBK1-/- MEFs, with a corresponding increase in pIRF3. 
This could be a result of the induction of IKKε expression that occurs at ~8 h 
following infection. 
 
Ideally, these experiments should be performed in macrophages as they are 
much more responsive to LPS and poly(I:C) stimulation; however, as they do 
not transfect well this limits their use. Macrophages are programmed to remove 
exogenous DNA they have engulfed and therefore the optimal mechanism for 
transfecting them is to use viral vectors. However, viral vectors may activate the 
pathways regulating TBK1 and IKKε activity. To address this limitation, viral 
vectors could be used to create stable cell lines. Once the DNA has integrated 
into the genome, the cells should switch off virally activated pathways allowing 
for their subsequent activation using exogenous stimuli. In macrophages Rab7, 
along with its effectors FYCO1 and RILP, have been shown to be required for 
lysosomal tubulation following stimulation with LPS (Mrakovic et al., 2012). 
FYCO1 is responsible for plus-end directed transport of late 
endosome/lysosome, whereas RILP interacts with the p150(Glued) subunit of 
the dynactin motor for minus end-directed transport (Pankiv et al., 2010) 
(Johansson et al., 2007b). Thus, as was seen in Chapter 3 (Figure 3.10) RILP 
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binding was significantly reduced by approximately 80% to the phosphomimetic 
Rab7S72E, compared to Rab7Wt and Rab7S72A. Thus, phosphorylation of Rab7 at 
S72 could be a mechanism for promoting association with specific effectors, 
and inhibiting association with others, such as RILP, which are more important 
for homeostatic functions. Furthermore, as kinesin has been shown to be 
paramount for the formation of tubular lysosomes in macrophages, this could 
support the hypothesis that inhibition of Rab7 binding to RILP occurs by 
increased phosphorylation of Rab7 at S72 following stimulation of TBK1- and 
IKKε-activating pathways during infection. 
 
Another process where Rab7 has been shown to be important and could be 
regulated by phosphorylation at S72 is MHC class II antigen presentation. 
When exogenous antigens are taken up into B cells, dendritic cells and 
macrophages they are exposed to an environment of increasing acidity and 
proteolytic activity as they progress along the endosomal pathway (Bertram et 
al., 2002). In the late endosomal compartment, these antigenic peptides 
associate with MHC class II molecules, which are then transported to the cell 
surface for presentation to CD4+ T cells. During this process these MHC class 
II-positive compartments form tubular structures, which originate from late 
endosome/lysosomes and polarize toward the T cell via retrograde transport 
(Chow et al., 2002). Furthermore, overexpression of Rab7 was shown to 
increase the rate of antigen processing and presentation in B cells (Bertram et 
al., 2002). These results also support a hypothesis in which phosphorylation of 
Rab7 at S72 could be a mechanism for redirecting Rab7 function from normal 
homeostatic functions toward being an essential component of the innate 
immune response. Future investigation should examine whether 
phosphorylation of Rab7 at S72 occurs on endosomal membranes of antigen-
presenting cells and examining the interactors required for the formation of 
tubular structures. 
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Chapter 5. Differential activities of pRab7(S72) and 
unphosphorylated Rab7 
 
5.1 Membrane-associated Rab7 is preferentially 
phosphorylated compared to cytosolic Rab7 
While the phosphomimetic Rab7S72E mutant is completely cytosolic, it is still 
unclear whether this mutant is an effective reporter of the effect phosphorylation 
at S72 would have on Rab7. The cytosolic localisation of Rab7S72E could be 
caused by inhibition of its interaction with REP1, as REP1 interacts with Rab7 
at S72, which would thereby prevent C-terminal prenylation and subsequent 
recruitment to endosomal membranes. This, however, is not an optimal 
indicator of what occurs in vivo, as inhibition of the REP1 interaction, following 
phosphorylation of Rab7 at S72 by TBK1 and IKKε, would only affect newly-
synthesised Rab7, whereas the increases observed following poly(I:C) and LPS 
stimulation by western blot would suggest that a much larger population is 
phosphorylated. Thus, I decided to perform subcellular fractionation to 
determine the localisation of pRab7(S72). 
 
GFP-Rab7Wt was transfected for 48 h in MEFs, following which they were 
stimulated with 10 µg/ml poly(I:C) for 4 h. Cells were lysed by allowing them to 
swell under hyperosmotic stress in a sucrose-containing buffer, following which 
they were passed through a 17.5-gauge needle (15-20 times). Nuclei and any 
remaining whole cells were removed by two centrifugations at 1000 × g, for 10 
min each. Cleared lysates were centrifuged at 100,000 × g for 1 h at 4°C to 
obtain the cytosolic (supernatant) and membrane (pellet) fractions. The 
membrane pellet was washed once in the sucrose-containing buffer, following 
which the membranes were dissolved in RIPA buffer. Both the cytosolic and 
membrane fractions were then treated with GFP-Trap® beads to 
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immunoprecipitate GFP-Rab7Wt, following which SDS-PAGE and western blots 
were performed to determine the ratios of pRab7(S72) to total Rab7.  
 
In the initial experiments, the total cytosolic and membrane fractions were 
analysed by western blot. However, as can be seen from Figure 5.1.A, the 
cytosolic fraction contained 10–20-fold more total Rab7 than the membrane 
fraction. While there was some pRab7(S72) in the cytosolic fraction it was a tiny 
amount in comparison to the membrane fraction. Furthermore, following 
stimulation with poly(I:C) there appeared to be a decrease in the  pRab7(S72) 
associated with the membrane. These experiments were performed using one 
10-cm dish per sample, which is the same condition as what had been used 
previously with the poly(I:C) and LPS stimulation experiments for total cellular 
changes in pRab7(S72). However, due to the different conditions used for the 
subcellular fractionation, a significant amount of material seemed to be lost 
during the experiment. To combat this, the amount of material was increased to 
one 20-cm dish per sample. Furthermore, the amount of material loaded from 
the cytosolic fraction was decreased to approximately 10% of the overall 
volume, so that the total Rab7 for each sample was similar. After increasing the 
amount of material used for the subcellular fractionation, it was clear that the 
overall ratio of pRab7(S72) to total Rab7 was significantly higher in the 
membrane fraction compared to the cytosolic fraction.  
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Figure 5.1. Subcellular fractionation of GFP-Rab7 in MEFs stimulated with 
poly(I:C). 
GFP-Rab7Wt was transfected in MEFs for 48 h, following which cells subjected to 
subcellular fraction by centrifugation at 100,000 × g for 1 h at 4°C. The entire 
membrane and cytosolic fractions were subjected to GFP-trap to immunoprecipitate 
the GFP-Rab7Wt, following which the entire fractions were loaded in (A) and 
approximately 10% of the cytosolic fraction was loaded in (B). pRab7(S72) was 
detected using the rabbit anti-pRab7(S72) antibody, following which the blots were 
stripped and reprobed with a mouse total (t)Rab7 antibody. From both experiments we 
can see a much higher ration or pRab7(S72) to total Rab7 is found in the membrane 
fraction compared to the cytosol. 
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Following the results of the subcellular fractionation, I purified the anti-
pRab7(S72) antibody to examine pRab7(S72) localisation by 
immunofluorescence. This had been previously attempted but we did not have 
a good antibody for total Rab7 to confirm that the staining was specific.  
 
MEFs were stained with the rabbit anti-pRab7(S72) antibody (1:500) for 2 h, 
followed by and anti-rabbit AlexaFlour 488 secondary antibody. The cells were 
post-fixed for 5 mins in 4% PFA. Following this, the cells were stained for total 
Rab7 using a rabbit anti-Rab7 antibody and anti-rabbit AlexaFlour 555 
secondary antibody. This method prevents the secondary antibody used for the 
anti-pRab7(S72)  antibody from accessing the total anti-Rab7 antibody. Thus, 
any colocalisation would not be a result of non-specific staining of the anti-
pRab7(S72)  antibody. The control sample was performed in the same manner, 
with the incubation with the total Rab7 antibody being substituted for PBS 
containing 1% BSA. 
 
From the results it is clear that a large proportion of the pRab7(S72)  pool is 
located on punctate structures, all of which co-stain for Rab7. However, only a 
minority of all of the Rab7-positive puncta are positive for pRab7(S72). This 
indicates that the pRab7(S72)-positive structures are a subpool of the total 
Rab7 population of late endosomes/MVB or lysosomes. The control sample 
shows high background, but no punctate staining reminiscent of the 
pRab7(S72) staining. 
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Figure 5.2. Localisation of pRab7(S72) by immunofluorescence. 
MEFs were stained for pRab7(S72), followed by a total Rab7 antibody.  The 
pRab7(S72) pool of organelles appear to be a sub-population of the total Rab7-positive 
compartment. The middle panel shows the double- and single-positive organelles 
highlighted by boxes in the top panel. The bottom panel shows control staining 
incorporating both secondary antibodies, but excluding the total Rab7 antibody, which 
is most notable in the perinuclear region. 
 
pRab7(S72) tRab7 Merge
pRab7(S72) A555 Merge
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5.2 Phosphorylation of Rab7 at S72 increases the rate of GTP 
hydrolysis in vitro 
Inactivation of all Rab proteins occurs via hydrolysis of the γ-phosphate of GTP 
to yield GDP, mainly through interaction with a GAP. GDP is then removed by 
interaction with a GEF. However, some Rabs have GAP-independent intrinsic 
activities for GTP hydrolysis, which is catalysed by a conserved glutamine 
residue (Q67 for Rab7), and GDP dissociation. It has been previously shown 
that the constitutively active mutation Q67L exhibits decreased intrinsic GTP 
hydrolysis, with no impairment in GTP binding (Spinosa et al., 2008). This 
mutation is in close proximity to the S72 residue, which, when phosphorylated, 
may also affect GTP hydrolysis and/or binding.  
 
His-tagged Rab7Wt was phosphorylated in vitro with IKKε at 30°C for 30 min. 
Following this, unphosphorylated and IKKε-phosphorylated Rab7Wt were bound 
to Ni2+ beads, loaded with [α-P32]GTP and incubated at 37°C for various time 
points to allow GTP hydrolysis to occur. The assay was performed in the 
absence of excess cold GTP. This will allow dissociation of GDP and further 
binding of [α-P32]GTP. This method is more efficient when looking at GTP 
hydrolysis, whereas performing the incubation step in excess cold GTP allows 
analysis of the hydrolysis rate per binding event and the nucleotide dissociation 
activity, as only the bound [α-P32]GTP would be hydrolysed and following 
dissociation of GDP, Rab7 would be more likely to bind cold GTP. 
 
The results revealed that phosphorylation of Rab7 at S72 caused a steady 
increase in GTP hydrolysis compared to the unphosphorylated control, which 
was significantly increased at both 60 (P = 0.0035) and 120 min (P = 0.0002). 
Furthermore, binding of [α-P32]GTP was increased in pRab7(S72). The assay 
was also performed in excess cold GTP (10 mM), but there was very little 
hydrolysis of [α-P32]GTP and difference between the unphosphorylated and 
pRab7(S72) proteins was not significant (n = 2, not shown). Statistical analysis 
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was performed using two-way ANOVA followed by Sidak’s multiple 
comparisons test. 
 
Figure 5.3. In vitro [α-P32]GTP hydrolysis activity of unphosphorylated and S72-
phosphorylated Rab7. 
The intrinsic GTP hydrolysis activity of pRab7(S72) was compared to 
unphosphorylated Rab7 using [α-P32]GTP. The top image shows the phosphorimager 
analysis and the bottom shows the quantification of three independent experiments. 
pRab7(S72) exhibits increased GTPase activity compared to unphosphorylated Rab7, 
which is significantly increased at both 60 (P = 0.0035) and 120 min (P = 0.0002). n = 3. 
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5.3  Pull-down and mass spectrometry of differential 
interactors of Rab7 following phosphorylation at S72 
 
Following the results of the subcellular fractionation and the 
immunofluorescence using the anit-pRab7(S72) antibody, which revealed that a 
significant proportion of pRab7(S72) was membrane-bound, I decided to do a 
pull-down and mass spectrometry using recombinant GST-Rab7 +/- TBK! 
phosphorylation to look for differential interactors between unphosphorylated 
Rab7 and pRab7(S72). In the earlier experiments investigating the differential 
interactions of Rab7Wt, Rab7S72A and Rab7S72E with RILP and ORP1L, ORP1L 
bound equally to all three proteins, whereas RILP binding to the Rab7S72E 
mutant was significantly decreased by around 80% (Figure 3.10). However, the 
phosphomimetic Rab7S72E mutation exhibits a completely cytosolic localisation, 
which is in complete contrast to the subcellular fractionation and the 
immunofluorescence results. Thus, the pull-down and mass spectrometry was 
performed to determine if phosphorylation of Rab7 at S72 affects interaction 
with different effectors.  
 
GST-Rab7 was bound to GSH-agarose resin, following which it was split into 
two samples, unphosphorylated and TBK1-phosphorylated GST-Rab7 samples. 
The pRab7(S72) sample was phosphorylation in vitro using His-TBK1 at 30°C 
for 30 min on a shaking hotblock. Samples were then washed once in TBK1 
buffer without kinase. Then, bound nucleotides were removed by washing twice 
with 1 M guanidine-HCl, and then loaded with GTPγS. Two 10-cm dishes of 
confluent HEK293 cells were used to prepare lysates, which were mixed 
together and pre-cleared of nonspecific binding proteins using empty GSH-
agarose beads, before splitting in two for the pull-down. Half of the pull-down 
was used for mass spectrometry and the other half was used for western blot 
analysis of interactors. 
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Prior to obtaining the mass spectrometry results, I decided to test the remaining 
samples from the pull-down for interaction of endogenous interaction RILP and 
ORP1L with the GST-tagged unphosphorylated Rab7 and pRab7(S72). The 
results revealed ORP1L interacted with both unphosphorylated Rab7 and 
pRab7(S72), whereas RILP interacted with only the unphosphorylated protein 
(Figure 5.4).  
 
 
 
Figure 5.4. Association of endogenous ORP1L and RILP to unphosphorylated 
and pRab7(S72) . 
GST-Rab7 bound to GSH-agarose beads was phosphorylated at S72 using TBK1. 
Following this both phosphorylated and unphosphorylated GST-Rab7 samples were 
incubated with HEK283 cell lysates. Half of the sample was used for mass 
spectrometry and the other half was loaded for western blot analysis. RILP, ORP1L 
and p150(Glued) were detected using specific antibodies, while total Rab7 was 
detected using a mouse anti-Rab7 antibody and pRab7(S72) was detected using the 
rabbit anti-pRab7(S72) antibody. 
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The mass spectrometry results identified a number of differential interactors for 
unphosphorylated Rab7 and pRab7(S72) (Table 5.1), as well as a larger 
number of common interactors (Table 5.2). Surprisingly, although the western 
blot of the mass spectrometry samples detected ORP1L and RILP interactions, 
neither was detected in the mass spectrometry analysis. However, the 
p150(Glued) subunit of the dynactin complex, which binds to ORP1L and RILP 
for microtubule minus-end directed transport of late endosomes, showed a 
specific interaction with pRab7(S72) in the mass spectrometry (Figure 5.4). This 
interaction was confirmed by western blot, which showed 2.7 time more 
p150(Glued) associated with pRab7(S72) compared to the unphosphorylated 
Rab7 (Figure 5.4). The p50 subunit of the dynactin complex interacted with both 
pRab7(S72) and unphosphorylated Rab7. Cytoplasmic dynein 1 intermediate 
chain 2 (DC1I2) and cytoplasmic dynein 1 heavy chain 1 (DYHC1) were also 
detected, with DC1I2 selectively binding unphosphorylated Rab7 and DYHC1 
binding both proteins, but with a 2.2-fold higher affinity for pRab7(S72). These 
results that phosphorylation of Rab7 at S72 seems to bypass the need of RILP 
for dynein recruitment, which agrees with the study of Vihervaara et al., which 
found that ORP1L was sufficient to recruit p150(Glued) and the dynein motor to 
Rab7-positive endosomes (Vihervaara et al., 2011). 
 
Other interesting interactors from the mass spectrometry data include TRAF3, 
TRAF4, REP1 and vimentin. Both REP1 and vimentin are known interactors of 
Rab7, whereas TRAF3 and TRAF4 are potentially novel binding partners. 
TRAF3, TRAF4, and REP1 were all only detected in the unphosphorylated 
Rab7 sample, with TRAF3 being the strongest hit. 
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Number of Peptides 
Identified Proteins Rab7-OH pRab7(S72) 
TNF receptor-associated factor 3 (TRAF3) 7 0 
Stress-70 protein, mitochondrial (GRP75) 3 0 
T-complex protein 1 subunit gamma (CCT3) 2 0 
Cytoskeleton-associated protein 4 (CKAP4) 2 0 
Cytoplasmic dynein 1 intermediate chain 2 (DC1I2) 2 0 
Rab escort protein 1 (REP1) 1 0 
TNF receptor-associated factor 4 (TRAF4) 1 0 
Transitional endoplasmic reticulum ATPase (TERA) 0 5 
Leucine-rich PPR motif-containing protein (LPPRC) 0 5 
Spectrin beta chain, non-erythrocytic 1 (SPTB2) 0 4 
Dynactin subunit 1 (p150(Glued)) - DCTN1 0 3 
Transportin-1 0 3 
Death-inducer obliterator 1 (DIDO1) 0 3 
CCAR1 0 2 
Developmentally-regulated GTP-binding protein 1 0 2 
Importin subunit beta-1 (IMB1) 0 2 
RRP12-like protein (RRP12) 0 2 
Transformer-2 protein homolog beta (TRA2) 0 2 
Rab1A 0 2 
Arginine/serine-rich coiled-coil protein 2 0 2 
Neutrophil defensin 1 (DEF1) 0 2 
Rab34 0 1 
 
Table 5.1. Mass spectrometry results of the proteins found to differentially 
interact with unphosphorylated Rab7 and pRab7(S72). 
A number of differential interactors were identified by mass spectrometry for 
unphosphorylated Rab7 and pRab7(S72). The list includes hits proteins with >3 
peptides detected and interesting hits for those with <3 peptides. The proteins 
highlighted in yellow are known interactors of Rab7, while the proteins in red are 
interesting hits as TRAF3 is involved in TBK1 and IKKε activation downstream of TLR3 
and TLR4 signalling. 
 
 
Chapter 5. Results 3 
 137 
 
Table 5.2. Mass spectrometry results of common interactors of 
unphosphorylated Rab7 and pRab7(S72). 
A large number of common interactors were identified by mass spectrometry for 
unphosphorylated Rab7 and pRab7(S72). The table shows the highest hits of the 
analysis. The proteins highlighted in yellow are known interactors of Rab7.  
Identified Proteins Rab7-OH pRab7(S72) 
Ataxin-2-like protein (ATX2L) 27 22 
Clathrin heavy chain 1 30 15 
Bcl-2-associated transcription factor 1 (BCLF1) 11 10 
Thyroid hormone receptor-associated protein 3 12 11 
Desmoplakin 4 16 
Actin, cytoplasmic 1 6 8 
Prohibitin-2  9 8 
Tubulin alpha-1B chain (TBA1B) 8 9 
Myosin-10 8 12 
Fatty acid synthase (FAS) 5 13 
Constitutive coactivator of PPAR-gamma-like protein 1  11 9 
Interleukin enhancer-binding factor 3 (ILF3) 5 7 
Prohibitin  8 7 
Protein LSM14 homolog A (LS14A) 7 3 
Exportin-2  3 7 
Endoplasmin 1 4 
Vimentin 8 5 
Cytoplasmic dynein 1 heavy chain 1 (DYHC1) 4 9 
Dynactin 2 (p50) - DCTN2 1 1 
AP-2 complex subunit beta 5 11 
AP-2 complex subunit alpha-1 5 9 
Fragile X mental retardation protein 1 (FMR1) 6 6 
Fragile X mental retardation syndrome-related protein 2 13 16 
Nuclear fragile X mental retardation-interacting protein 2  20 19 
Ras GTPase-activating protein-binding protein 1  9 6 
Ras GTPase-activating protein-binding protein 2  10 8 
Rab6C 1 1 
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5.4 Discussion 
The initial hypothesis of this project, conceived from experiments using GFP-
Rab7Wt, GFP-Rab7S72A and GFP-Rab7S72E, was that phosphorylation of Rab7 at 
S72 inhibited Rab7 recruitment to the membrane for activation. This hypothesis 
was supported by experiments showing that GFP-Rab7S72E is completely 
cytosolic (Figure 3.3) and appeared to decrease in EGFR degradation (Figure 
3.9). However, as the S72 residue is located in the switch II region of Rab7, on 
a site known to interact with REP1, I hypothesised that the Rab7S72E mutation 
could prevent interaction of newly synthesised Rab7S72E with REP1, thereby 
preventing its C-terminal prenylation, which would block its recruitment to the 
membrane and function. After the in vitro kinase screen and subsequent 
validation of the hits revealed that TBK1 and IKKε were the only two kinases of 
the 190 tested that phosphorylated Rab7 at S72, it was unclear why this would 
only affect newly synthesised Rab7, especially with the diversity of the 
phosphoproteomic screens S72 phosphorylation was detected in. 
 
To determine if the cytosolic localisation of Rab7S72E was a good indicator of the 
localisation of pRab7(S72) and not an artefact caused by an inhibition of its C-
terminal prenylation, subcellular fractionation was performed of GFP-Rab7Wt 
expressing MEFs to determine the correct localisation. Surprisingly, a large 
proportion of pRab7(S72) was located on the membrane compared to the 
cytosolic proportion (Figure 5.1). This result was confirmed by 
immunofluorescence using the anti-pRab7(S72) antibody (Figure 5.2). 
Interestingly, the anti-pRab7(S72) antibody staining revealed that only a 
subpool of the Rab7-positive organelles were positive for pRab7(S72). Future 
experiments should be performed to determine the identity of these endosomes, 
using labels such as Lysotracker or a pulse-chase experiment using 
fluorescently-labelled EGF.  
 
Chapter 5. Results 3 
 139 
Following these results, it was clear that the original hypothesis that 
phosphorylation inhibited Rab7 activity was most likely wrong; so two new 
hypotheses were generated as follows: 
 
1. Phosphorylation of Rab7 at S72 affects its GTPase activity. 
 
2. Phosphorylation of Rab7 at S72 affects Rab7 interaction with specific 
effectors. 
 
To test the first hypothesis, an in vitro kinase assay was performed using [α-
P32]GTP to determine if there was a difference in the intrinsic GTPase activities 
of pRab7(S72) and unphosphorylated Rab7. The results revealed that over a 
120-min period, there was an increasing rate of GTP hydrolysis in pRab7(S72), 
which was statistically significant at both 60 (P = 0.0035) and 120 min (P = 
0.0002). Furthermore, binding of [α-P32]GTP was increased in pRab7(S72) 
compared to unphosphorylated Rab7 (Figure 5.3). If phosphorylation of Rab7 at 
S72 were to weaken or inhibit the interaction between the switch I and II regions, 
the open conformation could allow for increased GTP association. Following 
GTP binding, intrinsic GTP hydrolysis would occur via the catalytic Q67 residue, 
allowing for GDP dissociation, followed by further binding of [α-P32]GTP and its 
subsequent hydrolysis. This experiment addresses the binding and rate of GTP 
hydrolysis. In a cellular context, other factors, such as recruitment of specific 
GEF or GAP, may further modulate GTP status of pRab7(S72). However, the 
results do provide good evidence that phosphorylation of Rab7 at S72 affects 
the interaction of the switch I and II regions, which could cause an inhibition of 
Rab7 function or it could affect binding of certain effectors that require 
interaction between these regions, such as RILP, which binds numerous 
residues within both regions when in the GTP-bound conformation. 
 
To test the second hypothesis, recombinant pGST-Rab7(S72) and 
unphosphorylated GST-Rab7 were used to for a pull-down and mass 
spectrometry analysis of differential interactors. Although a number of known 
interactors, including RILP and ORP1L, were not detected in the mass 
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spectrometry results, they were detected by western blot of the same samples 
used for the mass spectrometry pull-down. RILP was detected only in the 
unphosphorylated sample, whereas ORP1L was detected in both (Figure 5.4).  
 
Both RILP and ORP1L are involved in recruitment of the dynein-dynactin motor 
to late endosomes and lysosomes. The results of the mass spectrometry 
screen also detected both the p150(Glued) and p50(Dynamitin) subunits of the 
dynactin complex, along with cytoplasmic dynein heavy chain 1 (DHC1), 
cytoplasmic dynein 1 intermediate chain 2 (DC1I2) and cytoplasmic dynein 2 
light intermediate chain 1 (DC2L1). The p150(Glued) subunit was detected only 
in the pRab7(S72) sample, along with 2.1-fold more DHC1 compared to the 
unphosphorylated sample; p50(Dynamitin) and DC2L1 were detected equally in 
both; and DC1I2 was only detected in the unphosphorylated sample (Table 5.1, 
Table 5.2). Studies have shown differential requirements for different 
components of the dynein-dynactin motor for specific functions. Tan et al. 
showed that cytoplasmic dynein 1 light intermediate chain 1 (DC1L10, which 
was not detected in our study, is involved in recruitment of dynein to lysosomes 
and late endosomes, independent of RILP-dependent recruitment of dynactin 
(Tan et al., 2011). 
 
According to most studies published on the recruitment of p150(Glued) to 
Rab7-positive late endosomes and lysosomes, this occurs by its direct binding 
to RILP; however, evidence that p150(Glued) is not recruited in the absence of 
RILP is not very strong. Jordens et al. originally claimed that expression of the 
C-terminal half of RILP reduced p150(Glued) recruitment to lysosomes 
compared to overexpressed full-length RILP; however, the immunofluorescence 
images showing this are at a lower magnification than the full-length and do not 
appear to be very different from each other (Jordens et al., 2001). Furthermore, 
the absence of p150(Glued) from their subcellular fractionation analysis of 
p50(Dynamitin), Rab7 and α-tubulin localisation in cells overexpressing both 
forms of RILP raises questions as to why it was omitted. Vihervaara et al. 
ORP1L is capable of recruiting p150(Glued) to late endosomes/lysosomes 
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independent of RILP (Vihervaara et al., 2011). More recently, Kant et al., 
showed that RILP binds the HOPS complex and p150(Glued), and most 
mutations in RILP that affect HOPS subunit binding also affected RILP binding 
(van der Kant et al., 2013). They also found that the highest affinity for binding 
of p150(Glued) to Rab7-RILP was in the presence of the HOPS complex. Thus, 
RILP does not does not appear to be the major determinant of p150(Glued) 
recruitment to Rab7, and may be recruited to the complex by other factors. The 
increased interaction of p150(Glued) with pRab7(S72) could be a result of 
increased recruitment of other effectors required for the formation of a complex 
with Rab7-p150(Glued) that would be inhibited by the presence of RILP. 
Furthermore, as this experiment used recombinant Rab7 that was 
phosphorylated in vitro with TBK1, it is not known how much of the sample was 
indeed phosphorylated at S72 and was most likely a mixture of both 
unphosphorylated and phosphorylated Rab7. Thus, the presence of certain 
effectors in the pRab7(S72) sample at lower levels than unphosphorylated 
Rab7 could be an effect of them binding to Rab7 that has not been 
phosphorylated by TBL1 in vitro. However, these results still provide novel 
information on differential interactions with effectors as a result of Rab7 
phosphorylation at S72, which has never been investigated previously.  
 
Johansson et al. showed that binding of ORP1L promotes binding of the 
ORP1L-Rab7–RILP–p150(Glued) complex to membrane-associated αI-βIII 
spectrin, which then binds to the Arp1 subunit of dynactin (Johansson et al., 
2007a). Interestingly, this study also found that ORP1L but not RILP, is required 
for dynein-mediated transport of late endosomes, by mediating interaction 
between ORP1L and βIII spectrin. While βIII spectrin was not detected in the 
mass spectrometry results, αI spectrin, also known as spectrin alpha chain, 
non-erythrocytic 1 (SPTN1), and βII spectrin, or spectrin beta chain, non-
erythrocytic 1 (SPTB2), were detected (>4 peptides for each). βII spectrin was 
only detected in the pRab7(S72) sample, while αI spectrin was detected in both. 
Spectrin itself is a large, heterodimeric protein composed of α and β subunits. In 
humans, there are two α (αI and αII) and five β (βI–βV) subunits. Unfortunately, 
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the function of βII spectrin is not very well established, but it has been shown to 
be involved in hepatocyte proliferation through the transforming growth factor-β 
(TGFβ) signalling pathway by functioning as a Smad3/4 adaptor protein 
(Thenappan et al., 2011). TGFβ signals in early endosomes and is degraded 
via the proteasome and lysosome, indicating that Rab7 interaction with spectrin 
subunits could be involved in the regulation of TGFβ signalling (Kavsak et al., 
2000). 
 
Two of the most interesting hits from the mass spectrometry results were 
TRAF3 and REP1, both of which were specific interactors for unphosphorylated 
Rab7 (Table 5.1). The lack of the interaction of REP1 with the pRab7(S72) 
suggests that the concerns about Rab7S72E giving false indications because it 
does not interact with REP1, and as a consequence never gets prenylated, are 
most likely true. TRAF3 interaction with unphosphorylated Rab7 was the most 
surprising result for the entire analysis, as TRAF3 is a key regulator of IRF3/7 
signalling, upstream of TBK1 and IKKε. Unfortunately, I did not have time to 
confirm this by western blot, but the fact that TRAF4 also interacts specifically 
with unphosphorylated Rab7 is a good indicator that this is correct. Furthermore, 
TRAF6 has previously been identified as a Rab7 interactor in a large-scale 
analysis of protein-protein interactions in human cells, and TRAF6 is required 
for TrkA polyubiquitination and internalization, and NGF-dependent neurite 
outgrowth (Ewing et al., 2007). The possible significance of the interaction of 
Rab7 with TRAF3 will be discussed in more detail in the following Discussion 
chapter.   
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Chapter 6. Discussion 
6.1 Mechanisms of Rab7 regulation 
While many studies use phosphomimetic and phosphodeficient mutations to 
examine the effects phosphorylation at a specific residue may have on a 
proteins function, it is evident from the results of this study that the 
phosphomimetic Rab7S72E does not mimic the behaviour of a constitutively 
phosphorylated Rab7 at S72. Rab7S72E appears to be inactive, whereas the 
results of subcellular fractionation, immunofluorescence and pull-down all 
indicate that a large proportion of pRab7(S72) is located on endosomal 
membranes and is capable of interaction with certain effectors. Binding of RILP 
to Rab7 is believed to lock Rab7 in an active state, whereas phosphorylation 
appears to inhibit RILP binding and increase GDP/GPT turnover of Rab7. Thus, 
phosphorylation of Rab7 at S72 could increase the intrinsic GTPase activity of 
Rab7, but it may also be a mechanism of promoting interaction with certain 
effectors over others. As the S72 residue is also located in the switch II region, 
adjacent to sites required for the interaction with the switch I region upon GTP-
binding, this could also affect the active state of Rab7. It would be very 
interesting to see if the interaction between the switch I and II regions is 
maintained in the crystallisation of pRab7(S72) in the GTP-bound form.  
 
6.2 Phosphorylation of Rab7 at serine 72 via toll-like receptor 
signalling 
In this study, both TBK1 and IKKε were identified as kinases that phosphorylate 
Rab7 at S72 in vitro. Furthermore, stimulation of TLR3 and TLR4, both of which 
are upstream receptors responsible for the activation of TBK1 and IKKε, causes 
increased phosphorylation of Rab7 at S72 in MEFs. Interestingly, one of the 
biggest hits of the mass spectrometry analysis, of differential interactors for 
unphosphorylated Rab7 and pRab7(S72), was TRAF3, which specifically bound 
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to the unphosphorylated Rab7 sample (Table 5.1). TRAF3 is activated by TLRs 
that signal via the endosomal pathway. TLR3, 7, 8 and 9 are all internal 
receptors that recognise bacterial and viral nucleic acids, whereas the plasma 
membrane receptors recognise surface markers of invading pathogens 
(Janssens and Beyaert, 2002). TLR4 is the only plasma membrane-associated 
TLR that can activate the IRF3 pathway, and does so following internalisation 
and activation of TRAF3. The remaining plasma membrane TLRs (TLR1, 2, 5 
and 6) all signal from the cell surface.  
 
TLR3, 7, 8 and 9 all reside within the ER of resting cells and traffic to 
endosomes/lysosomes upon activation (Latz et al., 2004). It was originally 
believed that TLRs in the ER quickly traffic to endosomes upon activation; 
however, it is now believed that TLR7 and 9 pass through the Golgi, based on 
analysis of the carbohydrates of these TLRs in endosomes (Chockalingam et 
al., 2009). It is believed that TLR3 also passes through the Golgi for proteolytic 
processing in endosomes (Qi et al., 2012). This proteolytic processing is 
dependent on Unc93b1, and ER-localised molecular chaperone responsible for 
the trafficking of TLRs to endosomes/lysosomes. However, TLR3 is also found 
in the full-length form in endosomes/lysosomes and is signalling competent, but 
its half-life in HEK293 cells is approximately 3 h, compared to over 7 h for the 
cleaved form (Qi et al., 2012). This suggests that TLR3 could traffic to via two 
different mechanisms, one via the Golgi and the other direct from the ER to 
endosomes/lysosomes. 
 
Recently, there has increasing amount of evidence for substantial contact 
between endosomes and the ER, with some studies indicating that these 
contacts sites increase with endosomal maturation. Friedman et al. measured 
the association of early and late endosomes with the ER and found that 50% of 
early endosomes tracked over a 2-min period remained in contact with the ER, 
compared to >95% of late endosomes, in both COS-7 and U2OS cells 
(Friedman et al., 2013). Both early and late endosomes coupled to the ER were 
also found to be in contact with microtubules for transport towards the 
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perinuclear region as they mature (Friedman et al., 2013). This close 
association Rab7-positive organelles with the ER has been proposed as contact 
sites for the transfer of cholesterol to lysosomes, but could also allow for the 
transfer of TLRs and other proteins to the endocytic pathway, and the 
interaction of Rab7 with ORP1L could be a key regulator of this process (Rocha 
et al., 2009). For TLR3, this could explain why it is present in full-length and 
cleaved forms in endosomes/lysosomes, as the full-length may bypass the 
Golgi apparatus and traffic directly via contacts sites with the ER, following 
stimulation of the cleaved form that is already present in endosomes. Thus, this 
mechanism would allow for attenuation of the IRF3 signalling pathway following 
recruitment of full-length TLR3 from the ER much faster than if it were to pass 
through the Golgi. 
 
Binding of TRAF3 to Rab7 could allow faster recruitment of TRAF3 to activated 
TLR3 or TLR4, where it would bind TRIF (Figure 6.1). Activated TRAF3 could 
then bind TBK1 and IKKε to form a complex, which in turn could phosphorylate 
Rab7 on the membrane. A previous study investigating the role of the 26S 
proteasome adaptor Ecm29 in TLR3 signalling, found that an absence of 
Ecm29 attenuated TLR3 signalling, TRAF3 abundance, TBK1 activation and 
IRF3 translocation into the nucleus (Gorbea et al., 2013). More interestingly, 
they also found increased colocalisation of TBK1 and Rab7. Previously, I 
transfected GFP-TBK1 or GFP-IKKε with HA-Rab7 in HeLa cells to monitor their 
colocalisation, but was unsuccessful. Overexpression of TBK1 and IKKε results 
in their autophosphorylation in the catalytic domain, but this was insufficient to 
induce phosphorylation of Rab7. However, if Rab7 interacts with TBK1 and 
IKKε in a complex containing TRAF3, which is recruited to TLR3 or TLR4 in 
endosomes/lysosomes, then this would not occur in HeLa cells, as these do not 
express endogenous TLR3 or TLR4. It would be interesting ascertain the extent 
of colocalisation of pRab7(S72), Rab7, TBK1, IKKε, and TRAF3, before and 
after stimulation of TR3 or TLR4 in macrophage or dendritic cells, which 
express these constituents at higher levels than most other cell types. 
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6.3 Phosphorylation of Rab7 at serine 72 as a possible 
mechanism of controlling lysosomal tubulation  
An alternative hypothesis for the role of Rab7 phosphorylation at S72 could be 
a mechanism that allows for the formation of tubular lysosomes in macrophages 
and dendritic cells following infection. Stimulation of macrophages and dendritic 
cells with LPS causes the remodelling of the class II major histocompatibility 
complex (MHCII) compartment, a lysosome-related organelle, from a punctate 
morphology into tubular network that is believed to be involved in antigen 
presentation (Mrakovic et al., 2012). The formation of these tubular lysosomes 
requires Rab7, and its effectors RILP and FYCO1, as well as Arl8b, and its 
effector SKIP. RILP and FYCO1 regulate the dynein- and kinesin-mediated 
transport of lysosomes, respectively. Arl8b is another small GTPase that is also 
involved in the microtubule plus end-directed transport of lysosomes through 
regulation of the kinesin motor (Mrakovic et al., 2012). Expression of the 
dominant-negative GFP-Rab7T22N resulted in a significant reduction (67 ± 5%) 
in the number of tubular lysosomes per cell compared to GFP-Rab7Wt. 
Interestingly, overexpression of GFP-RILP also caused a significant reduction 
(51 ± 7%) in the number of tubular lysosomes compared to untransfected cells, 
even though it was still recruited to the few that were present. This indicates 
that the balance between Rab7-RILP and Rab7-FYCO1 is extremely important 
for tubulation.  
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Figure 6.1. Model of Rab7-dependent recruitment of TRAF3 to TLR3 in 
endosomes/lysosomes. 
Activation and dimerization of TLR3 occurs by binding of dsRNA in the early endosome. 
Signalling of TLR3 requires endosomal acidification, and the exchange of Rab5 for 
Rab7. TLR3 requires binding of TRIF to activate the downstream signalling pathway. 
Rab7 could then bring TRAF3, which can bind unphosphorylated Rab7, to the late 
endosome/lysosome, where it can then bind TRIF. TBK1 and IKKε then bind and form 
a complex with TRAF3, which could then phosphorylate Rab7 at S72. The TRAF3-
TBK1-IKKε complex phosphorylates IRF3 and/or IRF7, which dimerise and translocate 
to the nucleus to induce production of type I interferon. 
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Furthermore, it has been previously shown that Rab7 is expressed at low levels 
in resting B cells, but is upregulated following stimulation with CD40 ligand 
(CD40L) or bacterial LPS. Furthermore, overexpression of Rab7 in B cells also 
results in an increased rate of MHCII antigen presentation (Bertram et al., 2002). 
This function of Rab7 appears to be different to its normal homeostatic 
functions, which could implicate a requirement for differential regulation. 
Phosphorylation of Rab7 at S72 could inhibit RILP recruitment, thus allowing for 
the recruitment of other effectors, such as FYCO1, to allow for lysosomal 
tubulation and antigen processing. Indeed, increased phosphorylation of Rab7 
at S72 has been previously detected in a number of immunological screens, 
including LPS stimulation of macrophages (Weintz et al., 2010). Furthermore, in 
this study, LPS and poly(I:C) stimulation of MEFs increased phosphorylation of 
Rab7 at S72. In future work, it would be interesting to see if there was a subset 
of the pRab7(S72) localised to tubular lysosomes in macrophages and if this 
subset colocalised with other markers, such as RILP and FYCO1. Unfortunately, 
as FYCO1 did not bind to pRab7(S72) or unphosphorylated Rab7 during the 
pull-down, it is still unclear if the working model is sound. 
 
6.4 TBK1 & IKKε regulation of vesicular transport 
While most of the research into TBK1 and IKKε to date has investigated their 
roles in NF-κB and IRF signalling, both kinases may also be involved in the 
regulation of endosomal trafficking. IKKε plays an important role in the 
elongation of Drosophila mechanosensory bristle growth, by phosphorylating 
Nuf, a Rab11 effector, to control the trafficking of recycling endosomes in and 
out of the bristle tip (Otani et al., 2011). This phosphorylation of Nuf appears to 
inhibit dynein recruitment to incoming recycling endosomes, thereby promoting 
recruitment of Rab11 and their subsequent recycling. Knockdown of IKKε in 
Drosophila results in shortened bristle length, branching and cytoskeleton 
disorganization. The same study also showed that IKKε phosphorylates the 
mammalian homolog of Nuf, Rab11-FIP3.  
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TBK1 has also been shown to interact with the ESCRT-I subunit VPS37C, in a 
kinase activity-independent manner, indicating that it is an auxiliary subunit of 
the ESCRT-I complex (Da et al., 2011). As ESCRT-I is required for HIV-1 
budding, the authors examined the role of TBK1 in this process and found that 
knockdown of TBK1 results in more efficient budding of the virus. Although this 
process does involve activation of innate immunity, TBK1 did 
coimmunoprecipitate with ESCRT-I in unstimulated cells, indicating that it may 
play another role in regulating this complex. 
 
Thus, although most of the studies investigating TBK1 and IKKε activity have 
focused on their role in innate immunity, both kinases may play much larger 
roles in the regulation of intracellular vesicular transport pathways. This could 
also explain why there is phosphorylation of Rab7 at S72 under basal 
conditions, both in the unstimulated controls in the poly(I:C) (Figure 4.11) and 
LPS experiments (Figure 4.13), and in the phosphoproteomic screens where it 
was discovered in numerous tissues under basal conditions (Huttlin et al., 2010).   
 
IKKε and TBK1 are also abundantly expressed in the nervous system, where 
the NF-κB pathway important for neuronal survival, neuroprotection and the 
suppression of neuronal inflammation (Emmanouil et al., 2011; Mincheva et al., 
2011; Moser et al., 2011). Dysregulation of the NF-κB pathway has been 
associated with Huntington’s disease, multiple sclerosis and other 
neurodegenerative disorders, where Rab7 has also been implicated (Khoshnan 
and Patterson, 2011). It has been shown that the NF-κB pathway is activated by 
neurotrophins to promote cell survival in embryonic motor neurons in vitro 
(Mincheva et al., 2011). Unfortunately the authors did not examine whether 
TBK1 or IKKε were involved in this process; however, the expression of both 
TBK1 and particularly IKKε, which is predominantly induced following activation 
of the innate immune response, suggests that these kinases function in other 
mechanisms in the nervous system. It would be interesting to see if TBK1 
and/or IKKε played a role in the axonal transport of signalling endosomes and in 
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establishing polarity and growth of neurons, similar to the effects seen in 
Drosophila bristles. 
 
6.5 An alternative mechanism of Rab7 regulation 
Another kinase tested in the in vitro kinase, the G2019S mutant of leucine-rich 
repeat kinase 2 (LRRK2G2019S), which is the most common Parkinson’s disease 
mutation, has been shown to promote Rab7-dependent perinuclear clustering of 
lysosomes (Dodson et al., 2012). While in the in vitro kinase screen, there was 
no increase in phosphorylation of Rab7 at S72 with LRRK2G2019S, it did appear 
to phosphorylate elsewhere. In the original screen, which did not include the 
Rab7S72P control, LRRK2G2019S was one of the main hits; however, in the two 
subsequent rescreens it appeared to phosphorylate the Rab7S72P mutant more. 
LRRK2Wt has been implicated in a number of processes, including has been 
shown to regulate synaptic vesicle trafficking, endocytosis, macroautophagy, 
and retromer-dependent transport from late endosomes to the trans-Golgi 
network (Gomez-Suaga et al., 2014). The LRRK2G2019S mutation increases the 
kinase activity of LRRK2 and the effect of this mutation on lysosome positioning 
appears to require both microtubules and cytoplasmic dynein, indicating that 
LRRK2 is an inhibitor of Rab7-dependent microtubule minus-end directed 
transport (Dodson et al., 2012). Another recent study also showed that 
LRRK2G2019S decreases Rab7 activity and inhibits EGFR degradation (Gomez-
Suaga et al., 2014). The phosphorylation of Rab7 by LRRK2G2019S may 
represent another mechanism of Rab7 regulation by phosphorylation. 
 
Chapter 6. Discussion 
 151 
6.6 Future work 
While it is clear that pRab7(S72) is present on endosomal membranes, it is 
unknown exactly what subset of Rab7-positive membranes this pool is. Future 
work should investigate the nature of this endocytic compartment that is 
decorated with pRab7(S72). Unfortunately, as Rab7S72E does not localise to 
membranes we were unable to examine whether this phosphomimetic mutation 
has any effect on the speed or direction of transport of late 
endosomes/lysosomes containing this protein. To address this, it may be 
interesting to investigate the localisation of pRab7(S72) on tubulated lysosomes, 
following stimulation of macrophages or dendritic cells with LPS. This may allow 
visualisation of pRab7(S72) on a subdomain of these structures. Colocalisation 
with specific effectors could also provide further insight into the role of this 
phosphorylation on Rab7. 
 
Future investigation should also examine the interaction of Rab7 with TRAF3, 
REP1 and FYCO1, to determine if phosphorylation at S72 affects binding of 
these interactors in an isolated system. It would also be interesting to see if 
Rab7, TRAF3 and TBK1/IKKε colocalise in dendritic cells following stimulation 
of TRL3 or TLR4 by immunofluorescence and if they can form a complex in 
vitro using recombinant proteins.  
 
Finally, I believe it is important to confirm if TBK1 and IKKε are in fact 
responsible for phosphorylation at S72 in cells following stimulation of TLR3 
and/or TLR4. It would also be also interesting to see if stimulation of other 
receptors, such as the cytosolic MDA-5/RIG-I receptors caused phosphorylation 
of Rab7 at S72.  
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6.7 Concluding Remarks 
 
The major conclusions of this study are as follows: 
 
• Phosphorylation of Rab7 at S72 occurs following stimulation of TLR3 and 
TLR4 with viral dsRNA and bacterial LPS, respectively, possibly through TBK1 
and IKKε, which both phosphorylate Rab7 at S72 in vitro 
 
• TRAF3 has been identified as a new potential interactor of unphosphorylated 
Rab7, which may affect recruitment of TRAF3 to membranes following viral 
infection and subsequent activation of TBK1 and IKKε. 
 
• Phosphorylation of Rab7 at S72 promotes differential binding of known 
interactors, including RILP, p150(Glued) and REP1, while having no effect 
others, such as ORP1L. The enrichment of S72-phosphorylated Rab7 on 
endosomal membranes also supports a role of phosphorylation in the regulation 
of interaction with effectors. 
 
• Phosphorylation at S72 increases the intrinsic GTPase activity of Rab7, which 
may affect cycling of Rab7 from the cytosol to endosomal membranes and its 
activation state. 
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